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EXECUTIVE SUMMARY 
Intensive livestock production and management systems are associated with 
increased faecal-oral pathogen transmission which can contribute to a high 
prevalence of multiple Salmonella serovars in large dairy farms and feedlots.  
Outbreaks of salmonellosis in livestock often reflect a series of events that 
compromise host immunity and increase pathogen exposure.  High risk groups in 
cattle include neonates and post partum cows (Anderson, et al., 2001; House, et 
al., 2001a; Fossler, et al., 2005a) and variation in susceptibility to salmonella 
infection has been observed in sheep entering feedlots according to property of 
origin, body condition, and time of year (Norris, et al., 1989a; Norris, et al., 
1989b; Richards and Hyder, 1991; Kelly, 1995; Makin, 2011). The associated 
increase in the incidence of disease and contamination of livestock-derived food 
products imposes a significant risk to food safety via consumption of 
contaminated meat, milk, eggs and vegetables. The development and application 
of effective Salmonella vaccines offers a potential means of reducing industry 
associated losses and public health risks.   
Effective Salmonella vaccination therefore requires induction of protection 
against several Salmonella serovars and stimulation of both innate and acquired 
immune mechanisms.  Vaccine prophylaxis is normally achieved through 
vaccinating animals several weeks prior to virulent pathogen exposure.  This is 
not possible in neonates where exposure occurs at birth and in feedlots where 
livestock are sourced from diverse locations and vendors.  Additionally, direct 
physical handling of livestock to administer vaccines contributes to stress and 
may lead to carcass damage.  Conducting stressful procedures at feedlot induction 
when there is concurrent exposure to a diversity of pathogens contributes to an 
increased risk of disease.   
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Traditional vaccination methods are labour intensive and associated with carcass 
damage and adverse reactions.  Oral delivery of vaccines and medications via 
drinking water is a common practice in intensively managed poultry.  Oral 
vaccine delivery via drinking water avoids the stress of additional handling and 
provides a means of rapidly vaccinating large numbers of animals.  
The efficacy of Salmonella vaccination is largely influenced by the diversity of 
Salmonella serovars encountered and the interval between immunisation and 
pathogen exposure, which may be short in field settings, e.g., following birth, 
during transport and following introduction into feedlots.  The timing of virulent 
pathogen exposure may also have an impact on the safety of a Salmonella 
vaccine.  It is imperative to develop livestock vaccines that are capable of safely 
eliciting potent states of cross-protective immunity against a diversity of serovars.  
This thesis examines the capacity of the dam S. Typhimurium vaccine (serogroup 
B) to elicit cross-protection against a virulent challenge in models of neonate and 
adult ruminant models of salmonellosis, as well as investigating in-water vaccine 
delivery.  Cross-protective efficacy of the vaccine was evaluated against an 
emerging, clinically relevant, and multi-drug resistant strain of serovar Newport 
(serogroup C2-C3) that had been associated with clinical disease in calves and 
humans (CDC, 2002; Clark, 2004). Vaccinated calves challenged with S. Newport 
exhibited a significant attenuation of clinical disease and a concomitant reduction 
in S. Newport faecal shedding and colonisation of mesenteric lymph nodes and 
lungs compared to non-vaccinated control animals.  The safety and efficacy of a S. 
Typhimurium dam vaccine in adult sheep was demonstrated via novel oral 
delivery in drinking water (ad libitum). The capacity of S. Typhimurium dam 
vaccine to be delivered in drinking water to protect livestock from virulent 
Salmonella challenge offers an effective, economical, stressor free Salmonella 
prophylaxis for intensive livestock production systems. 
iv 
Oral delivery of live attenuated Salmonella vaccines minimises vaccine 
production costs, provides an opportunity for mass medication via drinking water, 
avoids carcass damage and reduces animal stress. The capacity to elicit cross-
protective immunity in calves and sheep suggests that dam mutant vaccines have 
potential application toward the prevention and control of Salmonella infection in 
commercial livestock production systems wherein livestock are exposed to a 
diversity of Salmonella serovars 
v 
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Terminology used in the thesis in reference to Salmonella  
The nomenclature for Salmonella is still evolving and under debate within the scientific and medical community (Euzeby, 1999; Brenner, et al., 
2000).  The nomenclature system based on the Kauffman-White scheme that involves allocation of Salmonella to serovars or serotypes based on 
the serological identification of O (somatic/LPS), H (flagellar), and K (capsular) antigens (Kauffman, 1973) were applied to this document in 
reference to Salmonella enterica subspecies enterica as outlined in Table 1.  This system is generally  accepted  by the Centres for Disease 
Control and Prevention (CDC), the World Health Organization (WHO) Collaborating Centre and Bergey's Manual of Systematic Bacteriology 
(Garrity, et al., 2004; Dougan, et al., 2011). The common names for Salmonella serovars were applied to this document. 
Table 0.1.  Examples of Salmonella Nomenclature 
Complete Name Common Name O-Antigen  Serogroup/Serotype 
Salmonella enterica subspecies enterica serovar Bovismorbificans 
Salmonella Bovismorbificans 
S. Bovismorbificans C2-C3 
Salmonella enterica subspecies enterica serovar Dublin 
Salmonella Dublin 
S. Dublin D1 
Salmonella enterica subspecies enterica serovar Newport 
Salmonella Newport 
S. Newport C2-C3 
Salmonella enterica subspecies enterica serovar Typhimurium 
Salmonella Typhimurium 
S. Typhimurium B 
Salmonella enterica subspecies enterica serovar Typhimurium UK-1 dam- 
Salmonella Typhimurium dam 
S. Typhimurium dam 
B 
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CHAPTER 1. INTRODUCTION  
This thesis describes the development of experimental salmonella challenge models 
in neonatal calves and adult sheep.  These models were then utilised to evaluate the 
protective efficacy of a S. Typhimurium dam attenuated vaccine and the efficiency of 
in-water delivery systems in adult ruminants. 
Chapter 2 of this thesis contains a review of the current literature relating to 
salmonellosis in ruminants including pathophysiology, risk factors, treatment, 
control, and salmonella vaccination. The review highlights the current status of 
Salmonella vaccines and approaches to assessing protective immunity.  
In Chapter 3, materials and methods used to conduct these experiments are described.  
The vaccine evaluated in this research is an attenuated modified live Salmonella that 
was developed by our collaborators in California.  The conduct of this work required 
AQIS, OGTR, and animal ethics approvals prior to initiation of research.  Methods 
applied across multiple experiments are presented and are referred to in subsequent 
chapters of the thesis. 
In Chapter 4, the development of a heterologous neonate model of salmonellosis and 
methodology for collection of observational and quantifiable data to be used in future 
vaccine trials is described.  The objective was to evaluate the effect of a clinically 
relevant, multidrug resistant strain of S. enterica serovar Newport on neonatal calves 
and to determine the challenge dose that induces clinical disease with minimal 
mortalities in neonatal calves.  The optimal dose of S. enterica serovar Newport in 
neonatal calves was determined to be 1010 CFU which was subsequently used to 
evaluate the cross-protective efficacy of the dam S. Typhimurium vaccine (Chapter 
5). 
Chapter 5 presents the results of a vaccination-challenge trial where the cross-
protective efficacy of the S. Typhimurium dam vaccine was demonstrated in neonatal 
calves using the heterologous neonatal model of salmonellosis described in Chapter 
2 
4.  In this experiment, the capacity of the S. Typhimurium dam vaccine  (serogroup 
B) to elicit cross-protection against a virulent, multi-drug resistant strain of S. 
Newport (serogroup C2-C3) that has been associated with clinical disease in recent 
salmonellosis outbreaks in cattle and calves was demonstrated.  These results were 
published in the journal Vaccine in March 2008. 
Chapter 6 describes the development of adult ruminant models of salmonellosis in 
sheep and the methodology for collection of observational and quantifiable data to be 
used in future vaccine trials is described.  The objective was to determine a challenge 
dose of industry relevant strains of S. enterica serovar Typhimurium and S. enterica 
serovar Bovismorbificans that would induce clinical disease with minimal mortalities 
in adult Merino sheep. The optimal dose of S. enterica serovar Bovismorbificans 
heterologous challenge was determined to be 109 CFU in adult Merino sheep and was 
used to evaluate the cross-protective efficacy of a S. Typhimurium dam vaccine in 
future trials.  The optimal dose of S. enterica serovar Typhimurium homologous 
challenge was determined to be 109 CFU in adult Merino sheep and used to evaluate 
the protective efficacy of the vaccine in Chapter 8. 
Chapter 7 describes a series of experiments conducted to determine the viability and 
stability of the S. Typhimurium dam vaccine in water and development of an in-water 
vaccine delivery model.  Oral delivery of vaccines via drinking water has the 
potential to rapidly immunise large numbers of animals with minimal stress, to avoid 
carcass damage due to injection site reactions and to reduce production costs. Hence, 
oral delivery via drinking water allows for cost effective salmonella prophylaxis in 
susceptible populations.  The objective was to determine if the S. Typhimurium dam 
vaccine would be viable in drinking water and to determine if adult ruminants could 
be effectively vaccinated with S. Typhimurium dam vaccine via oral delivery in 
drinking water, providing a potential means to effectively vaccinate large numbers of 
livestock.  These studies were submitted for publication in the journal Vaccine in July 
of 2011. 
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Chapter 8 presents the results of an in-water vaccination-challenge trial.  Adult sheep 
administered S. Typhimurium dam vaccine in water were challenged with virulent S. 
Typhimurium utilising the homologous salmonellosis challenge model established in 
Chapter 6. This study included assessments of vaccine safety and efficacy.   Adult 
merino sheep were vaccinated in drinking water -28 d, -7 d and 24 h pre and 24 h 
post-virulent S. Typhimurium challenge.  Significant attenuation of clinical disease 
(temperature, appetite, and attitude) as well as reductions in mortality, virulent S. 
Typhimurium faecal shedding and tissue colonisation were observed in sheep 
vaccinated at 28 and 7 d pre-challenge.  Furthermore, vaccination did not pose an 
increased risk of mortality in stock concurrently infected with virulent salmonellae.  
These results were published in the journal Vaccine in April 2011.  
The thesis concludes with a general discussion, conclusions and further research goals 
in Chapter 9. 
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CHAPTER 2. LITERATURE REVIEW 
Sections of this literature review were in part published in two book chapters on the 
topic of salmonellosis in ruminants.  These chapters were executed and reported by 
the candidate under the general supervision with the candidate's appointed supervisor, 
Associate Professor John K. House. 
Mohler, V.L. and House, J.K. (2009), 'Salmonellosis in Ruminants', in D.E. Anderson 
and D.M. Rings (eds.), Current Veterinary Therapy: Food Animal Practice (5th edn.; 
St. Louis: Saunders), 106-111. 
Mohler, V.L., Izzo, M.M., House. J.K. (2009).  Salmonella in Calves. Veterinary 
Clinics of North America-Food Animal Practice 25(1): 37-54 
2.1 Introduction  
There are over 2,500 different serotypes of Salmonella; all are potentially capable of 
causing disease in livestock and humans (Le Minor and Bockemuhl, 1989; Gelberg, 
2001; Popoff, et al., 2004; Popoff and Le Minor, 2005; WHO, 2005). The majority of 
Salmonella enterica subspecies enterica belong to one of ten distinct O-somatic 
antigen serogroups:  A, B, C1, C2, D1, D2, E1, E2, E3 and E4 (Iwen, 1998; Old and 
Threlfall, 1998; Brenner, et al., 2000; Wray and Davies, 2000). The most common 
serogroups isolated from cattle being B, C, D and E. 
Salmonella are endemic on many large intensive dairy farms and feedlot production 
systems. Livestock manure management systems reduce, but do not eliminate, 
Salmonella which are subsequently recycled, promoting faecal-oral transmission. 
Most Salmonella infections in livestock are sub-clinical (Norris, et al., 1989a; Higgs, 
et al., 1993; Kelly, 1995; Anderson, et al., 2001). Salmonellosis in livestock usually 
reflects a variety of management events and environmental stressors that contribute to 
compromised host immunity and increased pathogen exposure. While a diversity of 
Salmonella serovars may be endemic in a given production facility, the virulence of 
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these serovars is variable, reflected by a disparity among Salmonella isolates from 
surveillance and clinical submissions (Glynn, et al., 1998; Anderson, et al., 2001; 
Zhao, et al., 2007). In the literature, S. enterica serovars Typhimurium and Dublin are 
most frequently associated with disease in cattle worldwide with the virulence of 
other serovars being more variable. Conversely, the most commonly isolated serovars 
from cattle in Australia are S. enterica serovars Bovismorbificans, Typhimurium and 
Anatum (IMVS, 2010).  Typhimurium and Bovismorbificans are the serovars most 
frequently associated with disease in sheep (Kelly, 1995; Wray and Davies, 2000; 
Wray and Davies, 2004; IMVS, 2010). 
The diversity of Salmonella serovars present on farms and the potential for different 
serovars to possess virulence attributes requires the implementation of broad 
prophylactic strategies that are efficacious for all salmonellae. At the farm level, 
producers may implement programs to promote host immunity through provision of 
good nutrition and a comfortable environment. When this is accomplished, livestock 
health and productivity is promoted. In practice, consistent day to day implementation 
of these apparently simple principles is paradoxically complex, with numerous 
variables such as changes in weather conditions, mechanical breakdowns, variable 
feedstuff availability and quality, and labour compliance issues all having the 
potential to adversely impact management programs and, subsequently, host 
immunity. 
There has been significant progress toward developing an effective Salmonella 
vaccine using genetically modified Salmonella organisms, with the development of 
vaccines that provide good protection against homologous strains (Rankin and 
Taylor, 1967; Cameron and Fuls, 1976; Wray, et al., 1977; Meyer, 1980; Jelinek, et 
al., 1982a; Mukkur, et al., 1987; Wray and McLaren, 1987; Mukkur, et al., 1991a; 
Mukkur, et al., 1991b; Smith, et al., 1993; Hassan and Curtiss, 1994a; Segall, et al., 
1994; Hormaeche, et al., 1996; Dueger, et al., 2001, 2003a). A continued limitation 
has been the limited capacity to induce protection against challenge with unrelated or 
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heterologous strains (Rankin, et al., 1966; Rankin, et al., 1967; Mukkur, et al., 1987; 
Mukkur, et al., 1991b). The need to develop a Salmonella vaccine that protects 
against infection with the diverse array of Salmonella strains that challenge livestock 
continues. 
2.2 Salmonella enterica subspecies enterica (Salmonella) 
2.2.1. Physical characteristics 
Salmonella are a member of the Enterobacteriaceae family. They are gram-negative, 
mobile, non-lactose fermenting, facultative anaerobic rods  classified as a facultative 
intracellular parasite in humans and many animals (Old and Threlfall, 1998; Quinn, et 
al., 1999).   Salmonellae are capable of growth in minimal media at pH range from 
4.5 to 9.5 (Chung and Goepfert, 1970).  However, the optimal pH for the growth of 
Salmonella has been reported to range between 6.5 and 7.5 (Chung and Goepfert, 
1970; Park, et al., 2004).  Interestingly, S. Typhimurium has developed mechanisms 
for surviving exposures to pH levels as low as 3.0 (Goepfert and Hicks, 1969; Chung 
and Goepfert, 1970; Huhtanen, 1975; Foster and Spector, 1995) which is of 
considerable concern to food safety.   
2.2.2. Distribution and ecological characteristics 
Salmonella are ubiquitous in the environment and can survive for extended periods of 
time, which contributes to the transmission and re-infection of animals. Additionally, 
salmonellae are considered parasites of the gastrointestinal tract of mammals, birds, 
reptiles, fish and insects (Venkateswaran, et al., 1989; Levine and Levine, 1994; 
Alcamo, 2001; Beuchat, 2002; Coleman, et al., 2003; Leriche, et al., 2003; Miller, et 
al., 2006; Heithoff, et al., 2008b; Lynch, et al., 2009).  Salmonella typically infect the 
host via the oro-faecal route in the form of contaminated feedstuffs or polluted water 
(Levine and Levine, 1994; Smith, et al., 1994; Mead, et al., 2000; Alcamo, 2001; 
Davison, et al., 2006; You, et al., 2006).  Several surveys of dairy farms in the US 
report Salmonella contamination of the environment and up to 75% prevalence in 
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animals in the absence of disease or current outbreak (Smith, et al., 1994; Huston, et 
al., 2002; Woodward, et al., 2002). Laboratory experiments have demonstrated that S. 
Dublin survives in faeces for almost six years (Plym-Forshell and Ekesbo, 1996); 
while McLaren and Wary (McLaren and Wray, 1991) reported that Salmonella 
persisted in disinfected calf units for up to two years; and Kelly (1995) observed 
infection of previously naive sheep within 14 days (d) of exposure to salmonella 
contaminated sheep yards. Salmonellae are capable of proliferating in moist faecal 
material (Arrus, et al., 2006; Holley, et al., 2006; You, et al., 2006).  Soils and 
bedding with a mean dry matter content of 80% have been reported to support 
Salmonella growth for up to 25 weeks (Chandler and Craven, 1978, 1980; Arrus, et 
al., 2006; You, et al., 2006; Danyluk, et al., 2008). In laboratory experiments, 
Salmonella were demonstrated to rapidly proliferate in sheep yard material at 20% 
moisture content (Chandler and Craven, 1980; Ingram, 2008). This demonstrates that 
a wetting event, e.g. rain, overflowing water trough, and urine can promote the 
growth of salmonellae in the environment. 
The two Salmonella serovars most commonly reported to cause salmonellosis in 
cattle are S. Dublin and S. Typhimurium (Smith, et al., 1994; Wray and Davies, 2000; 
Davis, et al., 2007; Zhao, et al., 2007; Adhikari, et al., 2009).  Salmonella serovars 
commonly isolated from sheep internationally include S. Typhimurium, S. Arizonae, 
S. Derby, and S. Montevideo (Wray and Davies, 2000). In Australia S. 
Bovismorbificans has been the most commonly reported cause of salmonellosis in 
both cattle and sheep for the last 10 years (IMVS, 2010). Serovars S. Typhimurium, 
S. Bovismorbificans, S. Havana, and S. Anatum have been the predominant serotypes 
associated with disease in Australian sheep feedlots for decades (Kelly, 1995). 
2.2.3. Public health concerns 
The potential for Salmonella in livestock production to contaminate livestock-derived 
food products and other food products via effluent imposes a risk to food safety. The 
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CDC reported that an estimated 1.4 million human Salmonella infections occurred in 
the United States, with only 40,000 reported at a cost of 5 billion dollars (Mead, et 
al., 1999; Mead, et al., 2000; Thorns, 2000; Voetsch, et al., 2004; CDC, 2005, 2006, 
2010). In 2004 the WHO reported that over 3 million deaths were attributed to 
Salmonella infections worldwide (WHO, 2005). Most cases of human salmonellosis 
in developed countries are derived from contaminated foods such as eggs, milk, beef, 
and poultry or products that have been exposed to animal faeces, including fruits and 
vegetables (OzFoodNet, 2003; CDC, 2005; NIH, 2005; WHO, 2005). Recent 
statistics show that 40.3 cases of salmonellosis per 100,000 population were reported 
in Australia (OzFoodNet, 2003), while 13 per 100,000 population were reported in 
the United States between 2003 and 2004 (CDC, 2005). These statistics emphasise 
the growing need for food safety reform and implementation of Salmonella control 
measures in Australia. 
During investigations of salmonellosis, it is prudent to inform animal handling 
personnel of the human health risks Salmonella pose. Multidrug resistant strains of 
Salmonella are frequently implicated in disease outbreaks in calves, sheep and 
occasionally people. These risks have been highlighted in reports of human 
salmonellosis caused by the multidrug resistant S. Newport (CDC, 2002; Devasia, et 
al., 2005; Varma, et al., 2006); S. Typhimurium DT104 (Glynn, et al., 1998); and S. 
Brandenburg (Clark, et al., 2003; Clark, et al., 2004; Baker, et al., 2007) derived from 
livestock. Additionally, surveys report that hospitalisation rates are higher in human 
outbreaks of salmonellosis associated with antimicrobial resistant Salmonella than 
those outbreaks associated with pansusceptible Salmonella strains (Varma, et al., 
2005). 
Current research indicates that Salmonella isolates associated with human 
salmonellosis patients are distinct from those of animal origin (Heithoff, et al., 
2008b). This indicates that selective pressure within a host may give rise to bacteria 
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strain variants that show signs of enhanced fitness in the current host relative to the 
parental host from which the strain was derived or originated. 
2.3 Salmonella in Cattle and Sheep 
Salmonellosis is a common disease in intensively managed domestic animals, with 
consequences ranging from subclinical carrier status to acute fatal septicaemia.  
Disease manifestations associated with salmonellosis include: pneumonia, septic 
arthritis, meningitis, gangrene, ill-thrift and sudden death (Jones, 1992; Higgs, et al., 
1993; Mohler and House, 2009; Mohler, et al., 2009; Makin, 2011).  Outbreaks of 
disease in calves typically occur during the first 4 weeks of life (Anderson, et al., 
2001).  In sheep, salmonellosis is more common in intensive production systems, live 
export (Norris and Richards, 1989; Norris, et al., 1989a; Kelly, 1995; Makin, 2011) 
and lamb fattening.  Conversely, salmonellosis is relatively uncommon in pastoral 
and wool sheep operations.  
2.3.1. Clinical presentation 
Severity and duration of clinical disease is related to virulence of the strain, challenge 
dose, age of animal, immune status, nutrition and management practices.  Infections 
in calves are aggravated by poor husbandry, inadequate nutrition, immature immune 
response, inadequate passive transfer and undeveloped microflora in the 
gastrointestinal tract.  Variables that impact the risk for salmonellosis in sheep 
include season, dietary change, prior exposure to Salmonella, stocking density, new 
introductions, transport and lambing. 
Common findings in clinical cases include fever, depressed mentation, loss of 
appetite and scours containing blood and mucus (Deignan, et al., 2000; Wray and 
Davies, 2000; Gelberg, 2001; Quinn, et al., 2002; Smith, 2002; Mohler and House, 
2009).  Salmonella Dublin also has a propensity to cause respiratory disease in calves 
while S. Typhimurium is commonly associated with enteric forms of the disease in 
younger calves (Wray and McLaren, 1987; Mee, 1995; Tsolis, et al., 1999; Wray and 
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Davies, 2000; Quinn, et al., 2002; Smith, 2002; Mohler and House, 2009).  The 
pathophysiology of diarrhoea produced by salmonellae infection involves local 
release of enterotoxins and endotoxin leading to inflammation, submucosal 
infiltration of neutrophils into the intestinal mucosa, necrosis of enterocytes and 
villous atrophy (Wray and Davies, 2000).  Sloughing of the intestinal epithelial cells 
leads to acute haemorrhage, fibrin production, and increased fluid in the 
gastrointestinal tract due to poor absorption and hypersecretion (Wray and Davies, 
2000; Hodgson, et al., 2003).  Mediators of inflammation characterised by Th1-like 
cytokines such as interleukins (IL-1, IL-6, IL-12 and IL-18), interferon type II gamma 
(INF-γ), and tumour necrosis factor alpha (TNF-α) (Ramarathinam, et al., 1991; 
Ramarathinam, et al., 1993; Elhofy and Bost, 1999b; Elhofy, et al., 2000a; Mastroeni, 
et al., 2000; Tizard, 2000; Tam, et al., 2008; Dougan, et al., 2011); macrophage 
inhibitory factors and inducible nitric oxide synthases (iNOS) (Mastroeni, et al., 
1998; Schwacha, et al., 1998; Mastroeni, et al., 1999); and lactic acid can affect ion 
flux within the intestine creating a hyperosmotic state that draws fluid into the 
intestinal tract. This in turn leads to a net loss of water, sodium, potassium, and 
bicarbonate and contributes to the diarrhoea.  Afflicted animals lose body condition, 
become weak, dehydrated and emaciated.     
2.3.2. Risk factors 
The main risk factors associated with Salmonella infections in calves include poor 
health at birth, poor colostral immunity, receiving pooled colostrum, poor nutrition, 
presence of carrier or infected animals, level of environmental contamination, and 
inadequate hygiene.  With adult ruminants the main risk factors include mixing of 
animals from multiple sources, stocking density, transport, diet, and environmental 
contamination. 
i. Health at birth 
Dystocia and asphyxia during birth can compromise the normal physiological 
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transition phases that occur after birth and increase chances of mortality (Vaala and 
House, 2002a). Calves with low viability scores commonly suffer hypothermia, 
malnutrition and fail to consume adequate amounts of colostrum. Additionally, calves 
that are compromised at birth due to dystocia, premature birth and caesarean section, 
have lower uptakes of colostral immunoglobulins from the intestinal tract which can 
lead to failure of passive transfer (Sangild, 2003) 
ii. Colostral immunity 
Disease resistance is greatly influenced by passive transfer of maternal antibodies and 
cells via colostrum (Sangild, 2003; Cortese, 2009). Calves are born 
agammaglobulinaemic and immunologically naïve as no intrauterine transfer of 
immunoglobulin occurs in ruminants (Vaala and House, 2002b). Colostrum provides 
a concentrated source of immunoglobulins that are optimally absorbed from the 
intestinal tract of a neonatal calf during the first 24 hours (h) of life. Failure of passive 
transfer of immunoglobulins is related to time of colostrum ingestion, amount of 
colostrum consumed, the immunoglobulin and microbial quality of the colostrum and 
health of the calf at birth (Stewart , et al., 2005; Godden, et al., 2006; Chigerwe, et 
al., 2008; Chigerwe, et al., 2009; Mohler, et al., 2009). Calves devoid of passive 
immunoglobulins are highly susceptible to bacterial septicaemia (Barrington and 
Parish, 2002; Fecteau, et al., 2009). 
iii. Nutrition and feeding 
Adequate nutrition is critical for host immunity and calorie deprived animals are more 
likely to succumb to disease.  Poor nutrition and hygiene have been identified as risk 
factors for salmonellosis in calves (de Jong and Ekdahl, 1965; Warnick, et al., 2001; 
Smith, 2002; McGuirk and Peek, 2003; Mohler and House, 2009; Smith, 2009).   
Inadequate caloric intake can lead to increased cortisol release, poor immune function 
and increased susceptibility to disease (Pollock, et al., 1993; Drackley, 2008; 
Nonnecke, et al., 2009; Khan, et al., 2011). When considering the energy and 
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nutritional needs of calves, it is important to factor in seasonal conditions and 
exposure to the elements (Tomkins and Jaster, 1991; Danyluk, et al., 2008).   
The microbial quality of milk fed to calves is also important. On farms where calves 
are fed milk collected from recently calved and sick or “hospital” cows, it is not 
uncommon to isolate Salmonella from over 25% of the samples (Mohler, et al., 
2009).  Salmonella contamination and proliferation in calf milk can also be associated 
with poor cleaning and sanitation of milk feeding equipment and a lack of 
refrigeration, which carries significant risk when residual milk is held over for the 
next feeding. This is particularly pertinent during hot weather when proliferation of 
Salmonella is favoured.  Pasteurisation is effective in eliminating Salmonella 
contamination and, when properly executed, provides a robust risk management 
strategy for controlling transmission via colostrum and milk (Stewart , et al., 2005; 
Godden, et al., 2006).   
Feeding utensils, equipment and personnel often play a significant role in transmitting 
Salmonella between both calves and adult ruminants (Pacer, et al., 1989; Hardman, et 
al., 1991; Smith, et al., 1994; Heinrichs and Radostits, 2001; Fossler, et al., 2005a; 
Fossler, et al., 2005b; Oliver, et al., 2007). Salmonella infects the salivary glands and 
is shed in saliva and nasal secretions, thereby contaminating nipples, bottles, buckets, 
and oesophageal feeders (Richards and Fawcett, 1973; Nolan, et al., 1995).  Adequate 
cleaning and disinfection of feeding utensils is necessary to remove Salmonella 
contamination.   
Poor rumen fill due to fasting or anorexia and rumen imbalance have been identified 
as risk factors for salmonellosis in adult ruminants (Norris, et al., 1989a; Norris, et 
al., 1989b; Richards, et al., 1989; Richards and Hyder, 1991; Higgs, et al., 1993; 
Kelly, 1995; Lenahan, et al., 2010).  It is common for sheep and cattle to be held off 
feed for prolonged periods of time during assembly and transport and then undergo a 
rapid change in diet - from one typically of pasture, to a grain-pellet ration following 
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entry to feedlots.  Salmonella are rapidly cleared from the rumen of regularly fed 
ruminants, but maintain or increase their numbers when feed intake is decreased or 
interrupted for one or more days (Brownlie and Grau, 1967; Chambers and Lysons, 
1979; Mattila, et al., 1988; Lenahan, et al., 2010).  Feeding after a period of 
starvation is associated with proliferation of Salmonella in the rumen (Grau, et al., 
1968; Frost, et al., 1988) which is likely to be associated with provision of substrates 
for growth. Growth of Salmonella in rumen fluid is influenced by the type of feed 
consumed (Brownlie and Grau, 1967; Grau, et al., 1969; Lenahan, et al., 2010). 
Anorexia in ruminants is associated with low concentrations of volatile fatty acids 
and a high rumen pH that favours the growth of salmonellae (Chung and Goepfert, 
1970; Park, et al., 2004). Upon entering a new environment, it is not uncommon for 
sheep to not consume the diet offered due to lack of prior exposure or experience with 
the feed source.  Norris et al. (1990) reported 0.2% to 23% of sheep were non-feeders 
(classified as neophobic animals) following entry into feedlots.   
iv. Environmental contamination  
With the global trend toward intensive management of livestock, contamination of the 
environment is difficult to avoid (Anderson, et al., 2001; Huston, et al., 2002). The 
resilience of Salmonella and its capacity to survive for extended periods of time in the 
environment further contribute to the difficulties associated with attempts to eliminate 
Salmonella from the environment (Robertsson, et al., 1983; Wray, et al., 1987). 
Management practices in the calving barns and calf rearing areas can directly affect 
the incidence of disease (Robertsson, et al., 1983; Wray, et al., 1987; Heinrichs and 
Radostits, 2001; McGuirk, 2008). One study identified employment of part-time staff 
and lack of biosecurity protocols on farm as risk factors for isolation of salmonella 
(Davison, et al., 2006). Scrupulous attention to hygiene in the calving areas, reduction 
in faecal contamination and isolation of sick animals can reduce the environmental 
exposure of calves and assist in the control of Salmonella infection.   
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Facilities used to handle large numbers of livestock are prone to becoming 
contaminated with Salmonella and are subsequently a risk for pathogen transmission 
(Norris, et al., 1989a; Higgs, et al., 1993; Kelly, 1995; Davison, et al., 2006; 
Vanselow, et al., 2007a). Higgs et al. (1993), Kelly (1995), Makin (2011), and 
Vanselow et al., (2007a) all reported a low prevalence of Salmonella faecal shedding 
by sheep and cattle entering abattoirs and feedlots. This low prevalence of salmonella 
in the general ruminant population in Australia is supported by a slaughterhouse 
study by Vanselow et al. (2007a).  During the feedlot period, the prevalence of 
Salmonella excretion has been reported to rise from 0-2% to 26 - 97% within two 
weeks of entry (Higgs, et al., 1993; Richards, et al., 1993; Kelly, 1995; Makin, 2011). 
Faecal shedding contributes to environmental contamination, with infected animals 
shedding 106 to 1013 salmonellae per day in faeces (de Jong and Ekdahl, 1965; Nazer 
and Osborne, 1977; Mukkur, et al., 1987; Mukkur and Walker, 1992; Fecteau, et al., 
2003; Dueger, et al., 2003b; Mohler, et al., 2006; Mohler, et al., 2008).  
Environmental sampling conducted in sheep feedlots conducted by Makin et al 
(2011) demonstrated that loading and unloading yards and holding paddocks are 
frequently contaminated with salmonella.  Infection of sheep with S. Typhimurium, S. 
Bovismorbificans and S. Brandenburg via holding in contaminated yards from 3 days 
to 6 weeks has been documented in New Zealand (Robinson, 1967; Clark, et al., 
2004; Li, et al., 2005). Scenarios such as feeding hay on ground, mixing groups of 
sheep, weather changes, and overcrowding of pens can contribute to the 
contamination of yarding facilities with salmonellae and increase exposure to naive 
animals. 
Salmonella persistence and multiplication in the environment may contribute to 
outbreaks of salmonellosis in livestock that cannot be attributed to a recent source of 
infection. Salmonella has been reported to survive in manure-amended soils and  
manure slurries from 14 days to 7 years (Smith, et al., 1994; Baloda, et al., 2001; 
Huston, et al., 2002; Woodward, et al., 2002).  Holley et al. (2006) demonstrated that 
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an increasing inoculation dose of Salmonella increased  environmental survival time 
in manure-amended soils.  Laboratory experiments demonstrated that S. Dublin could 
survive in faeces for almost six years (Plym-Forshell and Ekesbo, 1996), while 
McLaren and Wray (1991) reported that Salmonella persisted in disinfected calf units 
for up to two years.   
The survival of Salmonella in the environment is dependent upon environmental 
factors such as temperature and moisture.  High soil moisture and low soil 
temperature increase Salmonella survival time, whilst freeze-thaw cycles significantly 
reduced Salmonella viability (Holley, et al., 2006).  You et al (2006) demonstrated 
that S. Newport was capable of a 4-fold increase in numbers following inoculation 
into a manure substrate over a 3 day period.  Under freezing conditions, Salmonella 
were shown to survive up to 7 years in ice cream (Wallace, 1938).  
v. Stress factors  
Transportation, high ambient temperatures, time of year, water deprivation, 
overcrowding, parturition, concurrent infections and sudden dietary changes are stress 
factors that have been known to contribute to Salmonella infections in ruminants 
(Counter and Gibson, 1980; Wray and Roeder, 1987; Giles, et al., 1989; Norris, et al., 
1989a; Richards, et al., 1989; Richards and Hyder, 1991; Higgs, et al., 1993; Kelly, 
1995; Evans and Davies, 1996; Losinger, et al., 1997; Higgs and Norris, 1999; 
Fossler, et al., 2005a; Fossler, et al., 2005b; Makin, 2011).  When immunity is 
compromised by concurrent disease, physiological or dietary stress, the infectious 
dose of salmonellae can be reduced to as few as several hundred organisms (Grau, et 
al., 1969).   
vi. New introductions and mixing of animals 
Poor quarantine procedures can contribute to the transmission of salmonellae (House 
and Smith, 1998; Anderson, et al., 2001; Warnick, et al., 2001; Huston, et al., 2002; 
Fossler, et al., 2005a; Fossler, et al., 2005b; Davison, et al., 2006; Vanselow, et al., 
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2007a).  Most Salmonella infections in livestock are sub-clinical (Anderson, et al., 
2001). Salmonella shedding by adult cattle can provide a source of infection for 
calves (Smith, et al., 1989; Nielsen, et al., 2004a). A single infected asymptomatic 
shedder may shed one million Salmonella per gram of faeces which can then 
contaminate the environment and other animals (Smith, et al., 1989; Huston, et al., 
2002).  Carrier animals usually appear normal and will go on to shed Salmonella in 
faeces and milk, maintaining a source of infection in the herd (Smith, et al., 1989; 
House, et al., 1993). 
Source of sheep has been identified as a risk factor for mortality associated with 
salmonellosis in the live sheep export industry (Norris and Richards, 1989; Norris, et 
al., 1989b; Richards, et al., 1989; Richards and Hyder, 1991; Higgs and Norris, 1999; 
Makin, 2011). The cause for this increased susceptibility for mortality has not been 
determined but is hypothesised to reflect differences in host immunity.  Pathogen 
exposure is inherent when livestock from various properties are introduced into 
feedlots and live export assembly depots.   
2.3.3. Pathogenesis of salmonellosis 
Faecal-oral transmission is the primary route of infection; other reported routes 
include the mucosa of the upper respiratory tract and conjunctiva. Following 
ingestion, Salmonella colonise the intestinal tract and invade the bowel through 
specialised cells in intestinal lymphoid tissue called M-cells, enterocytes (Holt, 2000; 
Wray and Davies, 2000; Hamada, et al., 2002; Reis, et al., 2003; Pabst, et al., 2005) 
and tonsilar lymphoid tissue (de Jong and Ekdahl, 1965; Gelberg, 2001). In the 
lymphoid tissue, Salmonella gain entry into mononuclear phagocytes and are rapidly 
disseminated throughout the body (Vazquez-Torres, et al., 1999; Worley, et al., 
2006). The capacity of Salmonella to infect calves via the tonsils was demonstrated 
by experimental challenge studies in oesophagectomised calves (de Jong and Ekdahl, 
1965).  In these calves Salmonella were isolated from tissues within 3 h of oral 
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challenge, indicating lymphoid involvement in systemic distribution. Other reported 
routes of infection include the mucosa of the upper respiratory tract through aerosol 
transmission and intranasal inoculation (Nazer and Osborne, 1977; Wathes, et al., 
1988; Hardman, et al., 1991).  The conjunctival route of infection has been utilised to 
experimentally infect sheep with S. Brandenburg (Li, et al., 2005). This route is 
suspected to be an important mode of transmission relevant to sheep passing through 
contaminated yards. 
The basic virulence mechanisms of Salmonella species include the ability to invade 
the intestinal mucosa, to multiply in the lymphoid tissues and to evade host defence 
systems leading to systemic disease. The diarrhoea associated with salmonellosis is 
largely believed to be mediated by the inflammatory response to infection. 
Salmonella Typhimurium requires a functional type III secretion system encoded by 
Salmonella pathogenicity islands 1 and 5 (SPI1 and SPI5) to cause diarrhoea (Wray 
and Roeder, 1987; Tsolis, et al., 1999; Zhang, et al., 2002; Zhang, et al., 2003). The 
main function of the invasion-associated type III secretion system is to translocate 
effector proteins into the cytosol of a host cell. The resulting cell death is associated 
with a pro-inflammatory response and influx of neutrophils into the intestinal mucosa 
(Wray and Davies, 2000). A positive correlation is observed between the severity of 
histopathological lesions detected in the ileal mucosa and the level of fluid secretion 
(Zhang, et al., 2002). Release of endotoxin, prostaglandins, and pro-inflammatory 
cytokines, e.g., IL-1 and TNF-α (Tizard, 2000) also promote vascular permeability 
and hypersecretion. Sloughing of the intestinal epithelial cells leads to acute 
haemorrhage, fibrin production, maldigestion and malabsorption (Wray and Davies, 
2000). The resulting hyperosmotic state within the lumen of the intestine draws fluid 
into the intestinal tract, contributing to a net loss of water, sodium, potassium, and 
bicarbonate. Mucosal damage also contributes to protein loss and a resulting 
hypoproteinemia.  
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The bovine host adapted S. Dublin and some strains of S. Typhimurium carry a 
plasmid that contains the Salmonella plasmid virulence (spv) gene.  The spv gene 
enhances virulence by promoting the intracellular survival of Salmonella in 
reticuloendothelial cells of liver and spleen, lymph nodes and macrophages (Nazer 
and Osborne, 1977; Counter and Gibson, 1980; Mee, 1995; Baumler, et al., 1998; 
Mastroeni, et al., 2000). Other non-adapted serovars may carry the virulence plasmid, 
however it is less common and the virulence attributes of these serovars are more 
variable. 
2.3.4. Pathology of salmonellosis 
Although pathologists associate salmonellosis with enteric lesions such as diphtheritic 
membranes, peracute infections often have few pathological findings (Tsolis, et al., 
1999; Wray and Davies, 2000; Gelberg, 2001). Lesions observed with peracute 
salmonellosis include pulmonary congestion and submucosal and subserosal petechial 
haemorrhages of multiple organs including the intestines and heart.  
Acute salmonellosis is typically characterised by diffuse catarrhal haemorrhagic 
enteritis with diffuse fibrinonecrotic ileotyphlocolitis (Tsolis, et al., 1999; McGavin 
and Carlton, 2001). The intestinal contents are watery, malodorous and may contain 
mucous or whole blood. Inflammation of the gall bladder is common and 
histopathological evidence of fibrinous cholecystitis is considered pathognomonic for 
acute enteric salmonellosis in calves. Enlargement, oedema and haemorrhage are 
commonly observed in the mesenteric lymph nodes (Tsolis, et al., 1999; McGavin 
and Carlton, 2001).  Abomasal mucosal erosions may be observed, particularly with 
S. Dublin infections. Microscopic thickening of the intestinal wall with macroscopic 
yellow-grey necrotic material overlying a red mucosal surface may be observed with 
chronic lesions (McGavin and Carlton, 2001).  However, in the case of carrier 
animals, especially cattle infected with S. Dublin, gross pathologies are rare (Wray 
and Davies, 2000; Nielsen, et al., 2004a).  
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2.3.5. Development of a carrier state 
Animals chronically infected with salmonella are sometimes referred to as 
“Salmonella Carriers” (Nielsen, et al., 2004a).  In the literature, prevalence of carrier 
animals within herds ranged from two to eight percent (House, et al., 1993; Losinger, 
et al., 1997; Huston, et al., 2002; Nielsen, et al., 2004a; Nielsen, et al., 2004b) with 
variations attributed to herd size, Salmonella serotype, population sampled and 
method of detection. Salmonella Dublin, which is host adapted to cattle, is more 
likely to produce a carrier state (Losinger, et al., 1997; Wray and Davies, 2000; 
Nielsen, et al., 2004a), however, multiple Salmonella serotypes have been reported to 
produce chronic infections in cattle (Losinger, et al., 1997; Wray and Davies, 2000; 
Wray and Linklater, 2000; Smith, 2002; Nielsen, et al., 2004a).  Carrier animals are 
capable of shedding high numbers of Salmonella either continuously or intermittently 
into faeces (Smith, et al., 1989; House, et al., 1993; Wray and Davies, 2000; Nielsen, 
et al., 2004b). It has been reported that stress may trigger the shedding of bacteria. 
Stressors include parturition and overcrowding (Counter and Gibson, 1980; Smith, et 
al., 1989; House, et al., 1993; Wray and Davies, 2000; Nielsen, et al., 2004b; Wray 
and Davies, 2004), transportation (Wray and Davies, 2000), introduction of new 
animals (Losinger, et al., 1997), and concurrent diseases such as bovine viral 
diarrhoea virus and parasitism (Wray and Roeder, 1987; Penny, et al., 1996). Carrier 
animals provide a reservoir for continuous infection of the herd and perpetuation of 
the carrier state within the herd. 
Chronic infections have experimentally been induced in lactating dairy cows through 
low dose intramammary inoculation of S. Dublin by Spier et al (1991).  House et al 
(1993) observed chronic S. Dublin infections in a group of heifers that were infected 
as neonates during a disease outbreak on a farm. Chronic infections in the calves were 
associated with dissemination of S. Dublin to mammary glands, lymph nodes and 
other tissues. Several studies have demonstrated that acutely infected animals that 
survive the initial Salmonella challenge are better able to clear the infection 
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completely and are less likely to become carriers (Wray and Davies, 2000; Wells, et 
al., 2001). 
2.4 Therapy  
Dehydration, electrolyte imbalances, endotoxaemia and bacteraemia are common 
clinical features of Salmonella infections in ruminants. The treatment of 
salmonellosis in calves is directed at replacing fluid and electrolyte losses, limiting 
inflammatory cascades through use of non-steroidal anti-inflammatory drugs, and the 
judicious use of antimicrobials (Smith, 2002; Fecteau, et al., 2003; Constable, 2004; 
McGuirk, 2008; Constable, 2009; Mohler and House, 2009). Bacteraemia is a 
common feature of salmonellosis in calves; prompt aggressive treatment with 
antimicrobials early in the infection is recommended (Wray and Davies, 2000; 
Constable, 2004; McGuirk, 2008; Constable, 2009; Fecteau, et al., 2009).  In sheep, 
the diversity of Salmonella serovars present during an outbreak and the potential for 
variable virulence between serovars requires the implementation of broad 
prophylactic strategies that are efficacious for all Salmonellae. There are no reports of 
controlled clinical trials evaluating treatment options for sheep.   
There is some controversy surrounding the use of antimicrobials to treat 
salmonellosis in livestock. Concern relates to selection for antimicrobial resistance 
and questions regarding its necessity and efficacy have been derived from experience 
in human medicine where invasive Salmonella infections are uncommon and routine 
use of antimicrobial therapy is not recommended. While there are a wide range of 
antimicrobials that include a gram negative spectrum that may appear appropriate for 
treatment of salmonellosis, most are not labelled for use in ruminants or not registered 
at a dose rate that provides therapeutic drug concentrations against all Salmonella 
strains.  In Australia, amoxycillin, amoxyclavulonic acid, trimethoprim-sulphadoxine 
and neomycin sulphate are  registered for use in the treatment of salmonellosis in 
ruminants (APVMA, 2010).   Conversely in the US, there are no antimicrobials 
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specifically labelled for the treatment of salmonellosis in ruminants. 
Antimicrobial resistance is common in virulent Salmonella serotypes (CDC, 1996, 
2002; Hoelzer, et al., 2010). Increased virulence has been observed in some 
antimicrobial resistant strains of Salmonella (Glynn, et al., 1998; Davis, et al., 2007; 
Zhao, et al., 2007; Adhikari, et al., 2009). This is reflected by the finding that calves 
infected by S. Typhimurium DT104 are 13 times more likely to die than calves 
infected with antibiotic sensitive strains of S. Typhimurium (Evans and Davies, 
1996). The spread of resistance genes by transformation, transduction and 
conjugations is well documented in Salmonella species and the Enterobacteriaceae 
family (Cardenas and Clements, 1993; Wray and Davies, 2000; Bueno, et al., 2009). 
Multi-drug resistant strains of Salmonella are frequently implicated in disease 
outbreaks in calves and occasionally people.   
Antimicrobial selection ideally should be based on the results of susceptibility testing 
utilising a Salmonella isolate recovered from the tissues of infected animals. Broad 
spectrum antimicrobials are usually employed pending the availability of 
susceptibility test results (Fecteau, et al., 2003; McGuirk and Peek, 2003; Bell, et al., 
2004; Constable, 2004; McGuirk, 2008; Constable, 2009). It has been reported in the 
literature that Salmonella show variable resistance to ampicillin, amoxycillin, 
amoxyclavulonic acid, ceftiofur, florphenicol, neomycin, sulphonamides, tetracycline, 
and trimethoprim-sulphonamides and resistance to penicillin, erythromycin, and 
tylosin.  In a recent Australian study, no resistance to amikacin, amoxicillin-
clavulanic acid and nalidixic acid was observed in Salmonella isolated from 
diarrhoeic calves and only 14% of isolates exhibited multiple resistance patterns 
(Izzo, et al., 2011) when compared to 26% from a US study (Berge, et al., 2006).  
Additionally,  overseas studies have demonstrated that Salmonella isolates from 
healthy animals are susceptible to most antimicrobials whereas the isolates obtained 
from clinically affected animals have higher levels of antimicrobial resistance (Blau, 
et al., 2005; Lundin, et al., 2008). 
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Because Salmonella are facultative intracellular pathogens, selecting an antimicrobial 
with good tissue penetration and the ability to attain intracellular therapeutic drug 
concentrations within macrophages is desirable. A number of experimental studies 
have evaluated the efficacy of antimicrobial agents in the treatment of salmonellosis 
in cattle. In a comparative experimental trial, amoxycillin and trimethoprim 
sulphoxidine were shown to have equivalent efficacy in the treatment of calves with 
Salmonella infections via oral (PO), intravenous (IV) and intramuscular (IM) routes 
when administered at doses based on minimal inhibitory concentration (MIC) and 
peak blood levels (Groothuis and van Miert, 1987). Similarly in an experimental 
challenge study, extra-label use of ceftiofur at 5 mg/Kg IM was shown to attenuate 
the severity of clinical disease and reduce faecal shedding of Salmonella (Fecteau, et 
al., 2003).  It is important to note that beta lactams, ceftiofur and amoxycillin, have 
poor intracellular activity (Tulkens, 1991; Rang, et al., 2001a).  Prudent use of 
antimicrobial drugs is recommended with an emphasis on establishing a herd 
diagnosis, susceptibility testing of invasive Salmonella serotypes, and using the 
narrowest spectrum of antibiotic indicated by the susceptibility data (Helmuth, 2000; 
Constable, 2004, 2009). 
Non-steroidal anti-inflammatory drugs (NSAIDs) have been utilised to attenuate 
endotoxin-induced inflammatory cascades. NSAIDs inhibit endotoxin-induced 
inflammation by blocking the arachidonate cyclo-oxygenase pathway reducing the 
formation of thromboxanes and prostaglandin (Rang, et al., 2001b; MacKay, 2002; 
Constable, 2009). Analgesic and antipyretic effects may persist after serum 
concentrations have dropped below detection due to extensive tissue binding (George, 
2003).  The therapeutic efficacy of NSAIDs in the treatment of salmonellosis in 
calves has not been documented in the literature. Extralabel use of the NSAID 
flunixin meglumine at 2.2 mg/kg IV once a day to 0.25 -0.33 mg/Kg three times a day 
for up to 3 days or meloxicam at 0.5 mg/kg IV/SC for a maximum of three days, has 
been anecdotally reported in the literature to improve outcomes and reduce 
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morbidities in calves and cows with non-specific diarrhoea (Rantala, et al., 2002; 
Barnett, et al., 2003; Todd, et al., 2007; Constable, 2009; Fecteau, et al., 2009). 
Precautions should be taken when administering NSAIDs to dehydrated calves as 
hypotension and reduced renal perfusion increase the risk of toxicity (George, 2003). 
Therefore, implementation of appropriate fluid therapy may reduce adverse 
consequences often associated with the administration of NSAIDs to dehydrated 
patients. In Australia, meloxicam, flunixin meglumine, ketoprofen and tolfenamic 
acid have been approved for use in cattle with meat withholding periods of 8, 7, 4 and 
7 days, respectively (MIMS, 2007; Smith, et al., 2008).   
2.5 Salmonella Vaccines and Vaccination 
Vaccination provides a relatively simple means of enhancing pathogen-specific 
immunity. In regard to salmonellae, historically the efficacy of vaccination has been 
limited. There are three general classes of Salmonella vaccines:  killed whole cell 
(bacterin), bacterial fractions (subunit), and attenuated modified live (MLV).   
While the use of Salmonella vaccines is common, most of the products on the market 
are bacterins of limited efficacy.  The potential benefit of attenuated live Salmonella 
vaccines has been recognised for many years and a small number are available 
commercially (Curtiss, et al., 1993).  
2.5.1. Bacterin vaccines 
Bacterin Salmonella vaccines are the most widely used vaccines in cattle. Bacterins 
are killed Salmonella whole cells, components and by-products. This ensures that 
there is no reverting to virulence and no risk of environmental contamination 
(Griffen, et al., 2002). Bacterins are mixed with adjuvants which enhance the immune 
response by increasing the stability of the antigens and targeting the antigen to 
antigen processing cells (Mastroeni, et al., 2000; Griffen, et al., 2002). There are 
conflicting reports regarding the efficacy of Salmonella bacterins. Experimental 
studies in cattle have produced equivocal results (Curtiss, et al., 1993; House, et al., 
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2001a; Anderson, 2005). The perceived limitations of killed Salmonella vaccines are 
the failure of these products to present antigens expressed in vivo, induce cellular 
immunity, and induce mucosal immunity (Robertsson, et al., 1983; Curtiss, et al., 
1993; Mastroeni, et al., 2000). 
Under field conditions neonatal exposure often occurs during the first few days of 
life, limiting the opportunity to stimulate acquired immunity in calves (House, et al., 
2001a). In the US, it is reported that up to 75% of calves are exposed to pathogens 
within their first 48 h of life which is an insufficient amount of time to induce 
protective acquired immunity using bacterins (Griffen, et al., 2002; Dueger, et al., 
2003b). Additionally, research  has demonstrated that neonatal calves have a dramatic 
decrease in systemic immune responses following birth, due to suppression of 
lymphocyte proliferation and diminished cytokine production (IFN-γ) (Rajaraman, et 
al., 1997; Cortese, 2009) which can further reduce response to vaccination as well as 
lead to increased susceptibility. Passive immunity acquired from maternal Salmonella 
bacterin vaccination and colostral transfer is limited, however partial protection has 
been reported in some experimental challenge trials (Jones, et al., 1988; Mortola, et 
al., 1992; Cortese, 2009).   
Adverse reactions in the form of anaphylactic reactions are occasionally reported in 
ruminants vaccinated with Salmonella bacterins (Mamak and Aytekin, 2009). The 
cause of these reactions is unknown but has been suggested to be associated with 
lipopolysaccharide (LPS) content of these products (Mastroeni, et al., 1994; Mamak 
and Aytekin, 2009).  While it has been demonstrated that transient tolerance to LPS 
can be induced with administration of sub-lethal doses LPS (Gupta and Reed, 1971; 
Fahmi and Chaby, 1993; Randow, et al., 1995), hypersensitivity reactions to LPS are 
more common (Hormaeche, et al., 1981; Mukkur, et al., 1987; Matsuura and 
Galanos, 1990; Mukkur, et al., 1991a; Mukkur, et al., 1991b; Mukkur and Walker, 
1992; Brennan, et al., 1994; Mastroeni, et al., 1994; Kweon, et al., 1998).   Generally, 
Salmonella vaccines are used in herds where it is likely that some animals may have 
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been recently infected with Salmonella. Following sub-lethal Salmonella infections, 
the sensitivity of animals to the lethal activity of LPS increases exponentially 
(Matsuura and Galanos, 1990). Other disadvantages of bacterin vaccines include 
injection site reactions and the requirement for multiple injections to induce adequate 
protection (Hjerpe, 1990; Griffen, et al., 2002).   
Despite their limitations, bacterins are still the most widely available and accepted 
vaccines. In Australia, a mixed bacterin vaccine, BOVILIS S Inactivated Salmonella 
Vaccine (Coopers Animal Health, AU) is registered for use in adult cattle (MIMS, 
2007; APVMA, 2010). There are currently no registered Salmonella bacterin vaccines 
for use in calves or sheep.  
2.5.2. Subunit vaccines 
Subunit vaccines are composed of bacterial fractions, surface antigens or flagella. 
These vaccines consist of a single protein that is purified using either conventional 
methods or recombinant DNA technology.  These vaccines are designed to isolate 
Salmonella antigens that will elicit an immune response without inducing adverse 
reactions or immunosuppression (Griffen, et al., 2002). Attempts to immunise mice, 
sheep and cattle with subunit vaccines have resulted in the induction of moderate 
immunity in innately resistant animals or against moderately virulent organisms 
(Mastroeni, et al., 2000; Dougan, et al., 2011). 
Salmonella Newport Bacterial Extract vaccine (AgriLabs Inc., USA), a relatively 
new subunit cattle vaccine composed of highly purified extracts of specialised 
bacterial proteins known as siderophore receptors and porins (SRP), is currently 
available in the US (Emery, et al., 2002; Anderson, 2005). This vaccine works on the 
absolute requirement for iron in order for the bacteria to survive. Identification of iron 
capturing mechanisms (transferrin-binding proteins) allowed development of vaccine 
candidates (Babiuk, 2002). These proteins are common to all strains of Salmonella 
and offer the potential to induce immunity to homologous and heterologous 
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Salmonella serovars. Field trials with Salmonella Newport SRP have been conducted 
on healthy beef and dairy cattle.   In beef cattle, SRP had no effect on faecal 
prevalence of Salmonella or health or performance (Dodd, et al., 2011).   However, 
dairy cattle administered Salmonella Newport SRP proteins prior to parturition 
demonstrated increased milk production, even in cattle without detectable shedding of 
Salmonella spp. or clinical signs of salmonellosis (Hermesch, et al., 2008).  No 
controlled clinical trials documenting the efficacy of this product at preventing 
salmonellosis in cattle have been reported in the literature.   
2.5.3. Attenuated or modified live vaccines  
The observation that calves exposed to low doses of virulent Salmonella were 
protected against subsequent high dose virulent challenge suggested that prevention 
of salmonellosis via vaccination with live vaccines was possible (Curtiss, et al., 1993; 
Barrow and Wallis, 2000; Mastroeni, et al., 2000). Modified live vaccines induce a 
broad immune response via stimulation of cellular, humoral and mucosal immunity 
similar to natural infection (Mastroeni, et al., 2000; Villarreal-Ramos, et al., 2000a). 
There are a number of naturally occurring and genetically manipulated attenuated 
Salmonella strains that have been used to immunise cattle against salmonellosis. The 
naturally occurring rough mutants were the first modified live Salmonella vaccines to 
be used in cattle (Mastroeni, et al., 2000). Although live rough mutants induce 
protective immunity, their stability is questionable and genetically altered attenuated 
strains have become more popular. 
The most widely tested genetically altered Salmonella mutant vaccines in cattle are 
auxotrophic and contain mutations that interfere with regulating genes needed for 
virulence.  Villarreal-Ramos et al. (1998) showed that SC administration of an 
avirulent Salmonella mutant induced protective immunity when compared to the 
more traditional oral route. It is generally accepted that the ability to deliver the 
27 
attenuated vaccine via the natural route of infection, orally in the case of Salmonella, 
and limited replication in the host, induces a longer duration of immunity. 
Table 2.1.  Genes Targeted in the Development of Attenuated Salmonella Vaccines 
Genes Target For 
Mutation 
Gene Function 
galE Conversion of UDP-galactose to UDP- Glucose 
aro Biosynthesis of PABA, DHB and aromatic amino acids 
pur Biosynthesis of adenine 
htrA Protection against heat stress and oxidative stress 
cya/crp Biosynthesis of cAMP and expression of AMP receptor 
PhoP/PhoQ Regulation of a number of virulence genes 
ompR/ompC/ompF Regulation and biosynthesis of outer membrane proteins 
dam Expression of DNA adenine methylase 
  
A list of the genes that have been targeted in the construction of avirulent and/or 
immunogenic Salmonella vaccines is presented in Error! Reference source not 
found. (adapted from Curtiss et al (1993) and Mastroeni et al (2000)). Vaccine 
constructs have included aromatic amino acid dependent (aro) (Smith, et al., 1984; 
Begg, et al., 1990; Mukkur, et al., 1991a; Mukkur and Walker, 1992; Smith, et al., 
1993; Mukkur, et al., 1995; Mukkur, et al., 1998; Villarreal-Ramos, et al., 1998; 
George, 2003),  htrA (Villarreal-Ramos, et al., 2000a), purE (Villarreal-Ramos, et al., 
2000a) and galE mutants (Wray, et al., 1977; Jelinek, et al., 1982a; Nnalue and 
Stocker, 1986; Wray and McLaren, 1987).  These vaccines are generally effective at 
inducing acquired protective immunity against homologous Salmonella challenge but 
have limited protective efficacy against heterologous Salmonella serogroups. 
Modified live Salmonella are capable of reducing faecal shedding of salmonellae and 
limiting the severity of disease in ruminants (Cameron and Fuls, 1976; Meyer, 1980; 
Robertsson, et al., 1983; Wray and McLaren, 1987; Jones, et al., 1991; Segall and 
Lindberg, 1993; Smith, et al., 1993; Smith, et al., 1994). 
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Attenuated Salmonella vaccines currently on the market provide homologous but not 
heterologous protection. An aro auxotroph S. Dublin vaccine (Entervene-D, Fort 
Dodge Animal Health, US) is available in the United States for the control of S. 
Dublin infections in calves and there is an aroA Salmonella Typhimurium vaccine 
(Vaxsafe® ST Vaccine, Bioproperties Pty Ltd, AU) available for use in poultry. 
Experimental studies with aro Salmonella vaccines in calves have demonstrated 
protective immunity to homologous and heterologous Salmonella when calves were 
challenged within 3 weeks of vaccination (Rankin, et al., 1966; Smith, et al., 1984). 
The heterologous protection is afforded by transitory T-cell independent non-specific 
protection which disappears about 1 month after immunisation, following clearance 
of the organisms from the reticuloendothelial system.  Thereafter, protection is 
limited to homologous challenge with recall of immunity presumably involving 
specific antigen recognition (Collins, 1974; Hormaeche, et al., 1991). 
It has been demonstrated that S. Typhimurium containing mutations in the dam gene 
which prevents DNA adenine methylase expression are avirulent, yet confer cross-
protective immunity to multiple Salmonella strains when used as MLV in murine 
(Garcia-Del Portillo, et al., 1999; Heithoff, et al., 1999; Heithoff, et al., 2001; 
Heithoff, et al., 2008a) and avian models of typhoid fever (Dueger, et al., 2001, 
2003a).  Additionally, S. Typhimurium dam vaccine has elicited both early 
(competitive exclusion) and late onset (adaptive immune) immunity in the protection 
of calves from virulent homologous S. Typhimurium challenge (Dueger, et al., 
2003b). The capacity of S. Typhimurium dam vaccine to confer cross-protective 
immunity in calves has been demonstrated using a virulent heterologous S. Dublin 
challenge (Mohler, et al., 2006).  These data are promising, as salmonellosis in 
livestock is associated with a diverse array of Salmonella serotypes (Kelly, 1995; 
Huston, et al., 2002; Fossler, et al., 2005b; Cummings, et al., 2009; Cummings, et al., 
2010) which necessitates cross protective efficacy which is lacking in current vaccine 
candidates. 
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Another potential benefit of the S. Typhimurium dam vaccine is that, in contrast to 
aroA Salmonella vaccines, dam mutant vaccines do not induce a transient state of 
immunosuppression following antigen exposure (Heithoff, et al., 2001). Vaccine-
induced immunosuppression is particularly undesirable from the standpoint of 
livestock immunisation, as producers often administer multiple vaccines 
simultaneously. It is important that one vaccine does not limit the immune response 
to concurrently administered vaccines. Immunosuppression is also undesirable from 
the standpoint of increasing susceptibility to disease, which is a potential issue for 
animals vaccinated upon entry to a feedlot.       
The stability of attenuations is of primary importance to avoid reversion to virulence 
and brings about issues of safety and efficacy (Nnalue and Stocker, 1986; Miller and 
Mekalanos, 1990; Curtiss, et al., 1993; Mastroeni, et al., 2000; Bueno, et al., 2009).  
Additionally, some mutations demonstrated to be avirulent in one species may be 
virulent in another.  For example, htrA and purE S. Typhimurium mutants, 
demonstrated to be avirulent in mice, were highly virulent in calves (Villarreal-
Ramos, et al., 2000a). Work to develop genotypically stable vaccines with two or 
three irreversible attenuating deletions to improve stability and increase 
immunogenicity is under development.  However, some combinations could prove to 
be too effective at attenuating a vaccine and reduce the ability of the vaccine to 
persist in the tissues and to induce protective immunity (Wilson, 1967; Curtiss, et al., 
1993; Hone, et al., 1999; Mastroeni, et al., 2000; Babiuk, 2002; Anderson, 2005; 
Bueno, et al., 2009).   
2.5.4. Vaccine immunology 
The field of immunology is one of active research in veterinary and human medicine.  
New and advanced methods for assessing immune function using cytokine 
expression, antibodies and lymphocytes are being developed.  Much of the research 
on immune mechanisms of Salmonella infection has been conducted in the murine 
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typhoid model (Tam, et al., 2008; Dougan, et al., 2011).  Murine models are very 
useful in the study of immune mechanisms; unfortunately, observations from these 
models have not always correlated with other species, including humans (Tam, et al., 
2008; Dougan, et al., 2011). 
Humoral and cellular responses of mice to infection with Salmonella have been 
characterised by the stage of infection.  The initial stage occurs when Salmonella 
invade the host tissues and extracellular organisms are targeted by antibody and 
complement, while those Salmonella that move into the intracellular space are 
removed by phagocytic cells (VanCott, et al., 1998; Mastroeni, et al., 2000; Dougan, 
et al., 2011).  Route of infection, host species/strain and virulence of the infective 
strain all influence immune responses to a Salmonella challenge.  The second phase 
of infection begins once the Salmonella have evaded the innate and humoral immune 
responses and become intracellular.  Natural resistance-associated macrophage 
proteins (Nramp) and cytokines (IFN-γ, TNF-α, IL-1, IL-6, IL-12 and IL-18) play a 
critical role in controlling infection and preventing proliferation.  Failure of the host 
to attenuate proliferation is associated with death. In surviving animals the final stage 
of infection involves clearance of the infection from the tissues via CD4+ T-cells, 
CD8+ T-cells, cytokines, IFN-γ and TNF-α, and to a lesser degree B cells and 
antibody production. Measurements of different components of the immune system to 
salmonella antigens have failed to predict the efficacy of Salmonella vaccines (Stabel, 
et al., 1993; Kweon, et al., 1998; Elhofy and Bost, 1999a; Sirard, et al., 1999; Elhofy, 
et al., 2000b; Holt, 2000; Mastroeni, et al., 2000; Tam, et al., 2008; Dougan, et al., 
2011). 
In ruminant models of salmonellosis, antibody response has been used to measure the 
immune response. High levels of Salmonella specific-serum IgM, IgG and IgA as 
well as some intestinal-specific IgA antibodies are produced in response to 
vaccination or natural challenge with salmonellae (Wijburg, et al., 2006). Variable 
humoral immune responses to LPS, LPS fragments, somatic O antigens (cell wall), 
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porins, surface antigens (Vi antigen) and flagellar H antigens have been observed in 
response to infections with different salmonella serovars (Mukkur, et al., 1987; 
Smith, et al., 1989; Begg, et al., 1990; Mukkur and Walker, 1992; House, et al., 
1993; Berthon, et al., 1994; Brennan, et al., 1994; Mukkur, et al., 1995).  There are 
67 known somatic O antigens.  Each serogroup carries one specific O antigen and 
several non-specific O antigens.  Salmonella serology in cattle has demonstrated that 
antibody response to LPS antigens are highly specific to somatic O antigens (Smith, 
et al., 1989; House, et al., 1993; Smith, et al., 1995; House, et al., 2001b; House, et 
al., 2001c).  However, antibody responses do not reliably predict protective 
immunity.  
In all animal models, route of infection has an effect on the type of response elicited 
and intensity of the response.  Oral administration of salmonellae vaccines are 
associated with lower serum and intestinal antibody responses when compared to IM 
and SC routes of vaccination (Lascelles, et al., 1988; Begg, et al., 1990; Mukkur, et 
al., 1991a; Mukkur and Walker, 1992).   In one study, oral administration of an aroA 
Salmonella mutant showed absence of vaccine specific immune response in sheep 
when compared to mice but ultimately provided significant protection from virulent 
challenge in both species (Brennan, et al., 1994).  Both Brennan et al (1994) and 
Lascelles et al (1988) observed that oral vaccination with an aroA mutant elicited 
protective immunity in sheep that was not attributable to local intestinal IgA 
production. Further research by Mukkur et al (1995) in sheep demonstrated only 
minimal contribution of both mucosal and systemic IgA antibodies following 
vaccination with an aroA mutant via IM or oral routes of administration. This finding 
indicates that secretory and circulatory IgA can contribute to the control of 
Salmonella infection but do not have major roles in providing protective immunity 
against salmonellae challenge (Wijburg, et al., 2006; Dougan, et al., 2011). 
Delayed type hypersensitivity reactions (DTH) have been used to assess cellular 
immune responses to Salmonella vaccination.  DTH is typically the expression of T-
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cell mediated immunity (Mastroeni, et al., 2000).  DTH responses to proteins, porins, 
LPS and Vi surface antigens have been reported in mice (Hormaeche, et al., 1981; 
Mukkur, et al., 1987; Cao, et al., 1992; Mukkur and Walker, 1992; Brennan, et al., 
1994), sheep (Mukkur, et al., 1987; Begg, et al., 1990; Mukkur and Walker, 1992; 
Brennan, et al., 1994; Mukkur, et al., 1995), calves (Robertsson, et al., 1982; Segall 
and Lindberg, 1993) and pigs (Stabel, et al., 1993).  In one study, DHT persisted in 
sheep following IM vaccination with an  
aroA mutant for a period of 6 months,` but offered limited protective immunity 
against virulent challenge at 6 and 12 m post vaccination (Mukkur and Walker, 
1992).  DTH responses have not been found to differentiate between immune and 
susceptible (unsensitised) individuals or predict vaccine efficacy. 
Previous studies indicate there are numerous methods available to measure the 
immune response to Salmonella and numerous antigens that can be investigated.  The 
results of these investigations have failed to identify the antigenic responses that 
equate with a protective immune response.  As such, vaccination challenge 
experiments are required to assess vaccine efficacy.  The body of work presented in 
this research was directed at developing an effective Salmonella vaccine for use in 
livestock and focused on studies that would provide a robust measure of efficacy of 
the dam S. Typhimurium vaccine in neonate and adult ruminant models of 
salmonellosis.       
2.6 Study Objectives 
This thesis presents research that is an extension of a project to develop an effective 
salmonella vaccine to prevent disease in livestock and promote human food safety 
initiated by Associate Professor John K. House and Professor Michael J. Mahan in 
2000.  The research was funded by the United States Department of Agriculture 
(USDA). Previous work conducted by the research team has demonstrated that S. 
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Typhimurium dam vaccine protects mice, chickens and calves against heterologous 
and homologous salmonella challenges. The objectives of this research were: 
 To develop models of neonatal salmonellosis using clinically relevant 
multidrug resistant Salmonella isolates that are heterologous to the S. 
Typhimurium dam vaccine. 
 To further evaluate the cross protective efficacy of the S. Typhimurium dam 
vaccine in neonatal calves. 
 To develop models of salmonellosis in adult sheep and to establish methods for 
evaluating clinical outcomes of ovine salmonellosis using clinically relevant 
Salmonella isolates. 
 To investigate the feasibility of in-water vaccine delivery as an option for 
inexpensively vaccinating livestock populations.  
 To evaluate the safety and efficacy of the S. Typhimurium dam vaccine when 
administered in drinking water to adult ruminants.  
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CHAPTER 3. GENERAL METHODS 
3.1 Introduction 
This chapter describes the general methods that were employed during the conduct of 
the project. Microbiological techniques used in the culture, growth, identification and 
re-isolation of the vaccine and challenge bacteria were core to each experiment. 
Animal husbandry and monitoring were critical to the overall success of the project. 
The protocols for cleaning, feeding, monitoring, handling and housing of animals 
needed to meet the requirements of the Animal Research Act 1985 (NHMRC, 2004) 
for the purpose of animal welfare and ethics; the Office of the Gene Technology 
Regulator (OGTR) to comply with the Gene Technology Act 2000, and section 46 A 
of the Quarantine Act 1908, AQIS Quarantined Approved Premises (QAP) 
(AQIS/DAFF, 2010) for the purpose of the importation and use of a quarantine 
approved biological. Protocols were established early in the project to facilitate 
training of support and animal care staff to ensure compliance with regulatory 
agencies and to ensure accurate data collection.  
3.2 Bacterial strains 
3.2.1. Vaccine strain 
Immunisations were carried out with Salmonella Typhimurium UK-1 dam- vaccine 
strain MT2313 (vaccine; S. Typhimurium dam) (Dueger, et al., 2001; Heithoff, et al., 
2001; Dueger, et al., 2003a, 2003b; Mohler, et al., 2006) which contained an 
insertion element, dam102::Mud-Cm, encoding chloramphenicol [Cmr] resistance in 
strain UK-1 [obtained from Roy Curtiss III (Hassan and Curtiss, 1994a)]. The vaccine 
was imported into Australia following approval by AQIS (Import Permit no:  
200203550) and maintained at EMAI under AQIS Quarantine. 
3.2.2. Challenge agents  
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i. Neonatal model of heterologous salmonellosis 
The challenge agent selected for the neonate model of salmonellosis was a clinically 
relevant Salmonella enterica serovar Newport (S. Newport 03-721) a multi-drug 
antimicrobial resistant strain (ampicillin, ceftiofur, chloramphenicol, clindamycin, 
oxytetracycline, spectinomycin, sulphonamides, tiamulin, tilmicosin, 
trimethoprim/sulphamethoxazole, tylosin)  isolated from a dairy cow with a history of 
chronic diarrhoea. The unique resistance to ceftiofur allowed this organism to be 
easily isolated and identified following administration to animals. The organism was 
obtained from Ms Jo Ann J. Yee from the Microbiology Laboratory at the Veterinary 
Medical Teaching Hospital, at University of California, Davis. The S. Newport 03-
721 was imported into Australia following approval by AQIS (Import Permit: 
200519069) and maintained at EMAI under AQIS Quarantine. 
The S. Newport 03-721 was passaged through a calf via oral administration at 1 x 
1011 CFU. The resulting challenge strain, S. Newport 03-721 -SP, was recovered from 
the spleen of the infected calf at 72 h post-ingestion. The isolate was identified by 
biochemical testing, antimicrobial susceptibility, and agglutination with serogroup C2 
specific antisera as described in sections 3.3.3 to 3.3.6 
ii. Ovine models of homologous salmonellosis 
The challenge agent selected for the ovine homologous model of salmonellosis was a 
Salmonella enterica serovar Typhimurium (S. Typhimurium 06-131) multi-drug 
antimicrobial resistant strain (apramycin, erythromycin, neomycin, novobiocin, 
sulphonamides, streptomycin) isolated from the tissues of a dead sheep during a 
mortality investigation at a feedlot in Western Australian by Dr John K. House from 
the Livestock Teaching and Research Unit at the University of Sydney, Camden, 
NSW in 2006. The unique resistance to neomycin sulphate allowed this organism to 
be easily isolated and differentiated from the vaccine following administration to 
animals. The virulence of the isolate was determined by Professor Mike Mahan and 
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Dr Doug Heithoff at the University of California Santa Barbara using a competitive 
index assay as described in Heithoff et al (2008b). Competitive index (CI) scores are 
based on the results of oral and intraperitoneal lethal dose50 (LD50) testing in mice 
(Conner, et al., 1998) and identification of the spv genes (Jones, et al., 1982; Gulig, et 
al., 1992), as well as genes encoding the spvB actin cytotoxin, required for systemic 
survival (Gulig, 1990; Matsui, et al., 2001), and the pef fimbriae implicated in 
adherence to the murine intestinal epithelium (Baumler, et al., 1996).   The CI score 
of an isolate is useful in predicting virulence of an isolate when compared to the 
index strain, S. Typhimurium UK-1 wild type.  It was determined that this isolate 
carried the spvB and pefA virulence genes and that it was virulent in a mouse 
inoculation assay (Heithoff, et al., 2008b) with a competitive index score of 0.545.  
The isolate was identified by biochemical testing, antimicrobial susceptibility, and 
agglutination with serogroup B specific antisera as described in Sections 3.3.3 to 
3.3.6. 
iii. Ovine models of heterologous salmonellosis 
The challenge agent selected for the ovine heterologous model of salmonellosis was a 
Salmonella enterica serovar Bovismorbificans (SMB 06-225) a multi-drug 
antimicrobial resistant strain (apramycin, erythromycin, neomycin, novobiocin, 
sulphonamides, streptomycin) isolated from the tissues of a dead sheep during a 
mortality investigation at a feedlot in Western Australian by Dr John K House from 
the Livestock Teaching and Research Unit at the University of Sydney, Camden, 
NSW in 2006. The unique resistance to neomycin sulphate allowed this organism to 
be easily isolated and differentiated from the vaccine following administration to 
animals. This isolate also carries the spvB and pefA virulence genes and was 
determined to be virulent in mouse inoculation studies (Heithoff, et al., 2008b) with a 
competitive index score of 2.716. The isolate was identified by biochemical testing, 
antimicrobial susceptibility, and agglutination with serogroup C2 specific antisera as 
described in Sections 3.3.3 to 3.3.6. 
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3.3 Microbiology  
3.3.1. Culture and growth of bacteria 
i. Storage of Salmonella isolates 
A frozen culture bank was established for the vaccine and each of the challenge 
strains in order to preserve isolates for use in future experimental procedures and to 
prevent genetic drift such as loss of virulence and resistance.  Colour coded Protect 
Bacterial Preservers (Technical Service Consultants Ltd, Lancashire, UK) were 
employed to cryopreserve the isolates. 
Several colonies from a culture plate containing the isolate were inoculated into 
sterile saline to form a thick suspension. One to two drops of the suspension were 
deposited aseptically into a Protect™ cryovial labelled with the isolate name, date 
prepared and contact details. Vials were closed and inverted several times to ensure 
uniform contact of the bacteria with the Protect cryopreservation beads and 
Protect cryoprotectant fluid. Prior to placement into a -70°C freezer or liquid 
nitrogen tank located in the Physical Containment Level 2 (PC2)/Quarantine 
Containment (QC2) Laboratories in Block 3 at EMAI, excess cryoprotectant solution 
was aseptically removed from each vial. Multiple vials were prepared for each isolate 
and stored in multiple locations to ensure culture bank security in the event of 
equipment malfunction or power failure. Quality control was performed on each 
cryopreserved isolate to confirm viability and purity of each isolate following 
procedures outlined in Section 3.3. 
ii. Preparation of bacterial culture plates 
A cryopreservation bead coated with isolate was aseptically removed from the 
appropriately labelled cryopreservation vial and allowed to thaw on a Luria agar (LA) 
(OXOID Ltd, AU) plate containing a selective antibiotic appropriate for re-isolation 
of the strain. Care was taken to ensure that the beads remaining within the 
cryopreservation vial did not thaw and were returned to the freezer or liquid nitrogen 
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as soon as samples were collected. The LA plate was labelled with the name of the 
isolate, date revived and expiration date. Once thawed, the sample was streaked 
across the LA plate for single colonies and incubated aerobically at 37°C overnight. 
Following incubation, the bacterial culture plate was stored at 4-8°C for no more than 
14 d. Quality control was performed on each revived isolate to confirm identity and 
purity. The procedures outlined in Section 3.3 were performed on the revived isolates 
prior to initiation of experimental procedures to confirm identity. 
iii. Bacteria solution preparation  
Vaccine and challenge bacterial strains were grown following procedures outlined in 
Appendix I:  Bacteria Growth and Dose Preparation Worksheet.  Vaccine and 
challenge dose titres were confirmed via serial dilutions plated onto LA plates 
containing appropriate antibiotics; colony serotype was confirmed via antisera 
agglutination (described in Section 3.3.4.) and biochemical testing (described in 
Section 3.3.5.). 
3.3.2. Salmonella selective media 
Salmonella enrichment and selective media were used to culture, isolate and identify 
Salmonella enterica subspecies enterica. The media were applied according to the 
Australian National Association of Testing Authorities (NATA) and Association of 
Analytical Communities (AOAC) guidelines (MacFaddin, 2000; Waltman, 2000; 
AOAC, 2005)  
i. Xylose lysine desoxycholate agar 
Xylose lysine desoxycholate agar (XLD) is a Salmonella selective and differential 
plating media. Sodium desoxycholate is the selective agent within the agar while the 
combination of sugars (xylose, lactose, and sucrose), the amino acid lysine and an 
H2S indicator system are used to identify Salmonella (Waltman, 2000). On XLD, 
Salmonella colonies are pink to red with black centres, which indicate H2S 
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production. A colour change in the plating media from orange-red to hot pink 
indicates fermentation of xylose, an alkaline reaction that is typical of Salmonella. 
To enhance the selectivity of the plates further, antibiotics were added to the XLD 
plating media. Chloramphenicol, at 20 μg/mL, was added to the XLD media (XLD-
CHL) to select for the vaccine strain. When selecting for the S. Newport 03-721 
challenge agent for the calf trials, ceftiofur sodium was added to XLD media at 8 
μg/mL (XLD-XNL). When selecting for the S. Typhimurium 06-131 and S. 
Bovismorbificans 06-225 challenge agents for the sheep trials, neomycin sulphate was 
added to XLD media at 10 μg/mL (XLD-NEO). 
Samples suspected of containing Salmonella were inoculated onto appropriate XLD 
agar plates and incubated overnight at 37°C. After overnight incubation, plates were 
examined for the presence of ‘black’ colonies with ‘pink rings’. Further biochemical 
testing was conducted on all suspect colonies as false positive results could be elicited 
by Proteus spp. and Citrobacter spp. (Waltman, 2000) and occasionally E. coli. 
ii. Mannitol selenite enrichment media 
Mannitol selenite (MSB) is a selective enrichment broth that uses sodium biselenite 
and mannitol to promote Salmonella growth and inhibit other enteric pathogens like 
E. coli. MSB utilises the ability of bacteria to reduce selenite to create an alkaline 
environment and the ability of Salmonella to utilise mannitol as a carbohydrate source 
(Waltman, 2000). 
Samples suspected of containing Salmonella were inoculated into vials containing 
MSB and incubated aerobically overnight at 37°C. After overnight incubation, 
samples were streaked onto XLD agar plates containing the appropriate selection 
antibiotic. 
iii. Tetrathionate enrichment media 
Tetrathionate (TRT) is a selective enrichment broth that uses tetrathionate, formed by 
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iodine and sodium thiosulphate, to produce an environment in which Salmonella can 
proliferate. The mode of action of TRT broth is poorly understood, but it is generally 
accepted that tetrathionate suppresses the growth of non-Salmonella through 
inactivation of the sulphyhydryl groups of enzymes (Waltman, 2000). 
Samples suspected of containing Salmonella were inoculated into vials containing 
TRT broth at a ratio of 1:10 and incubated aerobically overnight at 37°C. After 
overnight incubation, samples were streaked on appropriate XLD agar plates. TRT 
was only used in the initial study phases of the project in conjunction with MSB as 
enrichment media.  Previous research conducted with the vaccine strain had used 
TRT (Dueger, et al., 2001, 2003a, 2003b). However, variable results were observed 
with TRT when compared to MSB selective enrichment, a finding consistent with 
reports in the literature (Waltman, 2000; Feldsine, et al., 2002; AOAC, 2005). 
Therefore, the use of TRT was phased out of the project in preference to MSB; it 
gave more consistent and reliable results and is the generally accepted standard for 
enrichment of Salmonella spp. (AOAC, 2005). 
3.3.3. Presumptive Salmonella identification and serotyping 
Prior to initiating presumptive Salmonella identification and serotyping, a single 
colony from a Salmonella suspicious isolate was sub-cultured onto a sheep blood agar 
plate (SBA) and incubated aerobically at 37°C overnight. Sub-culturing onto a non-
selective growth media such as SBA, reduced the chance of cross-reactivity and 
inhibition of flagellar antigens from compounds in the selective media and ensured a 
pure culture from which multiple biochemical tests could be performed. 
i. Presumptive Salmonella identification 
Presumptive Salmonella identification was performed using the OXOID Salmonella 
Test Kit (DR1108; OXOID Ltd, UK). The OXOID Salmonella Test Kit detects the 
majority of common Salmonella spp. including S. Typhimurium and S. Enteritidis. In 
order to minimise cross reactions with other Enterobacteriaceae, antibodies to the 
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principal somatic antigens are removed during preparation of the antisera used in this 
assay. Consequently, the reactions are predominantly with flagellar antigens, however 
non-motile species S. Pullorum and S. Gallinarum will elicit positive reactions. Each 
kit contained a polyvalent antisera prepared against a wide range of Salmonella 
flagellar antigens which were used to coat latex particles. When mixed with a 
suspension of Salmonella, the latex particles coated with the antigen rapidly 
agglutinated to form visible blue clumps, indicating a positive reaction. 
On a clean microscope slide, three or four large circles were drawn with a water 
insoluble marker. A 15 μL drop of sterile saline was placed within each circle.  The 
isolate to be identified was selected from a colony from a pure culture that had been 
inoculated onto an SBA. The colony was emulsified into the drop of sterile saline 
using a sterilised loop. Then a 15 μL drop of the Salmonella Latex agglutinating sera 
(OXOID Ltd., UK) was pipetted into the suspension and mixed thoroughly. The slide 
was rocked after the addition of the latex agglutination sera and monitored for 
agglutination within the suspension for approximately two minutes. Agglutination of 
the suspension, appearing as blue clumps within a clear liquid, indicated that the 
isolate was positive for Salmonella flagellar antigens. Positive isolates were subjected 
to further serotyping and biochemical testing to confirm presumptive identification 
and to eliminate false-positives such as oxidase-positive bacteria species and E. coli 
(OXOID, 2004). 
Quality assurance was performed each day using a positive and negative control to 
ensure integrity of the test kit and validate test results. The positive control was a 
Salmonella Typhimurium ATCC® 14028 and the negative control was Escherichia 
coli ATCC® 25922 as recommended by the manufacturer's guidelines (OXOID, 
2004). Additionally, the vaccine and challenge strains were assessed alongside the 
positive and negative controls. 
3.3.4. Salmonella serogrouping 
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On a clean microscope slide, large circles were drawn with a water insoluble marker 
to form wells. A 15 μL drop of sterile saline was pipetted into each well on the slide 
and the test culture was emulsified into each drop of saline with a sterilised loop. To 
the first well on the slide, 15µL of sterile saline was added to the emulsion and acted as 
a negative control. To the second well, a 15µL of somatic O antisera of the suspected 
serogroup of the Salmonella isolate was added to the emulsion. In the event two 
serogroups were suspected, e.g., a cross-protective vaccination-challenge trial, then a 
third well was tested with the other suspected serogroup. The Salmonella somatic O 
antisera were:  group B, factors 1, 4, 12, and 27  (229731; BD Diagnostics, USA); 
group D, factors 1, 9, and 12 (229511; BD Diagnostics, USA); and group C2, factors 
6 and 8 (229501 BD Diagnostics, USA). 
The slide was then rocked to mix the emulsion after the addition of the antisera for 
one minute and observed for agglutination (white clumps). Isolate identification was 
verified following agglutination patterns shown in Table 3.1. Quality assurance was 
performed each day using a positive and negative control for each antisera used to 
ensure integrity of the substrate.  Pure cultures of the vaccine and challenge strains 
were also assessed alongside the positive and negative controls. 
 
Table 3.1.  Salmonella enterica subspecies enterica Serotype Identification Scheme 
Isolate Identification Antisera 
Serogroup Strain Saline (Control) B C2 D 
B Typhimurium NEG POS NEG NEG 
C2-3 Bovismorbificans NEG NEG POS NEG 
C2-3 Newport NEG NEG POS NEG 
D Dublin NEG NEG NEG POS 
Test Failure – Repeat POS NEG or POS 
NEG or 
POS 
NEG or 
POS 
POS – Agglutination (clumps in the suspension) observed; NEG – No agglutination 
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3.3.5. Biochemical identification of salmonella 
Since no one biochemical test can conclusively identify salmonellae, a combination 
of biochemical tests was used to classify and differentiate members of the 
Enterobacteriaceae family. The tests commonly utilised in the identification of 
salmonellae included fermentation of glucose, mannitol and dulcitol; inability to 
ferment sucrose, salicin and lactose; inability to hydrolyse urea and form indole from 
tryptophan; o-nitrophenyl-β-D-galactopyranoside (ONPG) negative and production of 
hydrogen sulphide (H2S) (Old and Threlfall, 1998; Quinn, et al., 1999; Jones, et al., 
2000; Waltman, 2000; Quinn, et al., 2002). The following biochemical tests were 
used to confirm that isolates were a Salmonella enterica subspecies enterica:  urea, 
triple sugar iron agar, ONPG, and indole. Salmonella suspicious or presumptuous 
isolates were sub-cultured onto SBA and incubated aerobically at 37°C overnight to 
ensure a pure culture from which multiple biochemical tests could be performed. 
i. Urea 
This test is used to determine the ability of the isolate to hydrolyse urea and confirm 
the presence or absence of the urease enzyme (MacFaddin, 2000). A colony from the 
sub-cultured isolate to be identified was inoculated onto Christensen’s urea agar slant 
with 2% urea and phenol red pH indicator (Difco, AU) and then incubated overnight 
at 37°C. A colour change in the media from buff-yellow to pink indicated a positive 
(alkaline) reaction and a urease positive isolate. Salmonella are unable to hydrolyse 
urea (Old and Threlfall, 1998; Jones, et al., 2000) and therefore produce a negative 
reaction (i.e., no colour change). The urea test is useful to differentiate Salmonella 
spp. from Proteus spp. and Citrobacter spp. 
ii. Triple sugar iron agar (TSI) 
TSI is a composite medium for the differentiation of Enterobacteriaceae based on 
varying abilities to ferment sucrose, lactose and glucose and ability to produce 
hydrogen sulphide (H2S) from an inorganic sulphur source (Holmes, 1998; Jones, et 
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al., 2000; MacFaddin, 2000). The medium was inoculated by stabbing the isolate into 
the base (butt) then streaking the isolate onto the slope. The TSI slants were incubated 
overnight at 37°C with loosened caps (aerobic). A yellow colour change in the media 
indicated an acid reaction due to the utilisation of glucose and production of lactic 
acid. A red-purple colour change in the media indicated an alkaline reaction caused 
by the breakdown of protein. The production of H2S was characterised by blackening 
of the TSI medium. Gas bubble formation in the butt of the media indicated anaerobic 
fermentation. The interpretation key used for TSI media reactions is depicted in Table 
3.2 (adapted from Jones et al.(2000)). 
Table 3.2.  TSI Reaction Interpretation Key 
TSI Reaction Regions Salmonella E. coli Proteus 
Butt Anaerobic metabolism AG AG AG 
Slope Aerobic metabolism ALK or NC A A 
H2S 
Produce H2S from 
sodium thiosulphate + - + 
AG, acid (yellow) and gas formation; A, acid (yellow); NC, No change in media colour; 
ALK, alkaline reaction (red); +, H2S (black); -, no H2S (no blacking of media) 
iii. ONPG 
This test is used to determine the presence or absence of the enzyme β-galactosidase 
in order to differentiate lactose delayed organisms from lactose negative organisms 
(MacFaddin, 2000). A colony from the sub-cultured isolate to be identified was 
inoculated into a vial containing 2.5 mL of 0.15% ONPG in 1% peptone water and 
incubated overnight at 37°C. A colour change in the media from clear to yellow 
would indicate the presence of β-galactosidase and confirm that the isolate was a 
lactose fermenter. Salmonella enterica subspecies enterica are generally non-lactose 
fermenters and ONPG negative (Holmes, 1998; Jones, et al., 2000; MacFaddin, 
2000). The ONPG test is useful for differentiating Salmonella enterica subspecies 
enterica from Citrobacter spp. and other Salmonella subspecies (Old and Threlfall, 
1998; Jones, et al., 2000; MacFaddin, 2000). 
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iv. Indole 
The indole test is used to determine whether an organism has the ability to split indole 
from the amino acid tryptophan. A single colony from the sub-cultured isolate was 
inoculated into a vial containing 10 mL of tryptone broth (Difco, USA) and incubated 
overnight at 37°C. After incubation, 1 mL of Kovac’s Reagent (TM246; OXOID 
Ltd., AU) was added to the vial and observed for the appearance of a red ring on the 
surface of the medium. A red ring indicated a positive indole test result. Salmonella 
spp. are unable to form indole. The indole test is useful for differentiating Salmonella 
spp. from Edwardsiella spp. and E. coli (Jones, et al., 2000; MacFaddin, 2000). 
3.3.6. Susceptibility and resistance testing procedures 
Antimicrobial susceptibility and resistance (ASR) testing was performed following 
the CDS Test method (Bell, et al., 2004; Bell, et al., 2008). Salmonella isolates, 
confirmed by biochemical and antisera testing, were sub-cultured onto either LA or 
SBA plates and incubated aerobically at 37°C overnight prior to initiating ASR 
testing. 
i. Preparation of samples 
A single colony forming unit (CFU) from a fresh culture plate was tapped with a 
sterile straight wire and inoculated into a tube containing 2.5 mL of sterile saline. The 
tube was capped and inverted several times to thoroughly mix the bacteria. The 
contents of the tube were poured onto a plain sensitivity agar (PSA) (Sensitest Agar 
CM0409; OXOID Ltd, AU) plate that was labelled with the isolate identification 
number, date and antibiotic test series. The plate was gently swirled to ensure the 
entire surface of the PSA plate was coated with bacterial solution. Excess bacterial 
solution was removed from the PSA plate using a sterile transfer pipette and 
discarded. The inoculated PSA plate was then placed face-up under a Bunsen burner 
to dry for at least 15 min but no more than 45 min. 
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Table 3.3.  Susceptibility and Resistance Testing Antibiotics 
Antibiotic Tested Disc Label Concentration (μg) 
Amikacin AK 30 
Amoxicillin/Clavulanic Acid AMC30 30 
Ampicillin AMP 20 
Apramycin APR 15 
Ceftiofur EFT 30 
Cefuroxime CXM 30 
Chloramphenicol C 10 
Erythromycin E 5 
Kanamycin K 50 
Nalidixic Acid NA 30 
Neomycin N 30 
Novobiocin NV 5 
Penicillin P 0.5 units 
Streptomycin S10 10 
Sulphonamides Compound S3 300 
Sulphamethoxazole SF 300 
Sulphamethoxazole/Trimethoprim 
19:1 SXT      25 (23.75/1.25) 
Tetracycline TE 30 
Trimethoprim W 5 
ii. Antibiotic challenge of isolates 
Following drying, antibiotic challenge discs (OXOID Ltd, AU)(Table 3.3) were 
applied to the inoculated PSA plates using an OXOID Disc Dispenser MKII 
(OXOID Ltd, AU). No more than eight antibiotic discs were applied to any one 
inoculated PSA plate. The PSA plates were then covered and placed right-side up in 
an incubator at 37°C for 16-18 h. At the end of the incubation period, the plates were 
removed from the incubator and the elapsed time was calculated to the nearest quarter 
of an hour. 
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iii. Antibiotic susceptibility and resistance 
The zone of inhibition, the area free from bacterial growth, was measured from the 
edge of the antibiotic disc to the edge of confluent bacterial growth (radii 
measurement) to the nearest 0.1 mm using a ruler or microcalipers following 
standardised techniques developed by Bell et al. (2004; 2008) and the standard 
protocol used by the Region Veterinary Laboratory at EMAI. Radii measurements < 6 
mm indicated that an isolate was resistant to the antibiotic impregnating the disc. 
Radii measurements > 6 mm indicated that the isolate was susceptible to the 
antibiotic impregnating the disc. Escherichia coli ATCC 25922 was used as a quality 
control to assess antibiotic discs. 
3.4 Neonate Models of Ruminant Salmonellosis 
3.4.1. Animal ethics and biosecurity approvals 
In vivo usage of the vaccine and S. Newport challenge strains was approved by AQIS 
using Approval for In Vivo Use (Direct or Indirect) of Restricted Imported Biological 
Material in Non-Laboratory Animals Permits (In vivo Approval Numbers:  vaccine; 
2003/077 and 2006/020 and challenge, 2006/006) as required by AQIS conditions for 
the use of imported biological products in non-laboratory animals (AQIS/DPIE, 
2010). 
The use of calves in this research was approved by the Animal Ethics Committee 
(AEC) at EMAI (AEC Reference: M05/029).   
3.4.2. Test system 
i. Species/strain 
Holstein-Friesian bull calves (Bos taurus) were the test system used in the conduct of 
this project. Cattle were chosen for this study as they will be one of the target species 
for application of the vaccine and the efficacy of attenuated live Salmonella vaccines 
is host species dependent. Calves were selected as this is a target subpopulation and 
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logistically easier to handle than adults. The mechanism by which live vaccines 
confer immunity is unknown and the strain requirements for an effective live vaccine 
are unknown. Previous studies have demonstrated species specific variation in 
response to vaccination, e.g., avirulent in one but pathogenic in another. 
ii. Source 
The calves used in the conduct of this project were obtained from either Moxey 
Dairies, Pty. Ltd., Gooloogong, NSW, AU or the EMAI Dairy Number 9, EMAI, 
Department of Investment & Industry, Menangle, NSW, AU. 
3.4.3. Selection criteria 
The criteria used to select calves were passive transfer of colostral antibodies and an 
observation of no physical abnormalities or deformities during physical examination. 
i. Passive transfer of antibodies 
Passive transfer of antibodies of colostral antibodies was assessed via measurement of 
serum proteins using a TS Meter handheld refractometer, (Catalogue #10400, 
American Optical Company, USA). Blood was collected from the jugular vein of 
each calf into a 10 mL red top serum separation vacutainer tube (BD Vacutainer® 
36643; BD, USA). Approximately 2.5 mL was transferred into a polypropylene 
microcentrifuge tube and allowed to stand for 30 minutes (min). Tubes were 
centrifuged for 10 min in a Beckman Microcentrifuge. Sera were placed onto the 
sample window of the refractometer and a total solids reading was recorded on a calf 
collection record. Two readings were recorded for each calf and the average of these 
readings was used to determine serum protein level. Calves with a serum protein less 
than 5.0 g/dL at 48 h of age were excluded on the basis of failure of passive transfer 
(Heinrichs and Radostits, 2001; Vaala and House, 2002b). 
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ii. Health and vigour 
Each calf underwent a veterinary health check prior to selection. Any calf with 
conformational defects, congenital abnormalities or poor vigour was excluded from 
selection. If a calf became injured or ill after selection, it was removed from the study 
and humanely euthanised (as described in Section 3.4.11). 
3.4.4. Animal identification 
Calves were individually identified with colour-coded ear tags. At birth, each calf 
received a National Livestock Identification System (NLIS) tag. The tag was affixed 
to the right ear of the calf as required by the National Livestock Identification 
System, Stock Disease Regulation 2004, Part 3 (Stock Diseases Act 2004) (NLIS, 
2004). In addition to the NLIS tag, a white plastic ear tag with temporary study 
identification number was placed into the right ear following selection for inclusion in 
the trial. At study initiation, each calf received a colour-coded ear tag with a unique 
study identification number following randomisation that was placed in the left ear. 
3.4.5. Management and housing of calves at source dairy 
Bull calves were collected from the maternity pen at the dairy and placed into a 
designated calf nursery area following birth. In the calf nursery area the calves were 
fed 2 L of pooled colostrum immediately after birth and then again at 12 h and 24 h. 
To reduce the chance of navel infection, the umbilical region of each calf was dipped 
in 7% iodine solution on arrival in the calf nursery and at 24 h of age. Following the 
third colostrum feeding, the calves were moved from the calf nursery to an isolation 
nursery to prevent contact with older animals and potential exposure to enteric 
pathogens. 
In the isolation nursery, the calves were placed into small groups of approximately 3-
4 calves of similar age. Each calf was trained to drink milk replacer from a plastic 
bucket. Calves were bucket fed Palastart Blue (Probiotec Pty. Ltd., AU), a non-
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medicated milk-replacer that was 20% fat and 24% protein. To reduce the chance of 
cross-contamination between calves of varying ages in the isolation facility, the 
youngest animals were fed first, gloves were changed between groups of calves, and 
any calves with loose stool or diarrhoea were fed last. 
Any calf that did not meet selection criteria during the collection period was removed 
from the isolation nursery area and excluded from the trial. All excluded calves were 
returned to the on-farm bull calf rearing facility for further assessment and treatment 
if appropriate. Any calf that met euthanasia criteria as described in Section 3.4.10 was 
humanely euthanised following on-farm protocols. 
3.4.6. Neonate animal management and husbandry 
i. Housing 
Calves were transported to EMAI Medium Security Animal Facility, Menangle, 
NSW and housed in PC2/QC2 Animal Rooms. Within the animal rooms, calves were 
individually housed in wire mesh pens on a raised mesh flooring. To ensure comfort 
and improve traction, a tubular matting material was used to line the back two-thirds 
of each pen. Each pen was equipped with a bucket holder and a plastic all-purpose 
bucket for administration of milk replacer and water. Colour-coded cage cards were 
affixed to each pen and included  the following information:  animal identification 
number, study identification, test articles/bacterial strains, group assignment, study 
initiation date, name of the study director and study monitor. Individual animal 
clinical assessments and observation records were maintained for each calf on the 
Individual Daily Animal Observation Records (see Appendix II:  Individual Daily 
Animal Observation Record for Calves for sample form) during the conduct of each 
experiment.  
ii. Nutrition 
Calves were bucket fed Palastart Blue (Probiotec Pty. Ltd., AU), a non-medicated, 
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milk-replacer that was 20% fat and 24% protein. Milk replacer was prepared 
following manufacturer’s instructions and fed at approximately 12-15% of estimated 
body weight of the calves over two feedings using Table 3.4. as a guideline. Calves 
were provided access to tap water ad libitum. All milk replacer preparation equipment 
was dedicated to a single animal room and milk buckets were assigned to individual 
calves to prevent cross contamination. 
Table 3.4.  Milk Replacer Feeding Volume Schedule 
Study Week Age of Calves (Days) 
Approximate Weight 
of Calves (Kg) 
Total Daily 
Volume (L) 
Acclimation 1-14 35 to 40 5.0 
1 7-21 38 to 43 6.0 
2 14-28 41 to 46 7.0 
3 21-35 44 to 49 7.0 
4 28-49 47 to 52 8.0 
5 35-56 50 to 55 8.0 
6 49-63 55 to 60 9.0 
7 56-70 60 to 65 9.0 
8 63-77 65 to 75 9.0 
iii. Husbandry and sanitation 
Prior to initiating each trial, the animal rooms used to house the calves and all 
equipment used in the care and maintenance of the calves were thoroughly cleaned 
and sanitised to ensure the environment was free from common scour pathogens and 
any other infectious agents that may have been harboured on equipment or within the 
room from previous experiments following procedures outlined in SOP 80.03.01, 
Schedule for Animal Room Housekeeping During the Conduct of Salmonella and 
Salmonella Vaccine Trials (see Appendix IV:  Standard Operating Procedure Animal 
Room Husbandry). Animal room floors and individual pens were flushed with water 
daily and with quaternary disinfectant at least twice a week following procedures 
outlined in Appendix IV. A quaternary ammonium disinfectant was selected due to its 
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stability in the presence of organic matter, non-corrosive to metal, and high efficacy 
against bacteria, moulds and viruses, as well as reduced risk to staff and animals with 
daily use (Walker, 2003; Mueller-Doblies, et al., 2010).  Additionally, quaternary 
ammonium disinfectants have been shown to be useful in the disinfection of surfaces 
and equipment contaminated with salmonellae and coliforms (Payne, et al., 2005; 
Lee, et al., 2007; Mueller-Doblies, et al., 2010).  Faecal material within the pen that 
could not be removed with low pressure hosing was scrubbed with a brush. Care was 
taken to avoid wetting the calves during this process. Equipment used in the 
preparation of milk replacer was cleaned after each feeding. Milk buckets were rinsed 
after each feeding and cleaned with warm soapy water. Weekly, the feeding 
equipment was sanitised with a quaternary disinfectant following cleaning. All 
husbandry procedures were recorded on the Daily Housekeeping Record (see 
Appendix IV). 
3.4.7. Biosecurity procedures 
Biosafety protocols recommend by Office of the Gene Technology Regulator 
(OGTR), Gene Technology Regulations Act 2001 (Government, 2010) for the 
handling of PC2 organisms as well as AQIS QAP regulations for handling a QC2 
organism (AQIS/DAFF, 2010; AQIS/DPIE, 2010) were followed to prevent release 
of the vaccine into the environment, to prevent cross contamination between 
vaccinated and non-vaccinated groups, and to ensure safety of all personnel working 
on this project. In compliance with OGTR regulations and AQIS QAP, standard 
operating procedures used for entry and exit into the PC2/QC2 Animal Rooms at 
EMAI during the conduct of the studies were developed and outlined in Appendix V:  
Standard Operating Procedure for Exit and Entry into Animal Rooms. The 
Institutional Biosecurity Committee (IBC) at EMAI approved the biosecurity 
protocols, as well as the use of animals and micro-organisms in these research (IBC 
Reference No: M05/029). All staff and researchers received biosecurity training and 
hazard awareness training prior to entry into the animal house facility. 
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3.4.8. Clinical assessment of calves 
i.  Attitude/mentation 
Attitude and mentation status of the calves was assessed daily at feeding time using 
the scoring system shown in Table 3.5 and recorded on the Individual Daily Animal 
Observation Record (Appendix II). An accumulative daily attitude score was 
developed to evaluate the mentation status of each calf. Daily accumulative attitude 
scores greater than 2 were considered abnormal. 
Table 3.5.  Attitude Scoring System 
Score Attitude Observation 
0 Standing; ready to be fed 
1 Stands with stimulus 
2 Stands with assistance 
3 Unable to stand but maintains sternal recumbency 
4 Lateral recumbency 
 
ii. Appetite 
The appetite of calves was monitored at feeding time. A schedule of the milk replacer 
feeding volumes offered to calves throughout the study is shown in Table 3.4. The 
volume of milk replacer consumed by each calf at each feeding was recorded to the 
nearest 0.1 L and recorded on the Individual Daily Animal Observation Record 
(Appendix II). Total daily intake was determined for each calf. 
iii. Rectal temperature 
The calves had rectal temperatures (RT) measured following morning feeding with a 
calibrated digital clinical thermometer (Livingstone Pty. Ltd., AU) and recorded to 
the nearest 0.1°C (range of 32.0 to 42.9°C) and recorded on the Individual Daily 
Animal Observation Record (Appendix II). During the acclimation and vaccination 
periods, RT was record weekly. The acclimation temperature readings were used to 
establish normal baseline temperature ranges for the calves. Vaccinated calves were 
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monitored for at least three days post vaccination to evaluate the effect of vaccination 
on RT (e.g., evidence of pyrexia). After virulent Salmonella challenge, RT were 
recorded daily during the post-challenge period. 
iv. Faecal composition score 
The faeces texture and composition of each calf was monitored twice daily. Faecal 
characteristics were evaluated using the scoring system shown in and recorded on the 
Individual Daily Animal Observation Record (Appendix II). A daily accumulative 
faecal score greater than 2 was considered abnormal. A dichotomous scale using 0 for 
normal (daily accumulative faecal score less than or equal to 2) and 1 (daily 
accumulative faecal score greater than 2) for abnormal was used to analyse faecal 
composition. 
Table 3.6.  Faecal Scoring System 
Score Faecal Characteristics 
0 Normal colour and texture 
1 Soft stool/runny 
2 Blood or casts in stool 
3 Diarrhoea (watery/increased frequency) 
 
3.4.9. Additional welfare observations 
Additional welfare observations were performed during the first 7 d post-challenge. 
Calves were observed between the morning and evening feedings and at midnight. 
During these observation periods it was considered normal for a calf to be standing or 
lying in sternal recumbency and abnormal to be in lateral recumbency. All 
observations were recorded on the Individual Daily Animal Observation Record 
(Appendix II). 
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3.4.10. Criteria for intervention and euthanasia of calves 
Criteria for intervention and euthanasia were established in compliance with the 
Australian Code of Practice for the Care and Use of Animals for Scientific Purposes 
(NHMRC, 2004), NSW Animal Research Act 1985 and approved by the EMAI AEC. 
Procedures for intervention and euthanasia criteria were as follows: 
i. Attitude:  
Assistance was provided to calves found in lateral recumbency. Animals were placed 
into sternal recumbency and then re-assessed. Any calf that failed to maintain sternal 
recumbency received an attitude score of 4 and was humanely euthanised (as 
described in Section 3.4.11). 
ii. Appetite: 
Calves that failed to consume milk replacer or were unable to reach a milk bucket 
were offered feeding assistance and encouraged to drink by study personnel. Any calf 
that failed to consume milk replacer, e.g., zero feed intake over two consecutive 
feedings, was humanely euthanised (as described in Section 3.4.11). 
3.4.11. Euthanasia of calves 
Euthanasia was performed when an animal met the criteria for euthanasia (described 
in Section 3.4.10) or at the completion of study. Calves were euthanised via IV 
injection of 60-80 mg/kg of pentobarbitone sodium. Intracardiac (IC) administration 
of pentobarbitone sodium was employed in sedated and unconscious animals. 
Euthanasia methods were approved by the EMAI AEC and followed guidelines set 
forth in the American Veterinary Medical Association (AVMA) Panel on Euthanasia 
(AVMA, 2001). 
3.5 Ovine Models of Ruminant Salmonellosis 
3.5.1. Animal Ethics and Biosecurity Approvals 
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In vivo usage of the vaccine was approved by AQIS on Approval for In Vivo Use 
(Direct or Indirect) of Restricted Imported Biological Material in Non-Laboratory 
Animals Permits (In vivo Approval Number:  2008/067) as required by AQIS import 
conditions for the use of imported biological products in non-laboratory animals 
(AQIS/DPIE, 2010). 
The use of animals in this research was approved by the AEC at EMAI (AEC 
Reference No: M09/013).   
3.5.2. Test system 
i. Species/Strain 
Merino wethers (Ovis aries) were the test system used in the conduct of this project. 
Adult male castrated sheep - wethers - were chosen as sheep are one of the target 
species for application of the vaccine and the logistics of evaluating the vaccine in 
sheep is more practical than adult cattle. 
The efficacy of attenuated live Salmonella vaccines is host species dependent. The 
mechanism by which live vaccines confer immunity is unknown and the strain 
requirements for a good live vaccine are unknown. Previous studies have 
demonstrated different responses in different species as well as age groups.  
ii. Source 
All sheep used in the conduct of this project were obtained from J.M. Stephen from 
the property "Warrane" in Armidale, NSW, Australia.  
3.5.3. Selection criteria 
The selection criteria for the sheep used in these research trials were: Australian 
Johne's Disease Market Assurance Program (MAP) status, health and sex. 
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i. Australian Johne's disease MAP 
The sheep flock maintained at the Warrane property had a MAP flock status of MN3. 
This status was obtained in 2003 and identifies the property to be of low risk of 
Johne's infection based on annual screening of sheep held on the property. Selection 
of sheep from a MAP certified property ensured that the gastrointestinal tract and 
immune system of the sheep were not compromised by Ovine Johne's disease. Johne's 
disease is associated with the infection of sheep with Mycobacterium avium 
subspecies paratuberculosis. Symptoms of Johne's disease may not manifest for 
many months to years and are typically associated with chronic wasting, ill thrift and 
scouring.  
ii. Health and vigour 
Prior to shipment the sheep were:  shorn; drenched with a broad spectrum 
anthelmentic, Q-drench® (Jurox Pty. Ltd., AU); treated for external parasites with 
Zapp pour-on lousicide (Bayer Australia Ltd., AU); and vaccinated with a 
commercial clostridial vaccine, e.g., 5-in-1. Each sheep underwent a veterinary health 
check on arrival. Any sheep with conformational defects, congenital abnormalities or 
poor vigour following shipment, were excluded from selection. If a sheep became 
injured or ill after selection, the animal was removed from the study and humanely 
euthanised (as described in Section 3.5.10.). 
3.5.4. Animal identification 
Sheep were individually identified with colour-coded ear tags. Each sheep had a 
NLIS tag affixed to the right ear which was labelled with a property identification 
code as required by the National Livestock Identification System, Stock Disease 
Regulation 2004, Part 3 (Stock Diseases Act 2004) (NLIS, 2004). In addition to the 
NLIS tag, a white plastic ear tag with a temporary study identification number was 
placed into the right ear following selection for inclusion in the trial. At study 
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initiation, each sheep received a colour-coded ear tag with a unique study 
identification number following randomisation. 
3.5.5. Sheep management and husbandry 
i. Housing 
Sheep were transported to EMAI Medium Security Animal Facility, Menangle, NSW 
and housed PC2/QC2 Animal Rooms. Within the animal rooms sheep were 
individually housed in wire mesh pens on raised mesh flooring. To ensure comfort 
and improve traction, tubular matting material was used to line the back two-thirds of 
each pen. Each pen was equipped with three plastic all-purpose buckets for 
administration of water and feed. Colour-coded cage cards were affixed to each pen 
and included  the following information:  animal identification number, study 
identification, test articles/bacterial strains, group assignment, study initiation date, 
name of the study director and study monitor. Individual animal clinical assessments 
and observation records were maintained for each sheep on the Individual Daily 
Animal Observation Record (Appendix III) during the conduct of each experiment. 
ii. Nutrition 
Sheep received a diet of oaten chaff (8 mega joules of metabolisable energy per 
kilogram of dry matter [MJ ME/kg DM]) and commercially prepared grain pellet (12 
MJ ME/kg DM) during the acclimation, vaccination and challenge phases of the 
experiment. Sheep were gradually introduced onto the grain pellet during the 
acclimation and vaccination periods. The amount of pellets and chaff fed to the sheep 
was approximately 1-2% body weight and adjusted to ensure that each animal 
received roughly 10 MJ ME/d/50 kg of body weight (BWT). Pellets and chaff were 
offered in separate feeders to facilitate monitoring of the eating habits of sheep with 
and without salmonellosis, as well as to determine if there were any feeding 
preferences.  
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Any sheep that refused to consume chaff and pellets during the acclimation period 
was offered 100-200 g of fresh rye or kikuyu grass in addition to regular diet to 
facilitate transition onto the diet. During the challenge phase of the trial, any sheep 
that became inappetent or anorexic was offered 100-200 g of fresh grass to stimulate 
appetite, to provide a familiar feed stuff, and to prevent anorexia. 
iii. Water intake 
Sheep were provided 6 L of tap water at the morning feeding period and at afternoon 
observation period. The volume of water consumed after each offering was recorded 
daily to the nearest 0.5 L and total daily water consumption was determined for each 
sheep from these data. 
iv. Husbandry and sanitation 
Prior to initiating each trial, the animal rooms used to house the sheep and all 
equipment used in the care and maintenance of the sheep were thoroughly cleaned 
and sanitised to ensure the environment was free from common scour pathogens and 
any other infectious agents that may be harboured on equipment or the room from 
previous experiments, following procedures outline in SOP 80.03.01, Schedule for 
Animal Room Housekeeping During the Conduct of Salmonella and Salmonella 
Vaccine Trials (see Appendix IV). Animal room floors and individual pens were 
flushed with water daily and with quaternary disinfectant at least twice a week, 
following procedures outlined in Appendix IV. Faecal material within the pen that 
could not be removed with low pressure hosing was scrubbed with a brush. Care was 
taken to avoid wetting the sheep during this process. Weekly, the feeding equipment 
was cleaned with a quaternary disinfectant and mats were scrubbed. All husbandry 
procedures were recorded on the Daily Housekeeping Record (see Appendix IV). 
3.5.6. Biosecurity procedures 
Biosafety protocols recommend by OGTR, Gene Technology Regulations Act 2001 
(Government, 2010) for the handling of PC2 organisms as well as AQIS QAP 
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regulations for handling a QC2 organism (AQIS/DAFF, 2010; AQIS/DPIE, 2010) 
were followed to prevent release of the vaccine into the environment, to prevent cross 
contamination between vaccinated and non-vaccinated groups, and to ensure safety of 
all personnel working on this project. In compliance with OGTR regulations and 
AQIS QAP, standard operating procedures used for entry and exit into the PC2/QC2 
Animal Rooms at EMAI during the conduct of the studies were developed and 
outlined in Appendix V. The IBC at EMAI approved the biosecurity protocols as well 
as the use of animals and micro-organisms in these research (IBC Reference No: 
M09/013). All staff and researchers received biosecurity training and hazard 
awareness training prior to entry into the animal house facility. 
3.5.7. Clinical assessment of sheep 
i.  Attitude/Mentation 
Attitude and mentation status of the sheep was assessed daily at feeding time using 
the scoring system shown in Table 3.7. and recorded on the Individual Daily Animal 
Observation Record (Appendix III). An accumulative daily attitude score was used to 
evaluate the mentation status of each sheep.  
 
Table 3.7:  Attitude Scoring System for Sheep 
Score Attitude Observation 
0 standing and ready to be fed (BAR) 
1 standing and quiet and alert (QAR) 
2 standing with head low 
3 stands with stimulus or standing but leaning on pen  
4 unable to stand or lateral recumbency 
 
ii. Appetite 
Individual feed intake of the sheep was monitored daily. Fresh feed was provided to 
the sheep each morning following observations, utilising feeding guidelines outlined 
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in Table 3.8. Each morning any chaff or pellets remaining from the previous feeding 
were weighed using a digital scale and refusal of pellets and chaff was recorded to the 
nearest gram onto the Individual Daily Animal Observation Record (Appendix III). 
Table 3.8:  Sample Feeding Plan for sheep 
Stage of Study Pellets per head/d Chaff per head/d 
Arrival 0 grams 800 -1000 grams 
Acclimation 100-300 grams 800-700 grams 
Challenge 200 - 400 grams 600-700 grams 
 
iii. Rectal temperature (RT) 
The sheep had RT measured prior to morning feeding with a calibrated digital clinical 
thermometer (Livingstone Pty Ltd, AU) and recorded to the nearest 0.1°C (range of 
32.0 to 42.9°C) onto the Individual Daily Animal Observation Record (Appendix III). 
During the acclimation period, RT was recorded twice weekly. The acclimation RT 
readings were used to establish normal baseline ranges for the sheep housed in the 
research facility. Vaccinated sheep were monitored for at least 4 d post vaccination. 
After the challenge with virulent Salmonella, RT was recorded daily. 
iv. Faecal composition score 
The faeces from each sheep were observed and scored twice daily. Faecal 
characteristics were evaluated using the scoring system shown in  and recorded on the 
Individual Daily Animal Observation Record (Appendix III). 
 An accumulative daily faecal score was used to evaluate the faecal composition of 
the sheep following challenge with virulent Salmonella. 
3.5.8. Additional welfare observations 
Additional welfare observations were performed during the first 7 d post-challenge. 
Sheep were observed midmorning following the morning feeding and at midnight. 
During these observation periods it was considered normal for a sheep to be standing 
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or lying in sternal recumbency and abnormal to be in lateral recumbency. Additional 
welfare observations were recorded on the Individual Daily Animal Observation 
Record (Appendix III).  
3.5.9. Criteria for intervention and euthanasia of sheep 
Criteria for intervention and euthanasia were established in compliance with the 
Australian Code of Practice for the Care and Use of Animals for Scientific Purposes 
(2004), NSW Animal Research Act 1985 and approved by the EMAI AEC. 
Procedures for intervention and euthanasia criteria for sheep used in these research 
trials were as follows: 
i. Attitude 
Any sheep that was unable to stand or found in lateral recumbency at any time 
received an attitude score of 4 and was humanely euthanised (as described in Section 
3.5.10). Any sheep that would not stand unless stimulated or leaned against pen 
gates/panels over a 48 h period, received an attitude score of 3 and was humanely 
euthanised (as described in Section 3.5.10). 
ii. Appetite 
Sheep that refused to eat chaff or pellets during the challenge phase of the trial were 
encouraged to eat by offering fresh grass. Any sheep that had failed to consume chaff, 
pellets or grass over three consecutive days (100% refusal) was humanely euthanised 
(as described in Section 3.5.10). 
3.5.10. Euthanasia of sheep 
Euthanasia was performed when an animal met the criteria for euthanasia (described 
in Section 3.5.9.) or at completion of the study. Sheep were euthanised via injection 
of 60-80 mg/kg of pentobarbitone sodium IV or IC in sedated or unconscious animals 
when IV injections were not possible. Euthanasia methods were approved by the 
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EMAI AEC and followed guidelines set forth in the AVMA Panel on Euthanasia 
(AVMA, 2001). 
3.6 Sample collection and processing 
3.6.1. Qualitative Salmonella faecal cultures 
Faecal samples were collected from animals prior to enrolment and once a week for 
qualitative detection of Salmonella. Cotton tipped swabs were inserted into the 
rectum of each calf or several pellets were collected from the rectum of each sheep 
and subsequently placed into a 10 mL enrichment broth, e.g., MSB. The broth 
containing the rectal swabs/pellets was incubated aerobically for 24 h at 37°C, and 
then plated onto XLD media. Plates were incubated aerobically for 24 h at 37°C.  
Identification and serotyping of Salmonella suspicious organisms isolated from the XLD 
plates was initiated following procedures outlined in Sections 3.3.3 to 3.3.5. Salmonella 
isolates collected from calves and sheep during the acclimation phase were submitted 
to the Institute of Medical and Veterinary Science, Salmonella Reference Laboratory, 
South Australia, Australia (IMVS) for comprehensive serotyping and phage 
identification. 
3.6.2. Quantitative Salmonella faecal cultures 
Quantitative faecal culturing was performed in order to quantify the number of 
Salmonella organisms shed into the faeces of an animal following vaccination and 
challenge. Prior to collection of faecal samples, sterile tubes were weighed and 
labelled. Faeces were collected per rectum from each animal using a clean disposable 
latex glove. Approximately 2 to 5 g of faeces were deposited into the appropriately 
labelled tube and placed on ice until processing. 
i. Sample processing 
Each tube was re-weighed to determine actual weight of sample collected then diluted 
approximately 1:4 with sterile, chilled PBS. The weight of the faeces within the tube 
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and volume of PBS added to the tube were recorded onto a data collection sheet 
(Appendix VI: Quantitative/Qualitative Faecal Culture Worksheet). A dilution factor 
for each sample was calculated using these values and used to determine the CFU/g 
faeces.  Samples were homogenised with an electronic homogeniser until a smooth 
emulsion was formed, and then placed on ice to await further processing. 
 
Table 3.9:  Dilution Scheme for Homogenised Faecal and Tissue Samples 
Tube ID Description Dilution in Tube Plating Factor 
1 Homogenised Sample (#1) TBD* 10 & 100* 
2 1:10 of #1 10* 1 x 103* 
3 1:10 of #2 100* 1 x 104* 
4 1:10 of #3 1 x 103* 1 x 105* 
5 1:10 of #4 1 x 104* 1 x 106* 
6 1:10 of #5 1 x 105* 1 x 107* 
* Final dilution and plating factors were based on the initial dilution calculated for 
Homogenised sample (Tube #1) based on sample weight and volume of PBS added. 
ii. Direct quantification plating 
Following homogenisation, the faecal samples were serially diluted into PBS 
following procedures outlined in Table 3.9.  One hundred μL of the homogenised 
sample was applied onto an XLD plate (spin plate) and 10 μL of the homogenised 
sample and each dilution of the homogenate were applied onto an appropriate section 
of XLD plate (dot plate). For the quantification of the vaccine, XLD-CHL plates were 
used to select for the vaccine strain. When quantification of the challenge agents was 
performed, XLD plates containing either ceftiofur sodium (XLD-XNL) or neomycin 
sulphate (XLD-NEO) were used. 
Spin and dot plates were incubated aerobically at 37°C for 24-48 h and black, H2S 
producing, CFU were counted (see Figure 3.2). The number of Salmonella organisms 
present in the original faecal sample in CFU per gram (CFU/g) was calculated based 
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on the sample weight, dilution factor and number of CFU counted.  The detection 
limit of this quantification method was approximately 40 CFU/g of faeces.   
iii. Selective enrichment quantification plating 
One millilitre of the homogenised faeces was inoculated into 9 mL of enrichment 
broth to give a 1:10 dilution. The inoculated broth was incubated aerobically for 24 h 
at 37°C, and then subcultured onto XLD with appropriate antibiotics. Plates were 
incubated aerobically for 24-48 h at 37°C. Presence of black, H2S producing, CFU 
indicated the presence of Salmonella and were recorded as a positive sample. When 
the concentration of Salmonella was below the detection limit of the direct 
quantification plating technique and positive on selective enrichment, samples were 
assigned a value of 10 CFU/g. Methods for selective enrichment were adapted from 
techniques reported by Dueger et al. (2003b) and Fecteau et al. (2003).  
Samples that were culture negative on selective enrichment were assigned a value of 
4 CFU/g which was determined to be the detection limit of selective enrichment 
method based on dilution factor. 
3.6.3.  Quantification of Salmonella in tissues 
The quantification of Salmonella in tissues was performed at the end of the challenge 
phase at necropsy. Quantitative tissue culturing was performed in order to determine 
the number of Salmonella organisms that had colonised in the tissues of an animal 
following vaccination or challenge. Prior to collection of tissue samples, sterile tubes 
were weighed and labelled with the animal identification number and tissue type. 
Tissues were collected using aseptic technique during necropsy. Approximately 2 to 5 
g of tissue were collected from each target organ and deposited into the appropriately 
labelled sterile tube and placed onto ice until processing.  Each tube was re-weighed 
to determine actual weight of sample collected, and then diluted approximately 1:4 
with sterile, chilled PBS. Bile samples were processed undiluted.   The weight of the 
tissue within the tube and volume of PBS added to the tube were recorded onto a data 
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collection sheet (Appendix VII:  Individual Animal Necropsy Quantitative Culture 
Worksheet). Tissue samples were processed following procedures outlined in Section 
3.6.2. 
3.6.4. Confirmation of isolate identity 
Identification and serotyping was initiated on at least two colonies from each 
Salmonella positive culture following procedures outlined in Sections 3.3.3. to 3.3.5.  
All results for isolate identification, serotyping and biochemical tests were recorded 
on the Salmonella Identification Testing Results Worksheet (Appendix VIII). 
3.7 Statistical Programs 
Statistical software programs used to analyse the data collected during the conduct of 
this research were Genstat, 12th Edition, VSN International, UK; StatsDirect 
statistical software, Version 2.4.1., StatsDirect Limited, England (Buchan, 2000);  
and SPSS for Windows (SPSS Inc., Chicago, Illinois)  
Continuous data were analysed using residual (or restricted) maximum likelihood 
(REML) analysis (Genstat, 12th Edition, VSN International, UK). Following analysis, 
data were presented as predicted model based means. Predicted means were obtained 
from the fitted model rather than the raw sample means. 
StatsDirect statistical software, Version 2.4.1., StatsDirect Limited, England 
(Buchan, 2000) was used to analyse repeated measures of non-parametric clinical 
data using the Wei-Lachin test (Wei and Lachin, 1984; Davis, 1991), Mann Whitney 
U, Students T test, analysis of variance (ANOVA) and Chi squared methods of 
analysis. 
For all statistical analyses, a significance level (P) of less than 0.05 was used to reject 
the null hypothesis. Data were presented in figures as group predicted means ± the 
standard error of the mean (SE).   
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Figure 3-1.  Faecal Scoring System for Sheep 
Score Faecal Characteristics Score Faecal Characteristics 
0 Normal pellets 
 
1 Soft (clumped pellets) 
 
2 Very Soft (dog poo) 
 
3 Pile (cow pat) 
 
4 
Diarrhoea 
(watery, casts) 
 
4 
Diarrhoea 
(watery, blood) 
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Figure 3-2.  Direct Quantification Plating Technique for Salmonella 
Spin Plates Dot Plate 
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CHAPTER 4. Dose Range Finding Study of Salmonella enterica 
subspecies enterica serovar Newport in Six-Week-Old Calves 
4.1 Introduction 
According to published reports of Salmonella challenge studies in calves, between 
109 and 1010 organisms are required to induce salmonellosis in six-week-old 
calves (Wray and Sojka, 1978; Jones, et al., 1991; Deignan, et al., 2000; Fecteau, 
et al., 2003; Dueger, et al., 2003b; Mohler, et al., 2006). However, the most 
common problems encountered when working with a new challenge organism is 
lack of virulence and variable virulence amongst strains.   This challenge dose 
trial was conducted in order to characterise the response of six to seven week-old 
calves to challenge with a multi-drug resistant Salmonella Newport 03-721 (SN 
03-721). 
Outcomes commonly used to evaluate vaccine efficacy in models of salmonellosis 
include attenuation of clinical signs, reductions in Salmonella faecal shedding and 
mortality.  To demonstrate a beneficial response to vaccination it is important that 
calves in the non-vaccinated group shed the challenge strain in faeces, display 
clinical signs commonly associated with neonatal salmonellosis, and for a 
proportion to succumb to infection.  While all of these outcomes could be induced 
by selecting a lethal dose, an excessively high challenge dose is likely to mask the 
beneficial effects of the vaccination and rapidly reduce sample size and ability to 
measure outcomes.  Another important consideration is the consideration of 
animal ethics committees, which do not look favourably on mortality models.  
Therefore, conducting challenge dose experiments to select the minimum dose 
required to achieve the desired model outcomes while minimising mortality and 
thus preserving statistical power, are critical to establishing vaccine efficacy. 
4.2 Experimental Design 
4.2.1. In vivo passage of S. Newport 03-721 (SN 03-721) 
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In vivo passage of S. Newport 03-721 (SN 03-721) through the target species was 
conducted on the isolate. Passage of the organism was considered important for 
induction of virulence factors that might not be expressed during extended storage 
and ensured that the selected organism was still capable of tissue invasion. 
Additionally, expression of virulence by the isolate and the ability of the isolate to 
establish infection in the target species could be verified prior to initiation of large 
scale dose range and vaccine efficacy evaluation trials. 
The challenge SN 03-721, described in Section 3.2.2.i, was passaged through a 
four-day-old Holstein-Friesian bull calf. The calf received 1.5 x 1011 CFU of the 
challenge candidate prepared following procedures outlined in Appendix I, in 500 
mL of LB administered PO on day 1 of the study period. After receiving the 
challenge, clinical assessments were performed on the calf every 6 h following 
procedures outlined in Section 3.4.8. 
When the calf demonstrated signs of salmonellosis (lethargy, pyrexia, diarrhoea, 
depressed mentation, inappetance) it was humanely euthanised and necropsied. At 
necropsy, tissue from the liver, spleen and lung were harvested using aseptic 
technique for culture and re-isolation of SN 03-721 following procedures outlined in 
Section 3.6 with media containing 8 µg/mL ceftiofur sodium. The tissue derived 
isolate was used as the challenge agent in the subsequent dose range and vaccine 
efficacy trials. 
4.2.2. Dose range trial of SN 03-721-SP in calves 
i. Calf selection 
Twelve calves meeting the study selection criteria described in Section 3.4.3 were 
transported to EMAI via commercial animal transport. On arrival, calves were 
placed into the PC2/QC2 Medium Security Animal House, Block 14.5, at EMAI 
and housed following procedures outlined in Section 3.4.6. 
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Calves were acclimatised for six weeks prior to initiation of the dose range study 
such that the calves would be of similar age and have experienced similar 
husbandry conditions as calves that were to be included in the subsequent vaccine 
efficacy challenge trials. Clinical assessment of the calves was performed twice a 
day during the acclimation period and rectal temperatures were recorded bi-
weekly to ensure that calves were healthy following procedures outlined in 
Section 3.4.8. A normal range for RT was established for the calves, based on 
mean RT ± two standard deviations as 37.9 – 39.4°C. Rectal temperature was 
recorded daily following virulent Salmonella challenge. Faecal swabs were 
collected for qualitative faecal cultures on all calves and then weekly through the 
acclimation period following procedures outlined in Section 3.6.1.  Salmonella 
Dublin was isolated from the faeces of two calves on arrival to the isolation 
facility. These two calves were culture negative for the subsequent five qualitative 
cultures and no abnormalities or signs of clinical disease were detected during the 
acclimation period and enrolled in the study. Another calf was removed from 
study during the acclimation period after becoming entrapped in a pen gate and 
suffering a fractured limb. 
At the end of the six week acclimation period (day 0), calves were randomly 
placed into two groups, low dose (n = 6) and high dose (n = 5). The average 
serum proteins [low dose 5.69 g/dL and high dose 5.81 g/dL (P = 0.09)], and age 
distribution [low dose 43.2 d and high dose 44.7 d (P = 0.12)], were similar 
between groups. The target dose level of the SN 03-721-SP challenge agent for 
the low and high dose groups was 5 x 109 and 5 x 1010 CFU/calf respectively. The 
SN 03-721-SP challenge agent was administered PO in 20 mL of PBS.  Following 
challenge, calves were clinically assessed following procedures outlined in 
Section 3.4.8.  Qualitative and quantitative faecal culturing was conducted 3, 7, 
10, and 15 d post-challenge, following procedures outlined in Section 3.6.2. 
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ii. Necropsy and tissue collection 
On day 15 post-challenge, surviving calves were humanly euthanised and 
necropsied. Approximately 2 to 5 g of tissue was obtained from the liver, lung, 
spleen, and mesenteric lymph node (MLN) of each calf to evaluate tissue 
colonisation of the challenge agent, as well as approximately 5 mL of bile from 
the gall bladder and contents from the lumen of the caecum and jejunum.  
Samples were processed following procedures outlined in Section 3.6.3. All gross 
pathological lesions were recorded on a necropsy record. 
iii. Statistical analysis 
Continuous data were analysed using REML analysis (Genstat, 12th Edition, VSN 
International, UK). A single variate, repeated measures model was fitted for the 
factors of time and treatment for variables CFU, temperatures, chaff and pellet 
refusal, and water intake. Following analysis, data are presented as predicted 
model based means. Predicted means are those obtained from the fitted model 
rather than the raw sample means. This is an important distinction, as predicted 
means represent means adjusted to a common set of variables, thus allowing valid 
comparison between means. A P value less than 0.05 was considered to be 
statistically significant. Differences between the individual means were 
determined by calculating an approximate least significant difference (LSD). A 
difference of means that exceeded the calculated LSD was considered significant. 
Repeated measures of non-parametric clinical data, faecal composition and 
mentation, were analysed using the Wei-Lachin test (Wei and Lachin, 1984; 
Davis, 1991) using StatsDirect statistical software, http://www.statsdirect.com, 
2002, CamCode, England (Buchan, 2000). Wei Lachin analysis of the data 
performed univariate group comparisons for individual time points and a 
multivariate comparison over the period analysed. Data are presented as the 
percentage of calves that displayed an abnormal attitude (cumulative daily score > 
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3) or had an abnormal faecal score (cumulative daily score > 3) over the course of 
the challenge period. Mann-Whitney U test was used to analyse non parametric 
tissue colonisation data that failed to meet conditions of normality with the 
Kolmogorov-Smirnov test. For all statistical analyses, a significance level (P) of 
less than 0.05 was used to reject the null hypothesis. Data is presented in figures 
as the group mean േ	SE. 
4.3 Results 
4.3.1. In vivo passage of SN 03-721 
Twenty-four hours following the administration of 1.5 x 1011 CFU of SN 03-721 
PO, the calf began to scour. By 60 h post-challenge the calf was moribund, 
anorexic, unable to maintain sternal recumbency and had a watery diarrhoea 
containing blood. The calf was euthanised following procedures outlined in 
Section 3.4.11.  
SN 03-721 was isolated from the liver, lung and spleen of the calf upon direct 
culture on to XLD-XNL. The isolates recovered from the liver, lung and spleen of 
the calf retained their antimicrobial susceptibility patterns. The isolate collected 
from the spleen was selected as the challenge strain for use in future trials and 
assigned the identifier of S. Newport 03-721-SP (SN 03-721-SP). This isolate was 
cryopreserved and maintained as a frozen culture bank following procedures 
outlined in Section 3.3.1. 
4.3.2. Effect of SN 03-721-SP challenge on calves. 
The actual dose of the SN 03-721-SP orally administered to calves was 3 x 109 
and 3 x 1010 CFU/calf in the low and high dose groups, respectively. While these 
levels were 60 % of the target, the doses were sufficient to produced clinical 
disease in all calves and two mortalities were observed in the high dose group. 
One calf died on day 3 post-challenge and the other calf was euthanised after 
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meeting euthanasia criteria on day 10 post-challenge. 
Significant differences in the mean RT of calves in the high and low dose groups 
were observed on days 1 through 3 and day 11 post-challenge (P < 0.05) and over 
the 14 d observation period (P < 0.001). The mean RT in both the low and high 
dose groups were above the normal range 48 h post-challenge (Figure 4-1). The 
mean RT of the low and high dose groups peaked on days 3 and 2 post-challenge 
respectively, and returned to the normal range by day 6 post-challenge in both 
groups. 
Significant differences in the mentation scores were observed in the high and low 
dose groups from day 7 to 14 post-challenge (P < 0.05) and over the 14 d 
observation period (P < 0.005) (Figure 4-2). The incidence of abnormal mentation 
was significantly higher in the high dose group when compared to the low dose 
group and abnormal mentation was observed in the high dose group 24 h post-
challenge and mentation scores remained elevated until the end of the challenge 
period.  
Diarrhoea was observed in the calves 24 h post-challenge with peak incidence 
occurring on study day 4 and 2 in the low and high dose groups, respectively. 
There were significant differences in the incidence of diarrhoea in the low and 
high dose groups on days 1 and 2 post-challenge (P < 0.05) (Figure 4-3). The 
incidence of diarrhoea was increased in the high dose group when compared to the 
low dose group over the 14 d observation period (P < 0.001). 
Faecal shedding of SN 03-721-SP was measured on days 3, 7, 10 and 15 post-
challenge (Figure 4-4). The high dose group shed significantly higher numbers of 
the challenge strain when compared to the low dose group (P < 0.05). On day 15 
post-challenge, the challenge strain was recovered from 2 of 6 and 2 of 3 calves, 
from the low and high doses groups respectively. 
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Calves demonstrated reduced appetites following challenge with SN 03-721-SP 
(Figure 4-5). Onset of appetite reduction was 48 h post-challenge in both dose 
groups. The high dose group consumed significantly less milk replacer when 
compared to the low dose group on days 2, 6, 7, and 8 post-challenge (P < 0.05) 
and over the 14 d observation period (P < 0.001). The appetites of the calves in 
the low dose group returned to pre-challenge consumption levels by study day 6, 
while the appetites of the surviving high dose calves remained depressed until the 
end of the 14 d observation period. 
4.3.3. SN 03-721-SP colonisation of tissue in calves 
Tissues were collected from six low dose calves and three surviving high dose 
calves. Gross pathological findings included enlarged mesenteric lymph nodes, 
ulcerated bile ducts, fibrin deposits in the small intestine, caecum and abomasum, 
ulcerations of the pylorus, mucosal erosions of the abomasum, small intestine and 
caecum, as well as serosal petechial haemorrhages (Figure 4.6). Additionally, 
trichobezoars, 5 to 12 cm in diameter, were observed in the abomasum and small 
intestines of the calves from both dose groups. The challenge organism was not 
isolated from the bile of calves in the low dose group using both direct and 
indirect selective enrichment culture techniques. There were no differences in 
tissue colonisation between the low and the high dose groups (Figure 4-7) and SN 
03-721-SP was recovered from at least one tissue in all calves. 
4.4 Discussion  
The data from the dose range finding study of the passaged SN 03-721-SP 
demonstrated that the isolate was capable of inducing clinical disease in six week 
old Holstein-Friesian bull calves following oral challenge. All calves in the low 
and high dose challenge groups developed clinical signs of salmonellosis which 
included fever, diarrhoea, decreased appetite and depressed mentation during the 
14 d post-challenge observation period. The clinical signs were biologically 
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significant in both groups with dose dependent changes in time to onset of and 
severity of changes in mentation, appetite, faecal composition, and rectal 
temperature.  
The aims of this study were to confirm virulence of the SN 03-721-SP challenge 
agent and to determine the dose that would induce clinical disease with low 
mortality in six-week-old calves. Dose range finding studies often incorporate 
several doses of the challenge agent at half log intervals which allows for 
statistical estimation of the lethal dose (LD90-100). One of the difficulties of 
developing a good Salmonella challenge model for evaluation of vaccines or 
antimicrobial efficacy studies is the identification of a suitable challenge strain. 
Occasionally, potential challenge strains prove to be avirulent in the test subjects. 
This issue was discussed with the EMAI AEC and it was decided that two dose 
groups would be utilised using doses that would be expected to cause disease 
based on doses published in the literature (Rankin and Taylor, 1966; Nazer and 
Osborne, 1977; Jones, et al., 1988; Mukkur, et al., 1991a; House, et al., 2001a; 
Fecteau, et al., 2003; Dueger, et al., 2003b; Mohler, et al., 2006). The logic of this 
decision was to minimise the number of calves that were challenged and to avoid 
the scenario of including larger numbers of calves, only to find that the strain was 
avirulent. The low dose (3 x 109 CFU) of the challenge agent in this study 
produced disease in 100% of the calves with no mortality and a rapid recovery, 
while the high dose (3 x 1010 CFU) produced disease in 100% of the calves with a 
40% mortality rate. The two dose levels verified that the challenge agent was 
virulent in 6 week-old calves and that the optimal oral dose was greater than 3 x 
109 CFU but less than 3 x 1010 CFU per calf.  
Necropsy findings demonstrated that gross pathology in the lymph nodes, gall 
bladder and intestines occurred after the administration of the challenge agent. 
However, the lungs, liver and spleen were grossly normal despite colonisation 
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with the challenge agent. Salmonella infections have been associated with 
colonisation of the lymph nodes, lung, liver, spleen, gall bladder and salivary 
glands in cattle (Wray and Davies, 2000; Fecteau, et al., 2003; Dueger, et al., 
2003b). In previous research, reduced tissue colonisation in calves challenged 
with S. Dublin was shown to correlate with resolution of clinical signs (Mohler, et 
al., 2006).  Results of this trial demonstrate that the minimum oral challenge dose 
of SN 03-721-SP required to produced clinical disease and colonisation of tissues 
in calves with minimal mortalities is 1010 CFU/calf over an observation period of 
14 d.  This dose was targeted in future Salmonella vaccine efficacy trials. 
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Figure 4-1.  Mean rectal temperatures of calves challenged with virulent SN 03-0721-SP 
RT were measured daily for 14 d following challenge. Data are depicted as mean RT ± SE. The data are presented in the context of the normal range 
(dashed grey lines) and baseline (solid grey line) established pre-challenge. *RT in the low dose group were significantly lower on days 1, 2 and 11 
post-challenge and significantly higher on day 3 post-challenge when compared to the high dose group (P < 0.05). 
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Figure 4-2.  Mentation scores of calves challenged with virulent SN 03-0721-SP 
Attitudes of the calves were scored twice a day. Data are presented as mean daily mentation score post virulent challenge ± SE. *The low dose group 
had significantly lower attitude scores when compared to the high dose group from day 7 to 14 post-virulent challenge (P < 0.05).   
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Figure 4-3.  Incidence of diarrhoea in calves challenged with virulent SN 03-0721-SP 
Faecal composition was assessed twice a day. Data are presented as the percentage of calves with diarrhoea following virulent challenge. *Significantly 
lower incidence in diarrhoea was observed in the low dose group on days 2 and 3 post-challenge when compared to the high dose group  (P < 0.05). 
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Figure 4-4.  Mean faecal shedding of virulent SN 03-721-SP in calves following challenge. 
Data are depicted as mean log10 CFU of SN 03-721-SP per g of faeces post-challenge ± SE. *Significant differences in faecal shedding were observed 
on days 3, 7, 10 and 14 post-challenge (P < 0.05). 
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Figure 4-5.  Mean appetite of calves following challenge with virulent SN 03-0721-SP 
Mean milk replacer consumption in L is depicted ± SE. Each calf was offered 8 L of milk replacer a day. *Milk replacer consumption 
was significantly lower in the high dose group when compared to the low dose group on days 2, 6, 7, and 8 post-challenge (P < 0.05). 
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Figure 4-6.  Necropsy findings of calves challenged with SN 03-721-SP 
(A)  Enlarged mesenteric lymph node 
with multiple irregular pink to red areas 
on the serosa suggesting serosal 
haemorrhage 
(B)  Fibrin deposits in the small intestine 
(C)  Ulcerated gall bladder (D)  Ulceration of the pylorus 
(E)  Trichobezoars  removed from the 
abomasum 
(F)  Abomasum with severe subacute 
active ulcerative abomasitis with  
perforatation 
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Figure 4-7.  Colonisation of tissues in calves with SN 03-721-SP following challenge. 
Tissue colonisation data are depicted as mean log10 CFU ± SE of virulent SN 03-721-SP, recovered by organ. 
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CHAPTER 5. Cross-protective Immunity conferred by a DNA Adenine 
Methylase Deficient Salmonella enterica serovar Typhimurium Vaccine in 
Calves Challenged with Salmonella serovar Newport 
The following is a re-formatted published manuscript:  
Mohler, V.L., Heithoff, D.M., Mahan, M.J., Walker, K.H., Hornitzky, M.A., 
Shum, L.W.C., Makin, K.J., House, J.K. (2008). Cross-protective Immunity 
conferred by a DNA adenine methylase deficient Salmonella enterica serovar 
Typhimurium vaccine in calves challenged with Salmonella serovar Newport. 
Vaccine 26: 1751-1758  
The study was designed, executed and reported by the candidate under the general 
supervision of the remaining authors, who were the candidate's appointed 
supervisors (principal and associate) with the exception of Drs Kate J. Makin and 
Lucy W.C. Shum, who provided assistance with calf husbandry, necropsy 
procedures and laboratory assistance. 
5.1 Introduction 
Salmonellosis in livestock usually reflects a variety of management and 
environmental events that contribute to compromised host immunity and 
increased pathogen exposure. Recent epidemiological studies of salmonellae on 
dairy farms have been able to identify risk factors that influence shedding of 
salmonellae. Those animals at highest risk include neonates and post-partum cows 
(Anderson, et al., 2001; House, et al., 2001a; Fossler, et al., 2005a; Fossler, et al., 
2005b). Increased herd size is considered a principal risk factor influenced by 
housing type, rodent/pest control, ration storage facilities, isolation protocols for 
sick animals, maternity pen practices, and surface water management (Huston, et 
al., 2002; Fossler, et al., 2005a; Fossler, et al., 2005b). Additionally, livestock 
manure management systems reduce, but do not eliminate, salmonellae, and the 
on-farm practice of recycling manure promotes faecal-oral pathogen transmission. 
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Although the implementation of sound nutritional and environmental programs 
that maintain and/ or promote broad-based host immunity contributes to livestock 
health and productivity, reliable implementation of these management programs is 
a formidable challenge, with numerous variables to consider such as weather, 
mechanical failures, variable feedstuff availability and quality, and labour 
compliance issues. Thus, although such epidemiological and management studies 
have enhanced our understanding of the risk factors resulting in salmonellae 
shedding, effective and reliable strategies for salmonellae control have not been 
established (Fossler, et al., 2005b). 
Salmonellae control strategies are further complicated by the fact that most 
infections of livestock are subclinical, as evidenced by the disparity among 
salmonellae isolates from surveillance and clinical submissions (Anderson, et al., 
2001). Additionally, some isolates are capable of asymptomatic colonisation and/ 
or persistence in a particular animal species while causing acute disease in another 
animal species (e.g., different types or classes of stock) (Counter and Gibson, 
1980; Gray, et al., 1995; Xercavins, et al., 1997; Uzzau, et al., 2000; Reen, et al., 
2005; Badie, et al., 2007). Thus, the diversity of salmonellae present on farms and 
feedlots, and the potential for different serovars to possess an array of virulence 
attributes, necessitates the use of broad prophylactic strategies that are efficacious 
for many serovars simultaneously. An effective approach for a number of years 
has been the therapeutic and prophylactic administration of antibiotics to 
livestock, but this option has become limited due to the emergence of multi-drug 
resistant pathogenic strains that present a bona fide risk to human health (CDC, 
2007). 
Vaccination is one of the best forms of prophylaxis against the development of 
disease caused by infectious agents. Although vaccination is generally highly 
specific in the protection conferred in immunised hosts (protection is limited to a 
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specific strain or closely-related set of strains), recent advancements have resulted 
in the development of vaccines that elicit cross-protective immunity to multiple 
strains of the same species. Many of these vaccine candidates are Salmonella 
modified live vaccines that contain mutations in global regulatory networks 
(Hassan and Curtiss, 1994a; Heithoff, et al., 2001; Nagy, et al., 2004). The 
molecular basis of cross-protection for these regulatory-mutant based vaccines 
appears to depend on the over expression of a number of potential antigens that 
may be shared among heterologous serotypes; they are also sufficiently attenuated 
for their capacity to cause acute disease in immunised animals.   
Salmonella Typhimurium containing a loss of function mutations in the gene 
encoding dam expression are avirulent, and confer significant protection to 
homologous and heterologous Salmonella challenge when used as modified live 
vaccines in murine (Garcia-Del Portillo, et al., 1999; Heithoff, et al., 1999; 
Heithoff, et al., 2001) and avian models of typhoid fever (Dueger, et al., 2001, 
2003a), as well as in a bovine model of salmonellosis (Dueger, et al., 2003b; 
Mohler, et al., 2006). The objective of this study was to evaluate the cross-
protective efficacy of a S. Typhimurium dam vaccine in calves challenged with a 
clinically relevant strain of S. Newport, which has recently emerged as a 
significant pathogen causing disease in cattle and humans (CDC, 2002; Clark, 
2004; Devasia, et al., 2005; Varma, et al., 2006; You, et al., 2006). 
5.2 Materials and Methods 
5.2.1. Bacterial strains and growth conditions 
Immunisations were carried out with dam-102::Mud-Cm Typhimurium UK-1 
vaccine strain MT2313 (S. Typhimurium dam) as described in Section 3.2.1. 
Challenge studies were performed with a derivative of a serovar Newport strain, 
03-721, a multi-drug antimicrobial resistant strain (SN 03-721-SP) as described in 
Section 3.2.2.i.  Strains used in infection studies were grown overnight in LB at 
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37°C following procedures outline in Appendix I. 
5.2.2. Calf selection and husbandry 
Holstein-Friesian bull calves used in the study originated from a single dairy in 
NSW, Australia. Calves were fed 2 L of colostrum from the dairy of origin at birth 
and again at 12 and 24 h of age. Passive transfer was assessed via measurement of 
serum protein using a handheld refractometer (American Optical Company, 
USA). Calves with a serum protein less than 5.0 g/dL at 48 h of age were 
excluded on the basis of failure of passive transfer. At 3 to 7 d of age, calves were 
transported to the Medium Security Animal Housing Facility at EMAI (Menangle, 
NSW, AU), randomly assigned to experimental groups and housed following 
procedures outlined in Section 3.4.6.  Vaccinated and non-vaccinated calves were 
housed in separate isolation rooms. Biosafety protocols approved by OGTR for 
containment of PC2 level organisms were followed to prevent cross 
contamination between groups and prevent release of the vaccine into the 
environment.  
Calves were bucket fed Palastart Blue (Probiotec Pty. Ltd., AU), a 20% fat, 
24% protein, non-medicated milk-replacer, twice daily at 15% of body weight as 
outlined in Section 3.4.6 and given tap water ad libitum. All milk-replacer 
preparation equipment was dedicated to a single room and milk buckets to a single 
calf. Equipment was cleaned and disinfected after each feeding. 
5.2.3.  Clinical assessment 
Clinical parameters evaluated twice daily included attitude, appetite, and faecal 
characteristics following procedures outlined in Section 3.4.8.  Rectal 
temperatures were recorded following the morning feeding for 3 d following each 
vaccination, once a week prior to and daily following virulent Salmonella 
challenge. Attitude and faecal composition were scored on an ordinal scale as 
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described in Sections 3.4.8.i  and 3.4.8.iv respectively.  Appetite was recorded to 
the nearest 0.1 L of milk-replacer consumed at each feeding.  An attitude score of 
4 at any time of the day, a failure to consume milk replacer, or an appetite score of 
0 over two consecutive feedings, constituted grounds for euthanasia. Post-virulent 
challenge, calves showing signs of salmonellosis were evaluated every 6 h. Calves 
were weighed prior to vaccination, prior to virulent challenge, and day 15 post-
challenge. Average daily weight gains were calculated for post-vaccination and 
post-challenge intervals. The study protocol was approved by the AEC at EMAI.  
5.2.4. Faecal sampling 
Sterile cotton-tipped applicators were used to collect faecal samples from all 
calves prior to enrolment and once a week for qualitative detection of Salmonella. 
Rectal swabs were placed into 10 mL of TRT and MSB broths, incubated for 24 h 
at 37°C and plated onto XLD and XLD plates containing chloramphenicol (20 
µg/mL) (XLD-CHL), to select for the vaccine strain. Both plates were incubated 
for 24 h at 37°C. Salmonella suspect colonies were sub-cultured for pure growth 
following procedures outlines in Sections 3.3.3 to 3.3.5.  Salmonella isolates were 
sent to the IMVS, Salmonella Reference Laboratory (South Australia, AU) for 
serotyping.  
Faecal samples were assessed for shedding of the S. Typhimurium dam vaccine 
strain on day 2 following each vaccination and following procedures outlined in 
Section 3.6.2.  The homogenised faecal material was plated onto XLD-CHL, 
which was selective for the vaccine strain.  Following virulent challenge, faecal 
samples were assessed for shedding of the SN 03-721-SP on days 3, 7, 10, 13 and 
15 post-challenge, using procedures outlined in Section 3.6.2.   The homogenised 
faecal material was plated onto XLD plates containing ceftiofur sodium (8 
g/mL) (XLD-XNL) which was selective for the challenge strain.  
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The numbers of Salmonella organisms present in faecal samples were calculated 
based on the sample weight, dilution factor, and number of colonies counted. Two 
colonies from each Salmonella positive faecal culture were sub-cultured and 
tested with O-antigen specific antisera to verify isolate identification following 
procedures outlined in Section 3.6.4. 
5.2.5. Salmonella isolation from bovine tissues 
Calves were euthanised and immediately necropsied using standard techniques 15 
d post virulent challenge. Approximately 1 to 2 g of tissue was obtained from the 
MLN, liver, lung and spleen, and 5 mL of bile was collected from the gall bladder 
of each calf. Samples were processed following procedures outlined in Section 
3.6.3.  
5.2.6. Statistical analysis   
Mean age, total plasma protein concentrations and body weight of vaccinated and 
non-vaccinated calves were compared using a student's T test. Clinical and 
quantitative Salmonella faecal culture data collected following SN 03-721-SP 
challenge reflected repeated measures of non-parametric data with uneven group 
sizes, and were analysed using the Wei-Lachin test (Wei and Lachin, 1984). 
Analysis of Salmonella faecal shedding was based on the results of quantitative 
Salmonella faecal cultures performed on study days 3, 7, 10, 13, and 15. Wei-
Lachlin analysis of the clinical data performs univariate group comparisons for 
each time point (d post-challenge) and a multivariate comparison over the post-
challenge period.  The statistical program utilised to perform student's T test, 
Mann-Whitney U, and Wei Lachlin test was StatsDirect statistical software 
(Buchan, 2000)(http://www.statsdirect.com, 2002, CamCode, England). 
5.3 Results 
5.3.1. Challenge dose trial  
A challenge dose trial was conducted in order to determine an optimum dose that 
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would induce disease while minimising mortality in order to maintain sample size 
and statistical power for measured outcomes. Similar to previous calf-challenge 
studies (Fecteau, et al., 2003; Dueger, et al., 2003b; Mohler, et al., 2006), seven-
week old calves were orally administered S. Newport challenge strain, 03-0721-
SP, at 3 x 109 (n = 6) and 3 x 1010 organisms (n = 5) for low and high dose, 
respectively. All of the calves in the low- and high- dose challenge groups 
developed clinical signs of salmonellosis (fever, diarrhoea, decreased appetite and 
depressed attitude) during the 14 d post-challenge observation period. The 
severity of these signs was greater in calves challenged at the high dose. There 
were significant differences in the severity of these outcomes (P < 0.05). One of 
the five calves administered the high dose died on day 3, and another was 
euthanised on day 10 post-challenge after meeting euthanasia criteria. Therefore, 
to reduce mortality and maintain sample size, a challenge dose of 1 x 1010 was 
targeted for the vaccine efficacy trial.   
5.3.2. Cross-protective efficacy of S. Typhimurium dam vaccine strain 
against virulent Newport challenge in calves 
More than 2500 serovars of S. enterica have been identified and classified 
typically by serotyping, based on antigenic variation in the lipopolysaccharide (O-
antigen) and phase 1 (H1) and phase 2 (H2) flagella on the surface of the 
organism (Ewing, 1986; Le Minor and Bockemuhl, 1989; Popoff, et al., 2004).  
These O- and H- antigens not only allow the classification of Salmonella into 
distinct serogroups (B, C1, C2-C3, D1, etc), they also constitute immunodominant 
antigens that contribute to virulence and protective immunity in infected animals 
(reviewed in (Dorsey, et al., 2005; Salazar-Gonzalez and McSorley, 2005)).  
Immunisation of calves with a S. Typhimurium dam vaccine strain (serogroup B) 
has been shown to elicit cross-protective immunity to serovar Dublin (serogroup 
D1) as evidenced by a significant reduction in clinical disease and reduced 
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colonisation of bovine tissues (Mohler, et al., 2006). Here we questioned whether 
vaccination of calves with S. Typhimurium dam can confer cross-protection 
against an emerging pathogen of livestock, S. Newport, strain SN 03-0721-SP.  
This strain is classified in the C2-C3 serogroup and has been associated with 
clinical disease in recent salmonellosis outbreaks in commercial dairy farms in 
California, USA, and with multi-drug resistance against a variety of clinically 
relevant antibiotics (ampicillin, ceftiofur, chloramphenicol, clindamycin, 
oxytetracycline, spectinomycin, sulphonamides, tiamulin, 
trimethoprim/sulphamethoxazole, tilmicosin, tylosin). Moreover, S. Newport 
expresses significantly different O- and H- antigens (O6,8,20: e,h; 1,2:[Z67]) from 
that expressed by the S. Typhimurium dam vaccine strain (O1,4,[7],12: i; 1,2) or 
that expressed by S. Dublin (O1,9,12[Vi]: g,p monophasic (Popoff and Le Minor, 
2005).  
Thirty calves were randomly assigned to two dose groups of 15 calves each. The 
average serum proteins (non-vaccinates 5.65 g/dL and vaccinates 5.62 g/dL [P = 
0.861]), age distribution (non-vaccinates 13.40 d and vaccinates 13.53 d [P = 
0.936]), and body weights (non-vaccinates 46.3 kg and vaccinates 44.8 kg [P = 
0.348]) were similar between groups.  Calves in the vaccinate group were orally 
vaccinated twice with S. Typhimurium dam (5 x 107 CFU) - once at 7 to 21 d of 
age and again 7 d following the initial vaccination. All calves were orally 
challenged with 2 x 1010 CFU (actual dose) of virulent S. Newport strain SN 03-
721-SP four weeks following the second vaccination. 
Vaccinated calves exhibited significantly lower mean rectal temperatures 
compared to non-vaccinates on days 5 and 6 post-challenge (P <0.05) and over 
the 14 d study period (P < 0.0001; Figure 5-1); temperatures returned to the 
normal baseline on day 5 and day 7 for vaccinates and non-vaccinates 
respectively. Vaccinated calves also exhibited significantly lower (improved) 
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attitude scores relative to non-vaccinates 24 h (day 1) post-challenge (P = 0.0473; 
Figure 5-2), and over the 14 d post-challenge observation period (P = 0.0161); a 
significantly lower incidence of diarrhoea in vaccinated versus non-vaccinated 
animals was also observed on day 6 post-challenge (P = 0.001) and over the 14 d 
post-challenge observation period (P = 0.0012; Figure 5-3). Additionally, 
vaccination resulted in a reduction of S. Newport faecal shedding compared to 
non-vaccinates on days 13 and 15 post-challenge (P = 0.0322; P = 0.0019), and 
over the 15 d faecal sample collection period (P = 0.004) (Figure 5-4). Moreover, 
vaccination resulted in a higher average daily weight gain over the challenge 
period, day 3 to day 15 post-challenge (P = 0.0012; Figure 5-5). 
There were no statistically significant differences in the appetites of the 
vaccinated and non-vaccinated calves following virulent challenge. A reduction in 
appetite of the calves was observed starting from 48 h post-challenge and 
persisted until study day 11. There was no statistical difference in mortalities 
between non-vaccinates and vaccinates challenged with S. Newport 03-0721-SP 
(P = 0.6121), although calf mortalities (n=1 and n=2, respectively) were observed 
during the course of the trial.  
5.3.3. Immunisation with S. Typhimurium dam confers cross-protection 
against virulent S. Newport colonisation of mesenteric lymph nodes 
and lungs of calves   
The ability of S. Typhimurium dam to confer protection against colonisation of 
lymph nodes and visceral organs was evaluated in calves. Vaccine efficacy was 
determined by enumeration of S. Newport strain SN 03-721-SP recovered from 
MLN, lungs, spleen, liver, and bile 2 weeks post-challenge. Significantly lower 
numbers of S. Newport were recovered from MLN (P = 0.0232) and lungs (P = 
0.0496) of vaccinates compared to non-vaccinates (Figure 5-6). Although S. 
Newport was isolated only from the spleen and liver of non-vaccinates (n = 1 and 
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n = 2, respectively), there was no statistically significant difference between 
vaccinates and non-vaccinates for these organs (P = 0.9630 and P = 0.5185 
respectively), or from bile contents derived from these two animal groups (P = 
0.9422). Taken together with the data in Section 5.3.2, these data suggest that 
immunisation with S. Typhimurium dam conferred significant cross-protection 
against virulent S. Newport challenge as evidenced by attenuation of clinical 
disease, reduced faecal shedding and reduced colonisation of the MLN and lung. 
5.4 Discussion 
The global trend towards intensive livestock production is associated with an 
increased incidence of disease and contamination of livestock-derived food 
products with a wide array of Salmonella serovars, which poses a significant 
increase in public health risk and industry-associated losses (CDC, 1996; Roels, et 
al., 1997; CDC, 2007). Vaccination represents a sustainable approach to 
prevention and control of Salmonella infection in commercial livestock 
production systems. Although vaccination is generally highly specific in the 
protection afforded to immunised hosts (e.g., the influenza vaccine is a trivalent 
inactivated vaccine that confers protection against the same three viral serotypes 
comprised within the vaccine formulation), recent advancements have resulted in 
the development of vaccines that confer cross-protective immunity to multiple 
strains of the same species. Herein, we show that vaccination of calves with dam 
mutant Typhimurium confers cross-protective immunity against an emerging, 
clinically relevant and multi-drug resistant Newport challenge, as evidenced by a 
significant attenuation of clinical disease, faecal shedding, and tissue colonisation. 
The development and application of Salmonella vaccines offers a potential means 
of promoting the health and productivity of livestock by reducing infection and 
clinical disease, thereby reducing Salmonella contamination of livestock, 
livestock-derived food products, and enhancing food safety. 
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On-farm studies have demonstrated that livestock are exposed to a diversity of 
serovars and that calves may be infected with salmonellae within hours of birth 
(Anderson, et al., 2001; House, et al., 2001a; Fossler, et al., 2005a; Fossler, et al., 
2005b). Effective Salmonella vaccination in livestock therefore requires induction 
of homologous and heterologous protection and the capability to stimulate both 
early- and late- onset innate and acquired immune mechanisms. Although the use 
of Salmonella vaccines is relatively common (Smith, et al., 1994), the majority of 
the products on the market are bacterins (inactivated S. enterica organisms) of 
limited efficacy. The rationale is that, under field conditions, neonatal exposure 
often occurs during the first few hours after life (House, et al., 2001a), minimising 
the opportunity of bacterins to confer protective immune mechanisms which may 
require stimulation by a stable source of diverse antigens for sufficient time to 
transition to the development of strong adaptive immune responses.  
The potential benefit of modified live attenuated Salmonella vaccines as immune 
cells has been recognised for many years and a small number are available 
commercially (Curtiss, et al., 1993). Vaccine constructs have included aromatic 
amino acid dependent (aro), streptomycin-dependent, and galE mutants (Habasha, 
et al., 1985; Da Roden, et al., 1992; Smith, et al., 1993; Villarreal-Ramos, et al., 
1998). These vaccines are typically effective at inducing acquired protective 
immunity against homologous Salmonella challenge. However, such live vaccines 
(e.g., aroA Typhimurium) have a limited capacity to confer protective immunity 
against heterologous Salmonella serovars as most cross-protective responses 
reported are highly dependent on transient, non-specific immune responses 
attributed to the persistence of the vaccine strain within the immunised animal 
(reviewed in (Hormaeche, et al., 1991; Hormaeche, et al., 1996; Harrison, et al., 
1997)) and thus, most cross-protective responses are negligible soon after the 
vaccine strain is cleared from the animal.   
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An ideal livestock Salmonella vaccine that is safe, stimulates rapid and sustained 
immunity in all classes of stock, and provides protection against the diverse array 
of Salmonella serovars encountered in these production systems, has yet to be 
developed. Currently, the most promising Salmonella live vaccine candidates that 
confer potent cross-protective immune responses include strains harbouring 
mutations in regulatory genes that control the expression of a number of potential 
antigens, including regulatory-mutant based vaccines involved in catabolite 
repression (cya crp; (Hassan and Curtiss, 1994a; Hassan and Curtiss, 1994b)),  
DNA methylation (dam; (Heithoff, et al., 2001)), and LPS core and O-antigen 
synthesis (rfaH (Nagy, et al., 2004)). Thus, although different Salmonella 
serovars possess different antigen repertoires, some of the antigens ectopically 
expressed by these modified live vaccines may be shared among heterologous 
serotypes, and expression of these shared diverse antigens may lead to potent 
cross-protective responses. Consistent with this notion, Salmonella dam mutant 
vaccines ectopically express a number of potential antigens that are normally 
induced during infection (Garcia-Del Portillo, et al., 1999; Heithoff, et al., 1999; 
Heithoff, et al., 2001), and have been shown to confer cross-protective immunity 
to multiple salmonellae in murine (Heithoff, et al., 2001) and avian models of 
typhoid fever (Dueger, et al., 2001, 2003a). Additionally, dam mutant vaccine 
technology has been applied to bovine salmonellosis, wherein S. Typhimurium 
dam vaccine conferred significant immunity to clinically relevant strains of 
Typhimurium (serogroup B) (Dueger, et al., 2003b) and Dublin (serogroup D1 
(Mohler, et al., 2006), two serovars that are frequently associated with disease in 
cattle (Anderson, et al., 2001).  
Herein we evaluated whether vaccination of calves with S. Typhimurium dam 
mutant can confer cross-protection against an emerging pathogen of livestock, S. 
Newport (serogroup C2-C3), which expresses a significantly different O-antigen 
from that expressed by S. Typhimurium or S. Dublin, and has been associated 
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with multi-drug resistance and clinical disease in recent salmonellosis outbreaks 
in commercial dairy farms. Vaccination of calves with S. Typhimurium dam 
conferred cross-protective immunity against a Newport challenge, as evidenced 
by a significant attenuation of clinical disease (improved attitude scores, increased 
daily weight gains and reduced fever and diarrhoea) and a reduction in Newport 
faecal shedding and colonisation of mesenteric lymph nodes and lungs compared 
to non-vaccinated control animals. Such Salmonella heterologous cross-protection 
suggests the potential application of this vaccine toward the prevention and 
control of Salmonella infection in commercial livestock production systems. 
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Figure 5-1.  Immunisation with S. Typhimurium dam confers protection against pyrexia in calves following virulent SN 03-721-SP 
challenge. 
Data are depicted as mean RT ± SE. The data are presented in the context of the normal range (dashed grey lines) and baseline (solid grey line) 
established pre-challenge. *RT were significantly lower in vaccinated animals than in non-vaccinates on days 5 and 6 post-challenge (*P < 0.05), and 
over the entire 14 day study period (P < 0.0001) 
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Figure 5-2.  Immunisation with S. Typhimurium dam improves mentation in calves following virulent SN 03-721-SP challenge. 
Data are depicted in percentage of calves with abnormal mentation. *Attitude scores were significantly lower in vaccinated animals than in non-vaccinated 
controls on day 1 post-challenge (*P = 0.0473), and over the entire 14 day study period (P = 0.0161). 
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Figure 5-3.  Immunisation with S. Typhimurium dam confers protection against diarrhoea in calves following virulent SN 03-721-SP challenge. 
Percent of calves with diarrhoea were scored on dichotomous scale of 0 or 1 for grossly normal stool or diarrhoea. *Incidence of diarrhoea was significantly 
lower in vaccinated animals than in non-vaccinated controls on day 6 post-challenge (*P = 0.0001), and over the entire 14 d study period (P = 0.0012). 
101 
 
Figure 5-4.  Immunisation with S. Typhimurium dam confers protection against shedding of virulent SN 03-721-SP in calves following challenge. 
Data are depicted as a mean log10 CFU of SN 03-721-SP per g of faeces post-challenge ± SE. Vaccinated calves shed less SN 03-721-SP in the faeces than non-
vaccinated controls. Significant differences in faecal shedding were observed on days 13 and 15 post-challenge (*P = 0.0322 and **P = 0.0019), and over the 
cumulative post-challenge period (P = 0.004). 
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Figure 5-5.  Immunisation with S. Typhimurium dam improves weight gain in calves following virulent SN 03-721-SP challenge. 
Data are depicted in average daily weight gain in Kg per d ± SE over the post vaccination and post-challenge intervals. The reduction in average daily weight 
gains following virulent challenge was significantly less in the vaccinated calves (*P = 0.0012).   
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Figure 5-6.  Immunisation with S. Typhimurium dam confers heterologous protection against SN 03-721-SP colonisation of mesenteric 
lymph nodes and lungs in calves. 
Data are depicted as mean CFU log10 by organ ± SE.  *Significantly lower CFU/g were recovered from MLN (P = 0.0232) and lungs (P = 0.0496) of 
vaccinated versus non-vaccinated calves.   
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CHAPTER 6. Adult Ruminant Models of Salmonellosis 
6.1 Introduction 
According to published reports of Salmonella challenge studies in sheep, between 
109 and 1012 organisms are required to induce salmonellosis in adult sheep 
(Jelinek, et al., 1982a; Mukkur, et al., 1987; Begg, et al., 1990; Mukkur, et al., 
1991b; Mukkur and Walker, 1992; Mukkur, et al., 1995; Wray and Linklater, 
2000). Mortality, diarrhoea, and rectal temperature are commonly used to assess 
clinical outcomes of salmonellosis in group housed animals. Individual outcomes 
for appetite, water consumption, and behaviour have not been reported in sheep. 
These challenge dose trials were conducted in order to ascertain the optimum dose 
of Salmonella that would induce clinical disease in adult sheep, while minimising 
mortality, to maintain sample size and statistical power for measured outcomes. 
Additionally, establishing protocols for monitoring salmonellosis in sheep allows 
for better understanding of the pathogenesis of salmonella infection which has not 
been reported in the literature and facilitates prediction of outcomes in clinical 
cases (i.e., mortality, morbidities) which could then be applied to salmonella 
outbreaks in feedlot situations.   
6.2 Experimental Design 
6.2.1. Isolate selection 
Isolates were selected from an outbreak of salmonellosis at a feedlot in Western 
Australia and considered industry and clinically relevant. The isolates included 
serotypes S. Bovismorbificans, S. Bredeney, S. Havana, S. Infantis, S. Kottbus, S. 
Singapore and S. Typhimurium. Eleven isolates, three S. Bovismorbificans and 
eight S. Typhimurium, were selected as candidates for use in the challenge models 
based on virulence testing that was conducted by the Department of Molecular, 
Cellular and Developmental Biology at the University of California, Santa 
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Barbara using procedures outlined in Heithoff et al. (2008b). A competitive index 
(CI) score was assigned for each isolate based on results of oral and 
intraperitoneal LD50 testing in mice (Conner, et al., 1998) and identification of the 
spv genes (Jones, et al., 1982; Gulig, et al., 1992) as well as genes encoding the 
spvB actin cytotoxin, required for systemic survival (Gulig, 1990; Matsui, et al., 
2001), and the pef fimbriae, implicated in adherence to the murine intestinal 
epithelium (Baumler, et al., 1996). Antimicrobial sensitivity and resistance (ASR) 
testing following procedures outlined in Section 3.3.6 was performed on the 
selected isolates in order to establish resistance and susceptibility profiles for use 
in re-isolation protocols. 
6.2.2. Verification of isolate resistance 
Eight of the eleven virulent isolates were identified to have resistance to neomycin 
sulphate, allowing differentiation from the S. Typhimurium dam vaccine:  five S. 
Typhimurium and three S. Bovismorbificans. These isolates were grown 
overnight on LA plates containing neomycin sulphate at 5, 10, 15, and 20 µg/mL 
to identify resistant clones and to determine the level of antibiotic required to 
ensure re-isolation of the virulent isolates from tissues, faeces and solutions 
containing the isolate, microbial flora and the vaccine strain. To ensure that 
isolates maintained resistance to antimicrobials, colonies were stored frozen and 
re-cultured following procedures outlined in Section 3.3.1 by plating onto media 
containing neomycin, then serial diluted onto selective media at incremental 
concentrations of neomycin and chloramphenicol. Plates were incubated 
aerobically overnight at 37°C and colonies were enumerated to determine 
recovery rate. 
6.2.3. Challenge dose trials in Merino wethers 
Strains used in these challenge studies were grown overnight in LB at 37°C 
following procedures outlined in Appendix I, and delivered to the sheep in a 10 
mL PO bolus resuspended in PBS. 
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i. Homologous dose range finding study 
Homologous challenge studies were performed with a derivative of a S. 
Typhimurium strain, 06-131, an industry-relevant, multi-drug antimicrobial 
resistant strain (apramycin, erythromycin, neomycin, novobiocin, sulphonamides, 
streptomycin) that was isolated from an outbreak of salmonellosis in sheep on a 
commercial feedlot in Western Australia (ST 06-131) as described in Section 
3.2.2.ii. 
Fourteen sheep were randomly placed into two groups, low dose and high dose, of 
seven sheep each. Sheep were orally administered ST 06-131 challenge strain at 5 
 108 and 5  109 organisms for low and high dose, respectively. 
ii. Heterologous dose range finding study 
Heterologous challenge studies were performed with a derivative of a S. 
Bovismorbificans strain, 06-225, an industry-relevant, multi-drug antimicrobial 
resistant strain (apramycin, erythromycin, neomycin, novobiocin, sulphonamides, 
streptomycin) that was isolated from an outbreak of salmonellosis in sheep on a 
commercial feedlot in Western Australia (SBM 06-225) as described in section 
3.2.2.iii. 
Fifteen sheep were randomly placed into two groups, low dose and high dose, of 
eight and seven sheep respectively.  Sheep were orally administered SBM 06-225 
challenge strain at 1.7  108 and 1.7  109 organisms for low and high dose 
respectively. 
iii. Sheep selection and husbandry 
Merino wethers, approximately 2 to 3 years in age, were sourced from a single 
flock in New South Wales, Australia (see Section 3.5.2). Faecal samples were 
collected from all sheep prior to enrolment in the study and underwent qualitative 
detection of Salmonella following procedures outlined in Section 3.6.1. No 
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salmonellae were detected in the sheep during the acclimation period. Sheep were 
transported to the Medium Security Animal Housing Facility at EMAI (NSW, 
AU), and randomly assigned to experimental groups and housed following 
procedures outlined in Section 3.5.5. Sheep received a diet of oaten chaff (8 MJ 
ME/kg DM) and commercially prepared grain pellet (12 MJ ME/kg DM) during 
the acclimation and challenge phases of the experiment. Sheep were gradually 
introduced to the grain pellet during the acclimation period. Sheep were offered 
600 g of oaten chaff and 300-400 g of grain pellets at the morning observation 
period during the challenge periods (roughly 9 MJ ME/d). 
iv. Clinical assessment of sheep 
Sheep were acclimated for approximately two weeks prior to initiation of the dose 
range study in order to establish normal ranges for behaviour, faecal scores and 
rectal temperatures, as well as to introduce the sheep to a diet of pellets and chaff. 
Clinical assessment of the sheep was performed twice a day during the 
acclimation period and RT was recorded bi-weekly to ensure that sheep were 
healthy, following procedures outlined in Section 3.5.7. The normal range of RT 
for the sheep used in these experiments based on the pre-challenge mean 
(baseline) RT ± two standard deviations was 37.5 – 39.8°C.  RT was recorded 
daily following virulent Salmonella challenge. 
During the challenge phase, sheep were clinically assessed following procedures 
outlined in Section 3.5.7.  Quantitative faecal culturing was conducted 3, 7, 10, 
and 12 d post-challenge following procedures outlined in Section 3.6.2. Appetite 
was recorded in g of chaff and pellets not consumed over each 24 h feeding 
period. Percent refusal of chaff and pellets was determined for each animal during 
the challenge period based on pre-challenge consumptions. An attitude score of 4 
at any time of the day, or failure to consume chaff or pellets (100% refusal of 
feed) for three consecutive feedings, constituted grounds for euthanasia as 
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described in Section 3.5.10. Sheep were weighed during the acclimation period 
prior and 12 d post-challenge. 
v. Necropsy and tissue collection 
On day 12 post-challenge, surviving sheep in the homologous and heterologous 
challenge studies were humanely euthanised and necropsied. Approximately 2 to 
5 g of tissue was obtained from the liver, ileum, spleen, and mesenteric lymph 
node of each sheep to evaluate tissue colonisation of the challenge agent. 
vi. Statistical analysis 
Continuous data were analysed using REML analysis (Genstat, 12th Edition, VSN 
International, UK). A single variate, repeated measures model was fitted for the 
factors of time and treatment for variables CFU, temperatures, chaff refusal, pellet 
refusal, and water intake. The Wald chi-square test was used to determine 
significant individual effects and/or significant interactions between factors. Any 
non-significant terms were dropped from the model and analysis repeated. The 
following analysis data are presented as predicted model based means. Predicted 
means are those obtained from the fitted model rather than the raw sample means. 
This is important as predicted means represent means adjusted to a common set of 
variables, thus allowing valid comparison between means. A P value less than 
0.05 was considered to be statistically significant. Differences between the 
individual means were determined by calculating an approximate LSD. A 
difference of means that exceeded the calculated LSD was considered significant. 
Repeated measures of non-parametric clinical data, faecal composition and 
mentation, were analysed using the Wei-Lachin test (Wei and Lachin, 1984; 
Davis, 1991) using StatsDirect statistical software, http://www.statsdirect.com, 
2002, CamCode, England (Buchan, 2000). Wei Lachin analysis of the data 
performed univariate group comparisons for individual time points and a 
multivariate comparison over the study period analysed. Data are presented as the 
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percentage of sheep that displayed an abnormal attitude (cumulative daily score > 
3) or have abnormal faecal score (cumulative daily score > 3) over the course of 
the challenge period. Tissue colonisation and were evaluated using ANOVA, the 
vaccine dose and body weight of sheep that did and did not develop pyrexia 
following vaccination was compared using unpaired t-test, and mortality results 
were compared using chi-square. 
6.3 Results 
6.3.1. Selection of isolates 
Virulence testing aided in the identification of virulent candidates for use in the 
challenge models. Three S. Bovismorbificans and five of the S. Typhimurium 
were selected as candidates for use in the development of ovine models of 
heterologous and homologous salmonellosis based on the results of the CI score 
and detection of virulence genes. Based on the results of the ASR testing, the 
eight selected isolates displayed neomycin sulphate resistance and 
chloramphenicol susceptibility (Table 6.1). This ASR profile was ideal, as it allow 
differentiation of the S. Typhimurium dam vaccine strain from these challenge 
isolates in a challenge -vaccination trial. 
6.3.1. Confirmation of isolate resistance 
When the isolates were plated for single colonies onto LA or XLD media 
containing neomycin sulphatesulfate at 30 µg/mL, no growth was observed. 
However, when the level of neomycin was reduced to 10 µg/mL, consistent 
growth from one of the S. Typhimurium isolates, S. Typhimurium 06-131 (ST 06-
131), and two of the S. Bovismorbificans isolates, S. Bovismorbificans 06-174 
and S. Bovismorbificans 06-225 (SMB 06-225) was observed.  Serial dilution 
plating of the isolates onto selective media containing neomycin sulphatesulfate at 
10 µg/mL was performed, and ST 06-131 and SBM 06-225 retained neomycin 
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Table 6.1: Results of antimicrobial susceptibility and resistance testing and virulence scores of salmonella challenge agent candidates 
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resistance and the antibiotic did not inhibit growth (Table 6.2).  When the level of 
neomycin was increased to 15 or 20 µg/mL, partial to complete inhibition in 
growth was observed in all of the isolates. From these data, ST 06-131 was the 
isolate selected as the challenge strain for the homologous salmonellosis model 
and SBM 06-225 was the isolate selected as the challenge strain for the 
heterologous salmonellosis model. . 
6.3.1. Dose range of S. Typhimurium 06-131 in sheep 
A challenge dose trial was conducted in order to determine an optimum dose that 
would induce disease while minimising mortality, in order to maintain sample size 
and statistical power for measured outcomes. All of the sheep developed clinical 
signs of salmonellosis (fever, diarrhoea, decreased appetite and depressed attitude) 
during the 12 d post-challenge observation period. No mortalities were observed 
in the low dose group. There were four mortalities in the sheep administered the 
high dose of ST 06-131 on days 6, 7, 8 and 11 post challenge, respectively. As 
expected, the severity of clinical signs was greater in sheep challenged at the high 
dose of ST 06-131. 
Sheep receiving the ST 06-131 challenge strain had significantly elevated 
predicted mean RT when compared to pre-challenge baseline RT from days 2 to 8 
post-challenge in the low dose and days 2 to 10 in the high dose (P < 0.05; Figure 
6-1). However, by day 8 post-challenge, the RT of the challenged sheep had 
returned to the normal range.  Dose level of the challenge strain did not have an 
effect on the predicted mean RT in the sheep over the 12 d observation period (P 
= 0.494) 
The dose of ST 06-131 had a significant effect on the mentation of the sheep 
during the 12 d observation period (P < 0.005). The incidence of abnormal 
mentation were significantly increased in the high dose group when compared to 
the low dose on days 7 to 10 post-challenge (P < 0.05; Figure 6-2).  
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Table 6.2:  Results of growth of isolates on selective media containing antibiotics. 
Salmonella Isolate Identification 
Plate 
Media 
ST 06-131 SBM 06-174 SBM 06-225 
1a 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6 
Plain XLD + + 38 5 1 NG + + 74 5 1 NG + + 13 1 NG NG 
XLD+ 
NEO 10µg/mL 
+ + 36 3 NG NG + + 42 4 NG NG + + 13 1 NG NG 
XLD+ 
NEO 15µg/mL 
+ 12 1 NG NG NG NG NG NG NG NG NG + 89 7 NG NG NG 
XLD+ 
NEO 20µg/mL 
NG NG NG NG NG NG NG NG NG NG NG NG NG NG NG NG NG NG 
XLD+ 
NEO 30µg/mL 
NG NG NG NG NG NG NG NG NG NG NG NG NG NG NG NG NG NG 
Luria + 
CHL 10µg/mL 
NG NG NG NG NG NG NG NG NG NG NG NG NG NG NG NG NG NG 
a: Series of six serial 1:10 dilution of stock solution (see Section 3.6) 
+: Too many colonies to count; NG - No growth 
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There was a significant increase in the incidence of abnormal faeces in the high 
dose group when compared to the low dose on days 7 to 11 post-challenge (P < 
0.05; Figure 6-3). The shedding of ST 06-131 challenge strain in faeces of the 
sheep was measured on days 3, 7, 10 and 12 post challenge (Figure 6-4). The 
predicted mean CFU/g of ST 06-131 shedding was significantly higher in the 
faeces of sheep from high dose group on days 10 and 12 post challenge (P < 
0.05).  
The dose level of ST 06-131 had a significant effect on the chaff appetite of the 
sheep over the course of the study (P < 0.001). Chaff refusals in the low dose 
group were significantly lower when compared to the high dose group on days 6 
to 11 post-challenge (P < 0.05; Figure 6-5).  Pellet refusals were significantly 
lower in the low dose group when compared to the high dose on days 8 and 11 
post-challenge (P < 0.05; Figure 6-6).  Nearly 100% refusal of pellets was 
observed from day 3 post challenge to completion of the study in the high dose 
group.  
Water consumptions were significantly reduced from days 2 to 11 post-challenge 
in the high dose group and days 2 to 9 post-challenge in the low dose when 
compared to pre-challenge water consumption levels (P < 0.05; Figure 6-7).  
Water consumptions were significantly higher in the low dose group on days 10 
and 11 when compared to the high dose group (P < 0.05).  Interestingly, following 
the challenge, water consumption was 2.43 ± 0.20 L, and 2.07 ± 0.20 L for the 
low and high dose groups, respectively, which was 144.2% and 115.5% of the 
mean daily water consumption during the five days preceding challenge. 
There was no difference in the mean body weights of the low and high dose 
groups over the course of the study (P = 0.158). Significant loss in predicted mean 
body weight was observed on day 12 post challenge at both dose levels when 
compared to acclimation and pre-challenge predicted mean body weights (P < 
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0.05; Figure 6-8). 
Colonisation of tissues was determined by enumeration of ST 06-131 recovered 
from MLN, spleen, liver, and ileum wall 12 d post-challenge. ST 06-131 was 
recovered from 7 of 7 and 3 of 3 sheep from the low and high dose groups, 
respectively. There was no difference between the mean CFU/g of ST 06-131 
recovered from the tissues of sheep from the low and high dose groups (Figure 
6-9). 
These data suggest that the ST 06-131 isolate was capable of producing clinical 
salmonellosis in adult sheep when administered as an oral bolus as evidenced by 
pyrexia, altered mentation, diarrhoea, reduced appetites, weight loss, faecal 
shedding and colonisation in tissues. The isolate retained neomycin resistance 
following in vivo oral challenge in sheep and was successfully re-isolated from the 
faeces and tissues when placed onto XLD plates containing 10 µg/mL neomycin 
sulphate (XLD-NEO). 
6.3.2. Dose range of S. Bovismorbificans 06-225 in sheep 
This challenge dose trial was conducted in order to determine an optimum dose 
that would induce disease while minimising mortality, in order to maintain sample 
size and statistical power for measured outcomes for use in a heterologous model 
of salmonellosis in sheep. All of the sheep developed clinical signs of 
salmonellosis (fever, diarrhoea, decreased appetite and depressed attitude) during 
the 12 d post-challenge observation period. There were three mortalities in the 
sheep administered the high dose of SBM 06-225 on days 6 (n=2) and 9 (n=1) 
post challenge, respectively.   No mortalities were observed in the low dose group. 
Sheep receiving the SBM 06-225 challenge strain had significantly elevated 
predicted mean RT when compared to pre-challenge baseline from days 2 to 10 
post-challenge in the low dose group and in the high dose group from day 1 to 12 
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post challenge (P < 0.05; Figure 6-10). While the dose of SBM 06-225 challenge 
did not have an effect on the predicted mean RT over the course of the 12 d 
observation period (P = 0.338), mean RT of sheep in the low dose group was 
significantly lower than the high dose group on day 2 post challenge (P < 0.05). 
Administration of SBM 06-225 had a significant effect on the mentation of the 
sheep over the course of the study (P = 0.0001).  Abnormal mentation was first 
noted on day 2 post-challenge in both groups with peak incidence occurring on 
day 4 and day 7 in the low and high dose groups respectively (Figure 6-11). 
There was a significant increase in the incidence of abnormal faeces in sheep 
receiving the SBM 06-225 challenge strain over the course of the study (P < 
0.0001). The incidence of abnormal faeces was significantly increased in the high 
dose group on days 3 and 4 post-challenge when compared to the low dose group 
(P < 0.005; Figure 6-12).  Shedding of SBM 06-225 challenge strain in faeces was 
evaluated on days 3, 7, 10 and 12 post challenge (Figure 6-13). The predicted 
mean shedding of the SBM 06-225 challenge strain was significantly higher in the 
high dose group on day 3 post challenge when compared to the low dose group (P 
< 0.05).  There was no difference in the shedding of SBM 06-225 in the low and 
high dose groups on days 7, 10, and 12 post challenge.  
The SBM 06-225 challenge had a significant effect on appetite of the sheep over 
the course of the study (P < 0.012, chaff; P < 0.001, pellets).  Chaff refusals in the 
low dose group were significantly reduced when compared to the high dose group 
day 2 post-challenge (P < 0.05; Figure 6-14). Additionally, the chaff refusals were 
significantly increased when compared to pre-challenge refusals (day 0) from day 
3 to 10 and day 2 to 11 post-challenge in the low and high dose groups 
respectively (P < 0.05). Pellet refusals were significantly less in the low dose 
group when compared to the high dose group on day 2 post-challenge (Figure 
6-15). And pellet refusals were significantly increased when compared to pre-
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challenge refusals (day 0) from day 3 to 10 and day 1 to 8 post-challenge in the 
low and high dose groups respectively (P < 0.05). 
Dose level of the SBM 06-225 challenge did not have a significant effect on water 
consumption of the sheep over the course of this study (P = 0.055), however, 
water consumption of the sheep was significantly reduced when compared to pre-
challenge consumptions on days 3, 4, 10 and 11 post-challenge in the low dose 
sheep and day 3 post-challenge in the high dose sheep (P < 0.05). Significantly 
improved water consumptions were observed in the low dose group on days 1 and 
2 when compared to the high dose group (P < 0.05; Figure 6-16). Following the 
administration of the SBM 06-225 challenge, mean water consumption of the 
sheep was 4.56 ± 0.94 L, and 2.94 ± 0.44 L in the low and high dose groups, 
respectively, which was 143.9% and 105.6 % of the mean water consumption 
during the five days preceding challenge for each group.  
There was no difference in the mean body weights of the low and high dose 
groups following the challenge (P = 0.963). Over the course of the study both 
groups showed a similar decrease in predicted mean body weight when compared 
to pre-challenge body weights (P < 0.05; Figure 6-17). 
Colonisation of tissues was determined by enumeration of SBM 06-225 recovered 
from MLN, spleen, liver, lung and ileum wall 12 d post challenge. SBM 06-225 
was recovered from 7 of 7 and 4 of 4 sheep from the low and high dose groups 
respectively. There was no difference in the mean CFU/g of SBM 06-225 
recovered from the tissues of sheep from the low and high dose groups (Figure 
6-18). 
6.3.3. Ovine salmonellosis gross pathology findings 
Gross pathological findings included enlarged mesenteric lymph nodes, ulcerated 
bile ducts, fibrin deposits in the small intestine, caecum and abomasum, ulceration 
of the pylorus, mucosal erosions of the abomasum, small intestine and caecum as 
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well as ecchymotic haemorrhages on the serosal surface intestines and mesentery 
(Figure 6-19). These findings were commonly associated with animals that were 
found dead or euthanised. Interestingly, very few lesions were observed in the 
sheep that survived to the end of the study.   Given that the sheep had shown 
clinical signs consistent with salmonellosis it suggests that the bowel is capable of 
healing quickly once the immune response controls the infection.   
6.4 Discussion  
The aims of this research were to identify virulent Salmonella candidates for use 
in the development of ovine models of homologous and heterologous 
salmonellosis.  Dose range finding studies often incorporate several doses of a 
challenge agent at half log intervals to enable statistical estimation of the lethal 
dose (LD90-100).  One of the difficulties of developing a good Salmonella challenge 
model for evaluation of vaccines or antimicrobial efficacy is the identification of a 
challenge strain. It has been well documented that prevalence of an isolate during 
an outbreak of salmonellosis does not always correlate with virulence (Rice, et al., 
1997; Tsolis, et al., 1999; Mahan, et al., 2000; Adaska, et al., 2008).  Every effort 
was made to ensure candidates used in the challenge models were virulent and 
industry relevant prior to in vivo usage. Unfortunately, potential challenge strains 
occasionally prove to be avirulent in the test subject due to variable expression of 
virulence within a particular host.  Two dose levels, one log difference between 
dose levels for each of the challenge isolates, were selected based on published 
ruminant models of salmonellosis (Rankin and Taylor, 1966; Nazer and Osborne, 
1977; Jones, et al., 1988; Mukkur, et al., 1991a; House, et al., 2001a; Fecteau, et 
al., 2003; Dueger, et al., 2003b; Mohler, et al., 2006). The logic of this decision 
was to avoid the scenario of including large numbers of sheep only to find that the 
strain was avirulent. 
The data from the dose range finding studies demonstrated that ST 06-131 and 
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SBM 06-255 were capable of inducing clinical disease in Merino wethers. And 
both isolates retained neomycin resistance following in vivo oral challenge in 
sheep and was successfully re-isolated from the faeces and tissues.   All sheep in 
the low and high dose challenge groups developed clinical signs of salmonellosis 
which included fever, diarrhoea, decreased appetite and depressed mentation 
during the 12 d post-challenge observation period.  However, there are no 
reported ovine salmonella challenge trials where attitude, appetite, and water 
consumption have been monitored in individual sheep with which to compare 
these results.  The mortalities in the sheep could be attributed to the development 
of septicaemia, acidosis (depressed mentation), diarrhoea, dehydration and 
anorexia. The hypothermia observed in these sheep prior to death was associated 
with release of endotoxin, acidosis, cardiovascular collapse and septic shock. 
From these results, a challenge dose of 1  109 CFU of ST 06-131 was selected as 
a target for use in homologous vaccine efficacy trials and 1  109 CFU of SBM 
06-225 for use in future cross protective vaccine efficacy trials, as these doses are 
likely to provide predictable induction of clinical disease with minimal mortality.  
The dose levels required to induce mortality, pyrexia and diarrhoea in sheep were 
within the ranges reported in the literature (Mukkur, et al., 1987; Mukkur, et al., 
1991b; Wray and Linklater, 2000).    
One interesting outcome of the ASR testing was the relative lack of antimicrobial 
resistance in the isolates. Antimicrobial resistance is a common feature in 
salmonellosis outbreaks (CDC, 1996, 2002; OzFoodNet, 2003). The isolates from 
the feedlot outbreaks were sensitive to tetracycline, trimethoprim-sulphonamide, 
amoxyclavulonic acid, ceftiofur and amikacin which are all approved for use in 
livestock (APVMA, 2010). None of the isolates tested were resistant to nalidixic 
acid which is not surprising as fluoroquinolones are not allowed to be used in 
livestock species in Australia (APVMA, 2010). It was interesting to note that all 
of the isolates from the outbreak were resistant to the antibiotic apramycin which 
119 
is commonly used in feedlots. 
Inanition and salmonellosis are the most common causes of death in exported 
sheep and contributes to 75% of mortalities reported (Jelinek, et al., 1982b; Norris 
and Richards, 1989; Norris, et al., 1989a; Norris, et al., 1989b; Richards, et al., 
1989; Higgs and Norris, 1991; Richards and Hyder, 1991; Higgs, et al., 1993; 
Kelly, 1995; Makin, 2011). During the conduct of this research it was observed 
that post virulent Salmonella challenge, feed intakes of the sheep were 
significantly reduced within 48 h of challenge and were anorectic within 72 h post 
challenge. Another observation was that challenged sheep preferentially selected 
the chaff component of the diet over pellets. This phenomenon persisted following 
clearance of the organism and resolution of clinical signs in the challenged sheep. 
Interestingly, it is reported that inappetence and poor rumen fill in feedlot sheep 
often precedes infection with Salmonella (Richards, et al., 1989; Richards and 
Hyder, 1991; Higgs, et al., 1993; Kelly, 1995). In contrast, the sheep in these 
research trials displayed inappetence following the virulent Salmonella challenge, 
not preceding it.  These studies demonstrate that inappetence and feed refusal, 
often called 'neopobia' in feedlot industry, may actually be attributed to 
salmonellosis.  
The commonly reported observation that sheep in a new environment may not 
consume a novel diet due to lack of experience with the feed source (neophobia), 
is believed to be a contributing factor to the observation of inanition. The number 
of non-feeders has been reported to range between 0.2% to 50% in various groups 
of sheep under varying conditions (Norris and Richards, 1989; Norris, et al., 
1989a; Norris, et al., 1989b; Norris, et al., 1990; Higgs and Norris, 1991; 
Richards and Hyder, 1991; Bailey and Fortune, 1992; Kelly, 1995; Higgs and 
Norris, 1999). During the acclimation phase of these studies, one of the 29 sheep 
(3.4%) displayed neophobia to pellets and chaff while 5 of 29 (17.9%) refused to 
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consume pellets. With poor rumen fill, feed withholding, anorexia and rumen 
imbalance identified as risk factors for salmonellosis in feedlot sheep (Norris, et 
al., 1989a; Norris, et al., 1989b; Richards, et al., 1989; Richards and Hyder, 1991; 
Higgs, et al., 1993; Kelly, 1995; Lenahan, et al., 2010), ensuring that sheep accept 
the diet offered is essential to maintaining the health of a flock. Finding ways to 
improve transition from pasture to pellet reduces the risk of neophobia and 
inanition. However, in this sample population, sheep demonstrated dietary 
preferences with avoidance of pellets, despite previous exposure and transition.  
Although a small sample size, these data suggest that animal preferences and 
salmonellosis may also be important factors in neophobia and inanition. 
Necropsy findings demonstrated that gross pathology in the lymph nodes and 
intestines occurred following the administration of the challenge agent. However 
the lungs, liver and spleen were grossly normal, despite colonisation with the 
challenge agent. Salmonella infections have been associated with colonisation of 
the lymph nodes, lung, liver, spleen, gall bladder and salivary glands in ruminants 
(Jelinek, et al., 1982a; Jelinek, et al., 1982b; Mukkur, et al., 1987; Norris, et al., 
1989a; Richards, et al., 1989; Higgs, et al., 1993; Mukkur, et al., 1995; Wray and 
Linklater, 2000; Vanselow, et al., 2007a). In previous dose range finding studies, 
low yield tissue colonisation of S. Dublin and S. Newport in calves were shown to 
be time dependent and correlated with resolution of clinical signs (Mohler, et al., 
2006; Mohler, et al., 2008). The sheep that survived to the end of the observation 
period were noted to have few to no gross lesions. It has been reported that 
acutely infected animals shed fewer Salmonella for shorter periods of time and 
these animals are less likely to become carriers (Smith, et al., 1979; Wray and 
Davies, 2000; Smith, 2002; Mohler, et al., 2009). 
This study outlines the development of homologous and heterologous models of 
salmonellosis for use in future challenge-vaccination efficacy trials with the 
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modified live S. Typhimurium dam attenuated vaccine in adult Merino wethers. 
Importantly, ST 06-131 and SBM 06-225 are both isolates that are relevant to the 
Australian sheep industry. Both isolates were capable of producing clinical 
disease in adult sheep which allowed for the development of criteria for assessing 
clinical outcomes (mentation, appetite, diarrhoea, pyrexia) and maintained 
antimicrobial resistance, which facilitated evaluation of faecal shedding and tissue 
colonisation.
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Figure 6-1.  Predicted mean rectal temperatures of sheep following challenge with ST 06-131 
RT were measured daily for 12 d following challenge. Data are depicted as a predicted mean RT ± SE. The data are presented in the context of the normal 
range (dashed grey lines) and baseline (solid grey line) established pre-vaccination. *RT were significantly increased when compared to baseline on days 
2 to 10 and on days 2 to 8 post-virulent challenge in the high and low dose groups, respectively (P < 0.05).   
123 
 
Figure 6-2.  Incidence of abnormal mentation in sheep following challenge with ST 06-131 
Data are depicted in percentage of sheep with abnormal mentation. *The incidence of sheep with abnormal mentation following challenge was 
significantly increased in the high dose group on days 7 to 10 post-challenge (*P = 0.05), and over the 12 d observation period (P <0.005). 
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Figure 6-3.  Incidence of abnormal faeces in sheep following challenge with ST 06-131 
Faecal composition was assessed twice a day. Data are depicted as percentage of sheep with abnormal faeces following challenge. *Significantly lower 
incidence of diarrhoea was observed in the low dose group when compared to the high dose group days 7 to 11 post challenge (P < 0.05). 
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Figure 6-4.  Predicted mean faecal shedding of following challenge with ST 06-131 in sheep. 
Data are depicted as a predicted mean log10 CFU of ST 06-131 per g of faeces post-challenge ± SE. *Significant differences in faecal shedding were 
observed on days 10 and 12 post-challenge between the low and high dose group (P < 0.05). 
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Figure 6-5.  Predicted mean chaff refusal in sheep following ST 06-131 challenge. 
Predicted mean chaff refusal is depicted ± SE. *Chaff refusal was significantly lower in the low dose group when compared to the high dose from days 
6 to 11 post-challenge (P < 0.05) and over the study period (P < 0.001). 
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Figure 6-6.  Predicted mean pellet refusal in sheep following ST 06-131 challenge 
Predicted mean pellet refusal is depicted ± SE. Pellet refusal was significantly reduced in the low dose group when compared to the high dose on 
days 8 and 11post-challenge (α P < 0.05). Pellet refusals in both groups was significantly increased days 2 to 11 when compared to day 0 refusals (α 
P < 0.05). 
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Figure 6-7.  Predicted mean water consumption in sheep following ST 06-131 challenge 
Predicted mean water consumption in L is depicted ± SE. Water consumption was significantly improved in the low dose group when 
compared to the high dose on days 10 and 11 post-challenge (α P < 0.05). 
  
129 
 
Figure 6-8.  Predicted mean body weights of sheep following ST 06-131 challenge 
Data are depicted in predicted mean BWT in Kg ± SE at acclimation, pre-challenge and day 12 post-challenge. *BWT of the low and high dose 
groups were significantly decreased on day 12 post challenge when compared to pre-challenge and acclimation weights (P < 0.05). 
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Figure 6-9.  Colonisation of tissues with ST 06-131 in challenged sheep. 
Tissue colonisation data are depicted as mean log10 CFU ± SE of ST 06-131, recovered by organ. 
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Figure 6-10.  Predicted mean rectal temperatures of sheep following challenge with SBM 06-225 
RT were measured daily for 12 d following challenge.  Data are depicted as a predicted mean RT  ± SE. The data are presented in the context of the 
normal range (dashed grey lines) and baseline (solid grey line) established pre-challenge. *RT were significantly increased when compared to baseline 
on days 1 to 12 and on days 2 to 10 post-virulent challenge in the high and low dose groups, respectively (P < 0.05). And the low dose was 
significantly lower when compared to the high dose on day 2 post-challenge (α P < 0.05). 
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Figure 6-11.  Incidence of abnormal mentation in sheep following challenge with SBM 06-225 
Data are depicted in percentage of sheep with abnormal mentation. Administration of the SBM 06-225 had an effect on mentation over the 12 d 
observation period (P = 0.0001). 
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Figure 6-12.  Incidence of abnormal faeces in sheep following challenge with SBM 06-225 
Faecal composition was assessed twice a day. Data are depicted as percentage of sheep with abnormal faeces following challenge. *Significantly 
lower incidence of diarrhoea was observed in the low dose group when compared to the high dose group days 3 and 4 post challenge (P < 0.05). 
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Figure 6-13.  Predicted mean faecal shedding of following challenge with SBM 06-225 in sheep. 
Data are depicted as a predicted mean log10 CFU of SBM 06-225 per g of faeces post-challenge ± SE. *Significant differences in faecal shedding 
were observed between the low and high dose group on day 3 post-challenge (P < 0.05). 
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Figure 6-14.  Predicted mean chaff refusal in sheep following SBM 06-225 challenge 
Predicted mean chaff refusals are depicted ± SE. Chaff refusal was significantly reduced in the low dose group when compared to the high 
dose on day 2 post-challenge (*P < 0.05) and significantly increased compared to day 0 refusal (α P < 0.05). 
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Figure 6-15.  Predicted mean pellet refusal in sheep following SBM 06-225 challenge. 
Predicted mean pellet refusals are depicted ± SE. Pellet refusal was significantly reduced in the low dose group when compared to the high dose on 
day 2 post-challenge (*P < 0.05) and significantly increased when compared to day 0 refusal (α P < 0.05). 
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Figure 6-16.  Predicted mean water consumption in sheep following SBM 06-225 challenge 
Predicted mean water consumption in L is depicted ± SE. *Water consumption was significantly improved in the low dose group when compared 
to the high dose on days 1 and 2 post-challenge (P < 0.05) 
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Figure 6-17.  Predicted mean body weights of sheep following SBM 06-225 challenge 
Data are depicted in predicted mean BWT in Kg ± SE pre-challenge and on day 12 post-challenge. No differences were observed in the body 
weights of the sheep post-challenge (P = 0.963). 
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Figure 6-18.  Colonisation of tissues with SBM 06-225 in challenged sheep. 
Tissue colonisation data are depicted as mean log10 CFU/g ± SE of SBM 06-225, recovered by organ. 
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Figure 6-19.  Necropsy findings of sheep challenged with Salmonella 
 
(A)  Enlarged mesenteric lymph node (B) Haemal lymph nodes within the 
mesenterymesentary 
 
(C) Enteritis in small and large intestines (D) Serosal petechiation and reddening 
 
(E)  Caecum - mucosal congestion ("tiger striping") 
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CHAPTER 7. Development of a Novel In-Water Vaccination Protocol for 
DNA Adenine Methylase Deficient Salmonella enterica serovar Typhimurium 
Vaccine in Adult Sheep 
The following is a re-formatted manuscript, currently under review for 
publication:  
Mohler, V.L., Heithoff, D.M., Mahan, M.J., Hornitzky, M.A., Thomson, P.C., 
House, J.K. (2011).  Development of a Novel In-Water Vaccination Protocol for 
DNA Adenine Methylase Deficient Salmonella enterica serovar Typhimurium 
Vaccine in Adult Sheep.  Vaccine (currently under review)  
The study was designed, executed and reported by the candidate under the general 
supervision of the remaining authors, who were the candidate's appointed 
supervisors (principal and associate). 
7.1 Introduction   
Salmonella continues to be one of the most common causes of gastroenteritis in 
the developed world.  There are over 2,500 different serotypes of Salmonella; all 
are potentially capable of causing disease in livestock and humans (Garrity, et al., 
2004; Popoff, et al., 2004; WHO, 2005).  Human disease is commonly linked to 
the consumption of contaminated foodstuffs such as poultry, eggs, milk, meat and 
vegetables (Pacer, et al., 1986; CDC, 1996; Glynn, et al., 1998; Mead, et al., 
1999; Mead, et al., 2000; CDC, 2002, 2005; WHO, 2005; CDC, 2006).  Animal 
production management strategies to prevent disease have not been successful and 
antimicrobial use in salmonellae contaminated facilities is causing growing 
concern regarding emerging antimicrobial resistance (WHO, 1997; CDC, 2002; 
Mølbak, 2005; WHO, 2005; CDC, 2008). 
Recent innovations have resulted in the development of modified live Salmonella 
vaccines that elicit cross-protective immunity to homologous and heterologous 
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salmonellae serovars (Jelinek, et al., 1982a; Smith, et al., 1984; Begg, et al., 1990; 
Hassan and Curtiss, 1994a; Heithoff, et al., 2001; Nagy, et al., 2004; Heithoff, et 
al., 2008a).  These vaccine candidates are attenuated live Salmonella that contain 
mutations in global regulatory networks that are thought to increase antigen 
exposure and/or modulate the immune response to confer protection.  While 
vaccination is generally a useful strategy to control infectious diseases, it has also 
been associated with increased production costs, carcass damage and adverse 
reactions (Bowersock and Martin, 1999; Giudice and Campbell, 2006; Murphy, et 
al., 2008; Savini, et al., 2008; Mamak and Aytekin, 2009).   
To address these livestock-production challenges, the use of in-water medication 
and vaccination to control and prevent disease is a common practice in intensively 
managed poultry (Vermeulen, et al., 2002) and swine (Kolb, 1996; Agerso, et al., 
1998; Walter, et al., 2001).  Additionally, use of impregnated baits and sachets 
have been employed to successfully vaccinate feral dogs and wildlife against 
rabies (Bergman, et al., 2008; Cliquet, et al., 2008; Niin, et al., 2008) and wild 
deer populations against tuberculosis (Nol, et al., 2008).  Conversely, very little 
information has been reported on the use of in-water or oral vaccination in 
livestock species such as cattle, goats and sheep, wherein the use of such practices 
may improve animal health and well-being, as well as conferring significant 
reductions in pre- and post- harvest bacterial loads. 
Salmonella Typhimurium containing loss of function mutations in the gene 
encoding the DNA adenine methylase (dam) are attenuated for virulence and 
confer significant protection to homologous and heterologous Salmonella 
challenge when applied as modified live vaccines in mice (Garcia-Del Portillo, et 
al., 1999; Heithoff, et al., 1999; Heithoff, et al., 2001; Heithoff, et al., 2008a), 
poultry (Dueger, et al., 2001, 2003a), and calves (Dueger, et al., 2003b; Mohler, 
et al., 2006; Mohler, et al., 2008).  The objective of the current studies was to 
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evaluate the stability and viability of the S. Typhimurium dam vaccine over a 24 h 
period for use in a novel in-water vaccination delivery system for livestock and to 
demonstrate the efficacy of in-water delivery to adult sheep.  
7.2 Materials and Methods 
7.2.1. Bacterial strains and growth conditions 
Immunisations were carried out with dam-102::Mud-Cm Typhimurium UK-1 
vaccine strain MT2313 (S. Typhimurium dam) as described in Section 3.2.1.  The 
wild-type Typhimurium strain MT2315 is a virulent derivative of strain UK-1, 
containing a Lac+ MudJ transcriptional fusion which is used to discern it from 
other Salmonella which are inherently Lac- (Conner, et al., 1998; Dueger, et al., 
2001). 
Strains used in these stability studies were grown overnight in Luria broth at 
37°C.  Cells were re-suspended in phosphate buffered saline (PBS), 137mM 8.0 
g/L of NaCl, (8.45mM) 1.2g/L Na2HPO4, (1.5mM) 0.2 g/L KH2PO4, and (2.7mM) 
0. 2g/L of KCl pH 7.2-7.4 for these studies, unless otherwise described.  Dose 
titres were confirmed via serial dilutions plated on Luria agar plates; colony 
serotype was confirmed via standard biochemical tests (urea, TSI, ONPG) and 
agglutination with serogroup B specific antisera [somatic O antisera group B, 
factors 1, 4, 5, 12, and 27 (BD Diagnostics,  USA)]. 
7.2.2. Salmonella isolation from test solutions 
Samples were serially diluted into PBS 1:10, plated onto XLD and XLD 
containing chloramphenicol at 20 μg/mL, to select for the S. Typhimurium dam 
vaccine (XLD-CHL) and incubated for at least 24 h at 37°C.  Several colonies 
from each experiment were evaluated using standard biochemical tests (urea, TSI, 
ONPG) and agglutinated with serogroup B specific antisera [somatic O antisera 
group B, factors 1, 4, 5, 12, and 27 (BD Diagnostics,  USA)]. 
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7.2.3. Stability of S. Typhimurium dam vaccine strain in water 
Twenty 50 mL polypropylene tubes were filled with 9 mL of sterile Milli-Q® 
water (DIH2O).  Three tubes each were inoculated with 1 mL of either S. 
Typhimurium dam vaccine (dam-) or S. Typhimurium dam+ (dam+) strains 
prepared following methods in Section 2.1 and reconstituted in PBS to dose 
concentrations of 104, 106 and 108 CFU/mL.  The remaining two tubes served as 
negative controls.  Samples were incubated at room temperature with loose caps.  
Viability of the bacteria strains was assessed 24, 48, 72, and 120 h post 
inoculation.  Fixed effects used to analyse viability and stability of the organisms 
were time, strain and inoculation dose.  
7.2.4. Stability of the S. Typhimurium dam vaccine in trough water with 
and without faecal contamination 
Ten litres of trough water were collected from the Mayfarm Sheep Yards at the 
University of Sydney (Camden, NSW, Australia) for use in this experiment.  
Faeces used in this trial were obtained from sheep and determined to be 
Salmonella free via inoculation into enrichment cultures.  At time zero (t = 0), 3 
mL of S. Typhimurium dam vaccine was prepared following methods in Section 
2.1 and reconstituted in PBS, then inoculated into 500 mL polypropylene jars 
containing solutions of either 297 mL of sterile DIH2O (n=6), 297 mL trough 
water (TRW; n=6) or 294 mL of trough water with 3 g sheep faeces (pellets) 
(TRW+F; n=6).  The final concentration of the S. Typhimurium dam vaccine in 
each jar was approximately 104 CFU/mL.  Samples were incubated at room 
temperature with loose caps.  To determine the homogeneity of the S. 
Typhimurium dam vaccine in drinking water, 3 jars from each group were 
vortexed prior to sampling (vortex) and the remaining 3 jars from each group were 
sampled from the upper layer of the sample (still) at each time point.  Viability of 
the vaccine was assessed at 6, 24 and 48 h post inoculation.  Fixed effects used to 
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analyse CFU/mL of the S. Typhimurium dam vaccine were time, solution and 
sampling method. 
7.2.5. Stability and viability of the S. Typhimurium dam vaccine in 
buffered water 
In this experiment, the S. Typhimurium dam vaccine was prepared following  
methods in Section 7.2.1 and reconstituted in sterile de-ionised water, then 
inoculated into 50 mL polypropylene tubes containing 19 mL of either DIH2O, 
PBS or PBS serial diluted 1:1 with DIH2O, to give solutions of 0.5X PBS, 0.25X 
PBS, 0.125X PBS, 0.062X PBS or 0.031X PBS.  The final concentration of the S. 
Typhimurium dam vaccine in each tube was approximately 105 CFU/mL at t = 0.  
Viability of the S. Typhimurium dam vaccine was assessed at 24 and 48 h post 
inoculation.  Fixed effects used to analyse CFU/mL of the S. Typhimurium dam 
vaccine were time and PBS concentration (solution). 
7.2.6. Effect of temperature on the viability of the S. Typhimurium dam 
vaccine in buffered water 
The S. Typhimurium dam vaccine was prepared following  methods in Section 
7.2.1 and reconstituted in PBS, then inoculated into 500 mL polypropylene tubes 
containing 199 mL of either PBS (n=6), 0.2X PBS [PBS dilute 1:5 in DIH2O] 
(n=6) or DIH2O (n=6) test solutions.  The final concentration of the S. 
Typhimurium dam vaccine in each jar was approximately 104 CFU/mL.  Three 
jars from each test solution were maintained at 37°C in an incubator and 3 jars 
were kept at room temperature (range: 22-26°C).  Viability of the S. Typhimurium 
dam vaccine and the pH of each the test solutions (CyberScan pH 510, Eutech 
Instruments, AU) were assessed at 6, 12 and 24 h post inoculation.  One 200 mL 
jar of each solution without vaccine served as the controls.  The controls were 
maintained at room temperature throughout the experiment and pH measurements 
were performed in quadruplet and sterility was monitored at each time point.  
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Fixed effects used to analyse CFU/mL of the S. Typhimurium dam vaccine were 
time, test solution, temperature and pH.   
7.2.7. Delivery of S. Typhimurium dam vaccine to adult Merino wethers 
via drinking water  
i. Sheep and husbandry 
Merino wethers, approximately 2 to 4 years in age, were sourced from a single 
flock in New South Wales, Australia. The flock was routinely monitored for, and 
determined to be free of, Johne's and virulent foot rot.  Faecal samples were 
collected from all sheep prior to enrolment for qualitative detection of Salmonella.  
Approximately 1 g of faeces was placed into 10 mL mannitol selenite (MSB) 
broths, incubated for 24 h at 37°C, and then plated onto plain XLD.  Suspect 
Salmonella colonies were sub-cultured for pure growth, tested for agglutination 
with Salmonella Test Kit [for detection of Salmonella Antigen (DR1108A) 
(Oxoid Ltd, UK)] and then assessed using standard biochemical tests (urea, TSI, 
ONPG).  No Salmonella were detected in the sheep during the acclimation period.  
Sheep were transported to the Medium Security Animal Housing Facility at 
Elizabeth MacArthur Agricultural Institute (EMAI), Department of Industry & 
Investment (NSW, AU), and randomly assigned to experimental groups.  Sheep 
were individually housed in wire mesh pens on raised mesh flooring.  Each pen 
was equipped with three plastic all-purpose buckets for administration of water 
and feed.  Biosafety protocols approved by the Australian Office of the Gene 
Technology Regulator (OGTR) for containment of PC2 level organisms were 
followed to prevent cross contamination between groups and prevent release of 
the vaccine into the environment.  Sheep received a diet of oaten chaff (8 MJ 
ME/Kg DM) and commercially prepared grain pellet (12 MJ ME/Kg DM).  Sheep 
were offered 600 g of oaten chaff and 300 g of grain pellets during morning, 
roughly 8-9 MJ ME/d. 
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ii. Clinical assessment 
Clinical parameters evaluated twice daily included attitude, water consumption, 
and faecal characteristics.  Rectal temperatures were recorded in the mornings 
prior to feeding - twice a week during the week prior to vaccination, and daily 
following vaccination. The normal range of rectal temperatures for the sheep used 
in these experiments based on the pre-vaccination mean ± two standard deviations 
was 37.6 – 39.5°C.  Clinical pyrexia was defined as a sheep with a rectal 
temperature above 40°C (Radostits, et al., 2007; Terra, 2009).  Attitude and faecal 
composition were scored on an ordinal scale outlined in Section 3.5.7.  Appetite 
was recorded in grams of chaff and pellets not consumed over each 24 h feeding 
period.  Percent refusal of chaff and pellets was determined for each animal 
following vaccination.  An attitude score of 4 at any time of the day, or failure to 
consume chaff or pellets (100% refusal of feed) for three consecutive feedings, 
constituted grounds for euthanasia.  The study protocol was approved by the 
Animal Ethics Committee at EMAI. 
iii. Experimental design 
A total of 22 sheep were used in the conduct of this study.  Two vaccination trials 
were conducted using fifteen and seven sheep, respectively.  In experiment A, 
fifteen sheep were randomly assigned to two dose groups on day -8:  107 CFU 
oral bolus vaccinates (n=7; [107OB]) and 107 CFU in-water vaccinates (n=8; 
[107IW]).  In experiment B, seven sheep were assigned to a 106 CFU in-water 
vaccinate group (n=7; [106IW]).  On day 6 during the acclimation period, all 
sheep received drinking water containing 20% phosphate buffered saline (0.2X 
PBS) to determine if the buffering agent would affect consumption prior to use 
during the vaccine trial.   
Prior to vaccination, all sheep were food and water fasted overnight. The S. 
Typhimurium dam vaccine was delivered in the drinking water of the 106IW and 
107IW vaccinates ad libitum over a 24 h period (t = -24 h to 0 h) via plastic 
drinking buckets maintained within each pen.  The vaccine was inoculated into 
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fresh water containing 20% PBS to a final volume of 6 L at the morning and 
evening observation periods.  The target concentration of the vaccine was 106 and 
107 CFU/L for the 106IW and 107IW vaccinate groups respectively.  Consumption 
of water containing the S. Typhimurium dam vaccine was recorded to the nearest 
0.1 L on vaccination day.  The sheep in 107OB vaccination group received the 
vaccine per os, reconstituted into 10 mL of PBS at t = 0 h. 
iv. Faecal sampling 
Prior to initiating the study, faecal samples collected from the sheep were cultured 
for Salmonella as described in Section 3.6.1.,  Salmonella was not detected prior 
to vaccination of the sheep used in this trial.  Faecal samples were assessed for 
shedding of the dam vaccine at 72 h post-vaccination.  Between 2 and 5 g of 
faeces were collected per rectum of each sheep using individual disposable latex 
gloves.  The faecal material was homogenised as a 1:4 dilution in sterile PBS, 
serially diluted, plated on XLD-CHL to select for the vaccine strain, and 
incubated for 24 h at 37°C.  Additionally, 1 mL of the homogenised sample was 
placed into 9 mL of MSB, incubated for 24 h at 37°C, and streaked for single 
colonies onto XLD-CHL.  The number of Salmonella organisms present in the 
faecal sample was calculated based on the sample weight, dilution factor, and 
number of colonies counted.  Two colonies from each Salmonella positive faecal 
culture were sub-cultured and tested with O-antigen specific antisera to verify 
isolate identification. 
v. Isolation of S. Typhimurium dam vaccine from ovine tissues 
Sheep were euthanised and immediately necropsied using standard techniques 96 
h following vaccination.  Approximately 1 to 2 g of tissue was obtained from the 
mesenteric lymph node (MLN), liver, and spleen of each animal.  Tissue sections 
were homogenised as a 1:4 dilution in sterile PBS, serially diluted, plated onto 
XLD-CHL, and incubated for 24 h at 37°C.  Additionally, 1 mL of the 
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homogenised sample was placed into 9 mL of MSB enrichment media, and 
incubated for 24 h at 37°C.  Colony counts were enumerated and MSB 
enrichments were streaked onto XLD-CHL.  Samples that were positive by 
selective enrichment in MSB, were recorded as 10 CFU/g and negative samples 
were recorded as 4 CFU/g. 
vi. Statistical analysis   
The statistical program Genstat (12th Edition, VSN International, UK) was utilised 
to perform residual (or restricted) maximum likelihood (REML) analysis.  Data 
from the stability and viability studies were analysed using a single variate 
repeated measures model where fixed effects of the model were time, treatment or 
temperature and their interactions, and the random effect was sample tube/jar, 
outcome variables included CFU/mL and pH.  Results of the sheep vaccination 
trial were analysed using a single variate, repeated measures model where the 
fixed effects of the model were time, treatment and their interaction, and random 
effects were animal and experiment (A vs. B), outcome variables included faecal 
shedding (CFU/g), rectal temperature, chaff & pellet refusal, and water intake.  
Prior to analysis, CFU data was converted to log base 10.  The Wald chi-square 
test was used to determine significant individual effects and or significant 
interactions between factors.  Any non-significant terms were dropped from the 
model and analysis repeated.  Following analysis, data are presented as predicted 
model based means.  Predicted means are those obtained from the fitted model 
rather than the raw sample means.  This is important, as predicted means represent 
means adjusted to a common set of variables, thus allowing valid comparison 
between means. 
 A P value less than 0.05 was considered to be statistically significant.  
Differences between the individual means were determined by calculating an 
approximate least significant difference (LSD).  A difference of means that 
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exceeded the calculated LSD was considered significant. 
The statistical program StatsDirect (version 2.7.8., http://www.statsdirect.com, 
England: StatsDirect Ltd 2008 (Buchan, 2000)) was utilised to perform analysis of 
variance and unpaired t-tests.  Tissue colonisation was analysed using analysis of 
variance.  An unpaired t-test was employed to analyse the following:  the effect of 
vaccine dose on pyrexia in sheep following vaccination, the effect of 0.2X PBS on 
the water consumption of sheep, and the effect of in-water vaccination on the 
water consumption of sheep. 
7.3 Results 
7.3.1. Viability and stability of S. Typhimurium dam vaccine strain in 
water 
In-water delivery of a modified live vaccine requires vaccine viability and 
stability in drinking water for effective livestock immunisation.  Here, vaccine 
viability and stability were initially examined in DIH2O to eliminate confounders 
such as pH, water hardness and bacterial contaminants. Note that, since the 
bacterial strains were reconstituted in 1X PBS, the final concentration was 
equivalent to 0.1X PBS in these experiments.  Three salient observations were 
made (Figure 7-1): 1). The CFU/mL of both the S. Typhimurium dam vaccine and 
isogenic dam+ strains was markedly stable at a 108 inoculation dose over the 120 h 
study period with 100.2% and 99.0% of the original inoculums remaining viable, 
respectively.  2). The dam vaccine and dam+ strains exhibited relatively mild, but 
significant reductions in viability over time at lower inoculation doses over the 
120 h study period, with 82.2% and 70.4% of the original inoculums remaining 
viable respectively (P < 0.05).  3) Significant CFU/mL differences were observed 
between dam- and dam+ strains at 24 h and from 24 to 72 h post inoculation at the 
106 and 108 dose levels, respectively (P < 0.05); however, no differences were 
observed in the predicted mean CFU/mL between the dose levels at 120 h post 
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inoculation, and strain alone did not have a significant effect on predicted mean 
CFU/mL (P = 0.728).  These data demonstrate that the S. Typhimurium dam 
vaccine has similar viability to the dam+ strain when inoculated into DIH2O, and 
inoculation dose has a significant effect on stability over the 5 d study period.   
7.3.2. Viability of S. Typhimurium dam vaccine in trough water with and 
without faecal contamination 
Salmonellae are capable of proliferating in moist faecal material (Arrus, et al., 
2006; Holley, et al., 2006) and, thus, faecal contamination may alter dose delivery 
for livestock immunisation.  Here, we assessed S. Typhimurium dam vaccine 
CFU/mL in DIH2O; trough water (TRW); and TRW + faeces (TRW + F) as a 
function of time at a dose concentration of 104 CFU/mL.  Note that the final 
concentration of PBS was equivalent to 0.01X PBS following inoculation with the 
S. Typhimurium dam vaccine reconstituted in PBS.  The CFU/mL of the S. 
Typhimurium dam vaccine in solutions of TRW+F was significantly higher than 
that observed in TRW at 24 to 48 h post inoculation (P < 0.05; Figure 7-2).  The 
predicted mean CFU/mL of the S. Typhimurium dam vaccine in TRW declined 
over the course of the experiment with 98%, 72.3% and 53.1% of the original 
inoculum viable at 6, 24 and 48 h post inoculation, respectively; the predicted 
mean CFU/mL of the S. Typhimurium dam vaccine in TRW+F was relatively 
stable over the course of the 48 h experiment with 102.2%, 105.9% and 93.8% of 
the original inoculum viable at 6, 24 and 48 h respectively.  Further, sampling of 
the S. Typhimurium dam vaccine from the surface of the trough versus vortexed 
samples did not have an effect on predicted mean CFU/mL over the course of the 
study (P = 0.94;Figure 7-3).  These data indicate that the vaccine was uniformly 
distributed within the trough water following inoculation and, thus, water 
consumption from the surface of the trough will not limit delivery of an effective 
vaccination dose.  Taken together, these data establish the viability and stability of 
the S. Typhimurium dam vaccine in trough water with and without faecal 
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contamination, suggesting that such vaccine persistence should be sufficient for 
oral dosing of livestock.  Moreover, the observed decline in vaccine viability in 
clean trough water over time provides an inherent mechanism for elimination of 
the vaccine following trough inoculation.   
7.3.3. Viability of the S. Typhimurium dam vaccine in buffered water 
Vaccine persistence may be prolonged by the addition of buffers to enhance 
vaccine stability (Kolb, 1996; Leigh, et al., 2008).  Thus, we examined the 
minimum concentration of PBS required for stability of the S. Typhimurium dam 
vaccine when inoculated into drinking water.  The concentration of PBS had a 
significant effect on the viability of the vaccine over the 48 h study period (P = 
0.005; Figure 7-4).  Solutions containing greater than or equal to 0.062X PBS had 
significantly increased predicted mean CFU/mL when compared to the DIH2O (P 
< 0.05), with solutions of PBS, 0.5X PBS and 0.25X PBS containing 103.2%, 
103.0 and 90.5% of the initially seeded 105 dose at 48 h post inoculation.  The 
minimum concentration of PBS required for improved viability of the S. 
Typhimurium dam vaccine in drinking water over a 24 h period was greater than 
or equal to 0.125X PBS.  Note that PBS concentrations of 0.2X PBS in 
combination with the S. Typhimurium dam vaccine does not compromise water 
intake in sheep (Mohler, et al., 2011).  These data suggest that inclusion of a 
buffering agent in vaccine formulation facilitates S. Typhimurium dam vaccine 
persistence, without compromising livestock water consumption.   
7.3.4. Effect of temperature and buffering agents on the viability of the S. 
Typhimurium dam vaccine 
Under field conditions, trough water temperatures are likely to vary and may 
affect viability or favour proliferation of the vaccine strain.  Here, we evaluated 
the effect of water temperature on viability and/or proliferation of the S. 
Typhimurium dam vaccine in drinking water with and without buffering agents.  
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Although the viability of the S. Typhimurium dam vaccine declined post 
inoculation, no significant differences in the predicted mean number of CFU/mL 
were observed across all solutions incubated at either room temperature (20-25°C) 
or 37°C over the 24 h time course (P = 0.22; Figure 7-5).  The capacity for the 
addition of PBS to significantly improve S. Typhimurium dam vaccine viability 
over the 24 h time course when compared to DIH2O, was independent of 
incubation temperature with a greater predicted mean CFU/mL in PBS and 0.2X 
PBS solutions when compared to the DIH2O control from 6 to 24h post 
inoculation (P < 0.05; Figure 7-6).   
The improved S. Typhimurium dam vaccine viability conferred by PBS was 
correlated, in part, to stabilisation of pH, which was significantly lower in DIH2O 
relative to that observed in PBS and 0.2X PBS solutions from 6-24 h post 
inoculation (P < 0.05; Figure 7-7).  Control solutions of DIH20 and PBS without 
inoculation of the S. Typhimurium dam vaccine exhibited only a mild decrease in 
pH over the experimental time course (data not shown).  Thus, the buffering 
capacity of PBS likely influences vaccine viability by preventing vaccine-
mediated acidification of the solution over the 24 h study period.  Note that the 
mild (half log) decrease in S. Typhimurium dam vaccine viability at the 6 h time 
point in buffered solutions (Figure 7-6) was not attributed to pH as no measurable 
change in pH was observed over the entire time 24 h time course.  Taken together, 
these data demonstrate that the viability of S. Typhimurium dam vaccine is similar 
during the first 24 h in solutions maintained at room temperature or 37°C and that 
the vaccine does not proliferate when inoculated into warm water.  Moreover, the 
buffering capacity of PBS in solution likely influences vaccine viability by 
preventing acidification and, thus, vaccine persistence can be controlled via 
inclusion/exclusion of buffering agents and stabilisers, providing an effective 
means for vaccine delivery in drinking water for ad libitum oral delivery under 
on-farm conditions.   
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7.3.5. Delivery of S. Typhimurium dam vaccine to adult Merino wethers 
via drinking water  
Delivery of an effective S. Typhimurium dam vaccine in drinking water to adult 
sheep requires that water consumption is not compromised, no adverse clinical 
reactions are manifested, effective colonisation occurs in host lymphoid tissues, 
and the vaccine is subsequently cleared, with minimal vaccine shedding from the 
immunised animals.  To address the potential issue of buffering agents on water 
consumption, sheep were offered drinking water containing 0.2X PBS during the 
acclimation period.  Water consumptions were compared to the mean water 
consumptions from the previous 5 days.  No differences in consumption of PBS 
treated water were observed when compared to mean untreated drinking water 
consumptions (P = 0.86).  These data establish that 0.2X PBS does not affect 
palatability or inhibit consumption of water by adult sheep.  Further, there was no 
evidence of refusal of the S. Typhimurium dam vaccine when delivered in-water 
containing 0.2X PBS (P = 0.81).  On the day of vaccination, water consumption 
of the in-water vaccinates was 1.9 ± 0.24 L and 2.4 ± 0.22 L for the 107IW and 
106IW groups respectively, which was 85.4 and 105.6 percent of the mean daily 
water consumption during the five days preceding vaccination for each group.   
Moreover, the mean in-water vaccination dose consumed was:  1.1  106 CFU 
(range 8.7 × 105 to 1.5 x 106 CFU/sheep) in the 106IW group and 1.5  107 CFU 
(range 1.2  107 to 1.8  108 CFU/sheep) in the 107IW group.  The sheep in the 
OB107 group received 9.4  106 CFU/sheep in a 10 mL oral bolus.  These data 
indicate that the S. Typhimurium dam vaccine was effectively delivered in water 
to sheep under field conditions. 
Next, we assessed clinical manifestations as a consequence of vaccination.  
Pyrexia (rectal temperature > 40.0oC) (Radostits, et al., 2007; Terra, 2009) was 
not observed in sheep from the 106IW vaccinate group (Figure 7-8).  This group 
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remained within the normal temperature range throughout the study and had 
significantly lower predicted mean rectal temperatures relative to that exhibited by 
the 107OB and 107IW vaccinates from 24 to 72 h post vaccination (P < 0.05).  In 
contrast, pyrexia was observed in 4 of 7 sheep in the 107OB group and 7 of 8 
sheep in the 107IW group at 48 and 72 h following vaccination (P < 0.001).  There 
was no difference in the predicted mean rectal temperatures of 107OB and 107IW 
vaccinates, even though the 107IW vaccinates consumed over a log more vaccine 
when compared to the 107OB vaccinates.  Taken together, these data indicate that 
the 106IW vaccinate group remained within the normal temperature range 
throughout the study period; moreover, no significant pyrexia differences were 
observed between the 107IW and 107OB vaccinate groups. 
There was no significant effect of vaccination treatment on chaff appetite (Figure 
7-9), pellet appetite (Figure 7-10), and water consumption (Figure 7-11) of the 
sheep over the course of the experiment.  Moreover, the attitude and faecal scores 
of all sheep remained at baseline values over the course of the study period.  
However, chaff refusal of the 107OB vaccinates was significantly increased when 
compared to the 106IW vaccinates at 72 h post vaccination (P < 0.05;Figure 7-9); 
and the water consumption of the sheep in the 107OB vaccinates was significantly 
higher than the 106IW and 107IW vaccinates during vaccination period, t 0 h (P < 
0.05; Figure 7-11).  Taken together, these data indicate that vaccine treatment had 
minimal effects on chaff appetite, pellet appetite, and water consumption. 
Colonisation of lymphoid tissue (e.g. intestine [Peyer’s patches]; mesenteric 
lymph nodes [MLN]; spleen) and visceral organs (e.g., liver) leads to the initiation 
of protective innate and adaptive immune responses.  Here we assessed the ability 
of the S. Typhimurium dam vaccine to colonise such host tissue sites via 
enumeration of CFU recovered from faeces, MLN, spleen, and liver at 96 h post-
vaccination.  Faecal shedding Significantly lower numbers of dam vaccine 
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shedding (2 logs less CFU/g faeces) were observed in the 106IW vaccinates when 
compared to the 107OB and 107IW vaccinates (P < 0.01; Figure 7-12); no 
differences were observed between 107OB and 107IW vaccinates (P = 0.9579).  
Moreover, the dam vaccine was recovered from the faeces of 1 of 7 of the 106IW 
vaccinates as compared to 8 of 8 and 7 of 7 sheep from the 107IW and 107OB 
vaccinates, respectively.  MLN colonisation  Significantly lower numbers of the 
dam vaccine were observed in the MLN of the 106IW vaccinates (2 logs less 
CFU/g) when compared to the 107IW vaccinates (P < 0.005); no differences were 
observed between the 107IW and 107OB vaccinates (P = 0.0854) and between the 
107OB and 106IW vaccinates (P = 0.2439).  Moreover, the S. Typhimurium dam 
vaccine was recovered from the MLN of 2 of 7, 8 of 8 and 4 of 7 sheep from the 
106IW, 107IW and 107OB vaccination groups respectively.  Spleen and liver 
colonisation  The S. Typhimurium dam vaccine was not recovered from the spleen 
and liver of the 106IW vaccinates, with only very low CFU recovered from one 
sheep from the 107IW and 107OB vaccinates groups. Collectively, these data 
indicate that in-water delivery of the S. Typhimurium dam vaccine to sheep over a 
24 h period is a viable administration route in adult ruminants, with minimal 
colonisation of spleen and liver and low-level shedding in faeces. 
7.4 Discussion 
The global trend towards intensive livestock production is associated with an 
increased incidence of salmonellosis via faecal-oral transmission.  Vaccination is 
a useful tool in the control of infectious diseases without the use of antimicrobials.  
Unfortunately, the most common methods of vaccination in livestock require 
animals to be handled by personnel that can further stress susceptible populations 
and cause carcass damage, adverse reactions, and resultant increased production 
costs (Bowersock and Martin, 1999; Giudice and Campbell, 2006; Murphy, et al., 
2008; Savini, et al., 2008; Mamak and Aytekin, 2009).  
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Delivery of an effective attenuated live vaccine in drinking water for livestock 
production requires that the vaccine is stable in drinking water under field 
conditions; does not affect water consumption or alter vaccine dosing and does 
not proliferate in the environment.  Here we show that the S. Typhimurium dam 
attenuated vaccine was stable in the drinking water of adult ruminants with or 
without buffering agents and remained viable under temperatures between 20°C 
and 37°C; does not compromise water consumption with the addition of buffering 
agents, and does not proliferate in drinking water contaminated with animal 
faeces.   
From a farm-management perspective, many of these features would have general 
utility in intensive livestock production systems and could be modified 
accordingly depending on the specific management/environmental strategies 
implemented.  For example, if the planned application called for a more prolonged 
vaccination period, the S. Typhimurium dam vaccine maintained highest viability 
in solutions containing at least 0.2X PBS.  Indeed, PBS has been used to enhance 
survival of live Mycoplasma gallisepticum vaccine in aerosol delivery systems to 
chickens (Bowersock and Martin, 1999; Giudice and Campbell, 2006; Murphy, et 
al., 2008; Savini, et al., 2008; Mamak and Aytekin, 2009) and did not negatively 
impact water consumption by sheep in our study. The sheep consumed 4 to 8% of 
their body weight in water per day, which was within the reported normal daily 
range of 5 to 20% (Singh, et al., 1976; Savage, et al., 2008). If the planned 
application were to deliver the vaccine over a 24 h period, it would not be 
necessary to include a buffering agent; moreover, replenishing water troughs with 
un-buffered water would promote elimination of the vaccine following the 
delivery period.   
Environmental parameters such as temperature and faecal contamination may 
adversely affect vaccine dosing of the animals.  For example, although our data 
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show that the S. Typhimurium dam vaccine is stable under temperatures between 
20°C and 37°C and does not adversely affect water consumption, ambient 
temperatures may need to be considered when delivering the S. Typhimurium dam 
vaccine to sheep, as higher environmental temperatures (40°C) encourage 
increased water consumption (Savage, et al., 2008) and could affect vaccine 
viability/stability.  Faecal contamination may affect dosing as it is not uncommon 
to find faeces or contaminated bedding/feed material in troughs used to supply 
animals with water, and Salmonellae are capable of proliferating in moist faecal 
material (Arrus, et al., 2006; Holley, et al., 2006).  Our studies show that although 
exposure to faecal-contaminated trough water increased the stability of the S. 
Typhimurium dam vaccine, no increase in vaccine CFU was observed.   
 A potential limitation to oral vaccine delivery in ruminants is the capacity of 
volatile fatty acids produced in the rumen to attenuate the survival of Salmonella 
(Chambers and Lysons, 1979; Mattila, et al., 1988).  The establishment of the S. 
Typhimurium dam vaccine in the MLN of adult sheep demonstrated that the 
vaccine is capable of bypassing the rumen and surviving in the gastrointestinal 
tract of adult sheep, indicating the opportunity for successful in-water prophylaxis 
in adult ruminants.  
The focus of these studies has been to evaluate the viability and vaccine dose 
stability of the S. Typhimurium dam attenuated vaccine in livestock drinking 
water over a 24 h delivery period.  The results of these studies indicate that 
drinking water is a feasible vaccine delivery option for adult ruminants. 
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Figure 7-1.  Viability of a S. Typhimurium dam vaccine following inoculation into de-ionised water at room temperature. 
Data are depicted as a predicted mean log10 CFU/mL ± SE. Significant difference between strains at same dose level are denoted by * for 106 and § for 
108 CFU/mL (P < 0.05). A significant difference from t = 0 inoculation dose level is denoted by α for  dam- 104, β for dam- 106, γ for dam+ 104 and Δ for 
dam+ 106 CFU/mL 
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Figure 7-2.  Viability of a S. Typhimurium dam vaccine when inoculated into trough water at room temperature. 
Six jars, each containing  DIH2O (black square), TRW (white circle) and TRW+F (grey triangle) were inoculated with S. Typhimurium dam vaccine at 
a dose of 104 CFU/mL at t = 0.  Data are depicted as a predicted mean log10 CFU/mL ± SE.  * Denotes a significant difference from DIH2O control (P < 
0.05) and α denotes a significant difference between TRW and TRW+F (P < 0.05). 
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Figure 7-3.  Effect of sampling technique on a S. Typhimurium dam vaccine following inoculation into trough water at room 
temperature.   
Six jars, each containing either de-ionised water, trough water and trough water with faeces were inoculated with S. Typhimurium dam vaccine at a 
dose of 104 CFU/mL at t = 0.  Three jars from each solution (n = 9) were vortexed prior to sample collection (white circle) while samples were 
collected from the surface of the remaining three jars each (n = 9) (grey triangle).  Data are depicted as a predicted mean log10 CFU/mL ± SE. 
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Figure 7-4 Effect of PBS concentration on the viability of a S. Typhimurium dam vaccine at room temperature. 
S. Typhimurium dam vaccine was inoculated into tubes containing either DIH2O (black square), PBS (white triangle) and 0.031X PBS (grey square), 
0.062X PBS (grey triangle), 0.125X PBS (grey diamond), 0.25X PBS (grey circle), 0.5X PBS (white circle) at a concentration of 105 CFU/mL at t = 0. 
Data are depicted as a predicted mean log10 CFU/mL ± SE.  *Denotes significantly different from PBS control (P < 0.05). 
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Figure 7-5.  Effect of incubation temperature on viability of a S. Typhimurium dam vaccine. 
S. Typhimurium dam vaccine was inoculated into six jars, each containing either PBS; 0.2X PBS or DIH2O to concentration of 2.5x104 CFU/mL at t = 
0.  Three jars from each solution were incubated at room temperature (20-26°C) (black square, dashed lines) or 37oC (grey circle; solid lines).  Data are 
depicted as a predicted mean log10 CFU/mL ± SE.  No differences between incubation temperatures were observed (P = 0.22). 
164 
 
Figure 7-6.  Effect of PBS on viability of a S. Typhimurium dam vaccine following incubation at room temperature and 37°C.   
Six jars, each containing either PBS (white circle); 0.2X PBS (grey triangle) or DIH2O (black square) were inoculated with S. Typhimurium dam to 
concentration of 2.5x104 CFU/mL at t = 0.  Three jars from each solution (n = 9) were incubated at RT or 37°C.  Incubation temperature (RT vs. 37°C) 
did not have a significant effect on viability ( P = 0.22).  Data are depicted as a predicted mean log10 CFU/mL ± SE.  *Denotes significant difference 
from DIH2O and β denotes significant difference between 0.2X PBS and PBS (P <0.05). 
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Figure 7-7.  Effect of a S. Typhimurium dam vaccine on solution pH. 
Six jars, each containing either PBS (white circle); 0.2X PBS (grey triangle) or DIH2O (black square) were inoculated with S. Typhimurium dam 
vaccine to a concentration of 2.5 x 104 CFU/mL at t = 0.  Three jars from each solution (n = 9) were incubated at RT or 37°C.  Data are depicted as a 
predicted mean pH ± SE.  *Denotes significant difference from DIH2O (P < 0.05). 
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Figure 7-8.  Predicted mean rectal temperatures following in-water immunisation of adult sheep with S. Typhimurium dam 
Data are presented as predicted mean RT ± SE; in the context of the normal range (dashed grey lines) and baseline (solid grey line) established pre-
vaccination; and the threshold for pyrexia (dashed black line). *RT of the 106IW vaccinates were significantly lower than the 107IW and 107OB 
vaccinates from time 0 to 72 h post vaccination (P < 0.05).  There was no difference in RT of the 107IW and 107OB vaccinates.   
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Figure 7-9.  Predicted mean chaff refusals following in-water immunisation of adult sheep with S. Typhimurium dam. 
Percent of chaff  refused was determined for each animal during the challenge period based on amount of offered chaff refused. Data are depicted as 
predicted mean chaff refusal ± SE. *Chaff refusal was significantly lower in the 106IW when compared to the 107OB vaccinates at 72 h post vaccination 
(P < 0.05). There was no difference in the chaff  refusals of the 106IW and 107IW vaccinates. 
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Figure 7-10.  Predicted mean pellet refusals following in-water immunisation of adult sheep with S. Typhimurium dam. 
Percent of pellet refused was determined for each animal during the challenge period based on amount of pellet refused over offered. Predicted 
mean pellet refusal ± SE is depicted. There was no difference in the pellet refusals of the 107OB, 106IW and 107IW vaccinates over the 72 h 
observation period. 
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Figure 7-11.  Predicted mean water consumption following in-water immunisation of adult sheep with S. Typhimurium dam. 
Data are depicted as predicted mean water consumption in L ± SE. *The water consumption of the 106IW and 107IW vaccinates was 
significantly lower than the 107OB vaccinates during 24 h post-vaccination period (P < 0.05) 
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Figure 7-12.  Colonisation of lymphoid tissue and visceral organs in adult sheep following in-water delivery of a S. Typhimurium dam. 
Data are depicted as mean log10 CFU/g by tissue ± SE.  Significantly lower numbers of the S. Typhimurium dam were shed into the faeces of the 106IW 
vaccinates when compared to the 107OB and 107IW vaccinates (aP < 0.01).  Significantly higher numbers of the S. Typhimurium dam were isolated 
from the MLN of the 107IW vaccinates when compared to the 106IW vaccinates (bP < 0.005).  Limit of detection is 4 CFU/g tissue. 
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CHAPTER 8. Protective Immunity Conferred by a DNA Adenine 
Methylase Deficient Salmonella enterica serovar Typhimurium Vaccine 
When Delivered In-water to Sheep Challenged with Salmonella enterica 
serovar Typhimurium 
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Immunity Conferred by a DNA Adenine Methylase Deficient Salmonella enterica 
serovar Typhimurium Vaccine When Delivered In-water to Sheep Challenged 
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8.1 Introduction 
Salmonella is the most commonly isolated infectious enteric bacterial pathogen of 
dairy cattle (1994; Vanselow, et al., 2007b) and the most common zoonotic 
disease associated with human consumption of beef and dairy products (Donnelly, 
1990; Troutt and Osburn, 1997). In recent years, there has been a rise in the 
incidence and severity of human cases of salmonellosis and emergence of 
multidrug resistant strains of Salmonella (CDC, 2002; Mølbak, 2005; CDC, 2008, 
2009). Prevalence studies indicate 16 to 73% of U.S. dairy farms are infected with 
Salmonella (Pacer, et al., 1986; Pacer, et al., 1989; Besser, et al., 1997; Dunne, et 
al., 2000; Kiessling, et al., 2002) and up to 50% of cull dairy cows are 
contaminated with Salmonella at slaughter (Troutt, et al., 2001). Naïve animals 
introduced to intensive production systems by either birth or transport are often 
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exposed to virulent salmonellae shortly after arrival (Gay and Hunsaker, 1993; 
House, et al., 2001a). One dairy field study demonstrated the potential magnitude 
of the exposure to salmonellae by demonstrating 67% of calves shedding 
salmonellae within 24 h of birth (House, et al., 2001a). Similar findings have been 
reported in sheep feedlots, where the prevalence of salmonellae faecal shedding 
was observed to increase from 1-2 to 17-89% within 14 d of entry (Higgs, et al., 
1993; Kelly, 1995).  
Vaccine prophylaxis is normally achieved through vaccinating animals several 
weeks prior to virulent pathogen exposure.  This is not possible in neonates and 
often not practically possible in feedlots where livestock are sourced from diverse 
locations and vendors. Vaccination of animals on arrival to feedlot facilities is an 
alternative approach to reduce the incidence and severity of disease. However, 
implementing an effective Salmonella vaccination program upon arrival to feedlot 
facilities poses a number of technical and logistical challenges, as livestock have 
often undergone variable periods of feed deprivation and varying degrees of stress 
due to transport, altered environmental conditions, and changes in social grouping. 
These stresses and concurrent exposure to a diversity of pathogens contribute to 
the risk of disease.  Direct physical handling of livestock to administer vaccines 
may contribute further stress and negatively impact stock health and welfare. In 
contrast, oral vaccine delivery in drinking water significantly reduces the stress of 
additional handling, and is a means of rapidly vaccinating large groups of animals.  
However, the efficacy of Salmonella vaccination in feedlots is largely influenced 
by the interval between immunisation and pathogen exposure, which may be short 
in field settings. Therefore it is desirable for the onset of immunity to be rapidly 
initiated post vaccination. Additionally, exposure of livestock to virulent 
Salmonella during transport may negatively impact vaccine efficacy when 
administered upon arrival at the feedlot. Finally, the timing of virulent pathogen 
exposure may also impact on the safety of Salmonella vaccines as administration 
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of aro attenuated Salmonella vaccines either 24 h prior or 48 h following virulent 
Salmonella exposure has been reported to exacerbate salmonellosis disease 
manifestations (Foster, et al., 2008).  
Modified live attenuated Salmonella vaccines deficient in the dam gene have been 
shown to confer cross-protective immunity to multiple salmonellae in murine 
(Heithoff, et al., 2001; Heithoff, et al., 2008a), avian (Dueger, et al., 2001, 2003a) 
and bovine models of salmonellosis (Dueger, et al., 2003b; Mohler, et al., 2006; 
Mohler, et al., 2008) and have been demonstrated as safe. Protective immunity in 
S. Typhimurium dam immunised mice directly correlated with increased levels of 
cross-reactive opsonising antibodies and memory T cells and a diminished 
expansion of myeloid-derived suppressor cells (MDSCs) that are responsible for 
immune suppression associated with several conditions of host stress including 
chronic microbial infections, trauma and cancer (Heithoff, et al., 2008a). 
Additionally, infection of mice with S. Typhimurium dam showed reduced multi-
tissue innate immune cytokine responses relative to wild type, which may 
contribute to the reduced disease manifestations and protective immunity 
observed in vaccinated animals (Shtrichman, et al., 2002; Simon, et al., 2007). 
Thus, S. Typhimurium dam vaccines have been demonstrated to be safe and 
efficacious in experimental models of salmonellosis and therefore are suitable 
candidates for application in livestock production systems. Delivery of vaccines in 
drinking water provides a potential means of effectively vaccinating large 
numbers of livestock in a feedlot setting. The objective of this study was to 
determine if adult ruminants could be effectively vaccinated and protected from 
virulent homologous challenge via oral delivery of S. Typhimurium dam vaccine 
in drinking water.  
8.2 Materials and Methods 
8.2.1. Bacterial strains and growth conditions 
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Immunisations were carried out with dam-102::Mud-Cm Typhimurium UK-1 
vaccine strain MT2313 (S. Typhimurium dam) as described in Section 3.2.1. 
Challenge studies were performed with a derivative of a Salmonella Typhimurium 
strain, 06-131 (ST 06-131, challenge) as described in Section 3.2.2.ii. 
Strains used in infection studies were grown overnight in LB at 37°C, following 
procedures outline in Appendix I.  Vaccine and challenge dose titres were 
confirmed via serial dilutions plated on Luria agar plates, colony serotype was 
confirmed via standard biochemical tests (urea, TSI, ONPG) and agglutination 
with serogroup B specific antisera [somatic O antisera group B, factors 1, 4, 5, 12, 
and 27  (BD Diagnostics, USA)]. 
The vaccine strain was delivered to vaccinated sheep via drinking water over 24 h. 
Each sheep had an individual bucket of drinking water. The vaccine strain was 
inoculated into fresh water containing 20% phosphate buffered saline (PBS) to a 
final volume of 5L and target concentration of 1  107 CFU/L at the morning and 
evening feeding. Water consumption was recorded to the nearest 0.1 L for the 24 
h vaccination periods.  
8.2.2. Sheep selection and husbandry 
Merino wethers, approximately 2 to 4 years in age, were sourced from a single 
flock in New South Wales, Australia, using selection criteria outlined in Section 
3.5.3.  Faecal samples were collected from all sheep prior to enrolment in the 
study and underwent qualitative detection of Salmonella following procedures 
outlined in Section 3.6.1. No salmonellae were detected in the sheep during the 
acclimation period. Sheep were transported to the Medium Security Animal 
Housing Facility at EMAI, and randomly assigned to experimental groups and 
housed following procedures outlined in Sections 3.5.5 and 3.5.6.  Sheep received 
a diet of oaten chaff (8 MJ ME/kg DM) and commercially prepared grain pellet 
(12 MJ ME/kg DM) during the acclimation, vaccination and challenge phases of 
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the experiment. Sheep were gradually introduced to the grain pellet during the 
acclimation and vaccination periods. Sheep were offered 700 g of oaten chaff and 
250 g of grain pellets at the morning observation period during the challenge 
periods (roughly 9 MJ ME/d). 
8.2.3. Clinical assessment 
Clinical parameters evaluated twice daily included attitude, water consumption, 
and faecal characteristics. Rectal temperatures (RT) were recorded in the 
mornings prior to feeding twice a week during the acclimation period, once daily 
for seven days following vaccination and then daily following virulent Salmonella 
challenge. The normal range of RT for the sheep used in these experiments based 
on the pre-vaccination mean ± two standard deviations was 38.4 – 39.6°C. 
Clinical pyrexia was defined as a sheep with a RT above 40°C (Radostits, et al., 
2007; Terra, 2009). Attitude and faecal composition were scored on an ordinal 
scale twice a day using procedures outlined in Sections 3.5.7.i and 3.5.7.iv, 
respectively. Appetite was recorded in grams of chaff and pellets not consumed 
over each 24 h feeding period. Percent refusal of chaff and pellets was determined 
for each animal during the challenge period. An attitude score of 4 at any time of 
the day or failure to consume chaff or pellets (100% refusal of feed) for three 
consecutive feedings constituted grounds for euthanasia. Sheep were weighed 
during the acclimation period, prior to virulent challenge and 13 d post-challenge. 
Average daily weight gains were calculated for pre-challenge and post-challenge 
intervals. The study protocol was approved by the AEC at EMAI. 
8.2.4. Experimental design 
A total of 100 sheep were used in the conduct of this study. An initial challenge 
dose trial was conducted in order to determine an optimum dose that would induce 
disease while minimising mortality, in order to maintain sample size and 
statistical power for measured outcomes. Sheep were orally administered ST 06-
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131 challenge strain at 5  108 (n = 7) and 5  109 organisms (n = 7) for low and 
high dose, respectively. Following this, two vaccination-challenge trials 
(Experiments A and B) were conducted using 42 and 44 sheep respectively, 
although the results from these were analysed together. In Experiment A, 44 sheep 
were randomly assigned to three dose groups on day -28: non-vaccinates (n = 15), 
7 d pre-challenge vaccinates (n = 14; challenged 7 d post-vaccination [7 d]) and 
28 d pre-challenge vaccinates (n = 15; challenged 28 d post-vaccination [28 d]). In 
Experiment B, 42 sheep were randomly assigned to three dose groups on day -7: 
non-vaccinates (n = 14), 24 h pre-challenge vaccinates (n = 14, vaccinated 24 h 
prior to challenge [24 h pre-challenge]) and post-challenge vaccinates (n = 14; 
vaccinated 24 h post-challenge [24 h post-challenge]).  
The vaccine strain was offered to the 28 d, 7 d and 24 h pre-challenge groups in 
drinking water for 24 h following overnight food and water fasting. The 12 h 
fasting prior to vaccination was intentional, in order to mimic the fasting livestock 
experience with mustering and road transport to feedlot facilities. The sheep in the 
24 h post-challenge vaccination group received the vaccine as an oral bolus 
delivered via a syringe (on day 1) to ensure that the sheep consumed an adequate 
dose of the vaccine. This group was included to assess safety of the vaccine in 
livestock that are already infected with virulent salmonellae. 
All sheep were orally challenged with 1  109 CFU (actual dose) of ST 06-131 on 
day 0 which was 28 d, 7 d, and 24 h following vaccinations for the 28 d, 7 d, and 
24 h pre-challenge vaccination groups, respectively, and 24 h preceding 
vaccination of the 24 h post-challenge vaccination group.   
8.2.5. Faecal sampling 
During the acclimation phase, faecal samples were collected from sheep and 
screened for Salmonella following procedures outlined in Section 3.6.1.  
Salmonella suspect colonies were  sub-cultured for pure growth and identity 
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confirmed following procedures outlined in Section 3.6.4. Salmonella isolates 
were sent to the IMVS, Salmonella Reference Laboratory (SA, Australia) for 
serotyping.  
Faecal samples were assessed for shedding of the S. Typhimurium dam vaccine 
strain 3 d post vaccination and days 3, 7, 10 and 13 post virulent challenge. 
Shedding of the challenge strain, ST 06-131, was assessed on days 3, 7, 10, and 
13 post-challenge. Between 2 and 5 g of faeces were collected per rectum of each 
sheep. The faecal material was homogenised as a 1:5 dilution in PBS, serially 
diluted, plated on XLD plates containing chloramphenicol (20 µg/mL) (XLD-
CHL) to select for the S. Typhimurium dam vaccine strain, or XLD plates 
containing neomycin sulphate (10 g/mL) (XLD-NEO) to select for the challenge 
strain, and incubated for 24-48 h at 37°C. Additionally, 1 mL of the homogenised 
sample was placed into 9 mL of MSB enrichment media, incubated for 24h at 
37°C, and streaked for single colonies on XLD-CHL and XLD-NEO. The 
estimated number of Salmonella organisms present in the original faecal sample 
was calculated based on the sample weight, dilution factor, and number of 
colonies counted. Two colonies from each Salmonella positive faecal culture were 
sub-cultured and tested with O-antigen specific antisera to verify isolate 
identification following procedures outlined in Section 3.6.4.   
8.2.6. Salmonella isolation from ovine tissues 
Sheep were euthanised and immediately necropsied using standard techniques 13 
d post virulent challenge. Approximately 1 to 2 g of tissue were obtained from the 
ileum wall, MLN, liver, lung, and spleen for each animal. Tissue sections were 
homogenised as a 1:4 dilution in PBS, serially diluted, plated on XLD-NEO and 
XLD-CHL, and incubated for 48 h at 37°C. Additionally, 1 mL of the 
homogenised sample was placed into 9 mL of MSB enrichment media, and 
incubated for 24 h at 37°C. Colony counts were enumerated and MSB 
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enrichments were streaked onto XLD-NEO and XLD-CHL. Samples positive by 
selective enrichment in MSB were recorded as 40 CFU/g and negative samples 
were recorded as 1 CFU/g. 
8.2.7. Statistical analysis   
Continuous data were analysed using REML analysis (Genstat, 12th Edition, VSN 
International, UK). A single variate, repeated measures model was fitted for the 
factors time and treatment for variables CFU, RT, chaff & pellet refusal, and 
water intake. The Wald chi-square test was used to determine significant 
individual effects and or significant interactions between factors. Any non-
significant terms were dropped from the model and analysis repeated. Following 
analysis, data are presented as predicted model based means. Predicted means are 
those obtained from the fitted model rather than the raw sample means. This is an 
important distinction, as predicted means represent means adjusted to a common 
set of variables, thus allowing valid comparison between means. 
A P value less than 0.05 was considered to be statistically significant.   
Differences between the individual means were determined by calculating an 
approximate LSD. A difference of means that exceeded the calculated LSD was 
considered significant. 
Ordinal data (attitude and faecal scores) was analysed using a proportional odds 
ordinal logistic regression model with random effects (Agrestis, 2002) using 
ASRemL 3.0 statistical software (Gilmour, et al., 2009). The fixed effects of the 
model were time, treatment and their interaction, and random effects were animal 
and experiment (A vs. B). Significance of fixed effects was assessed using Wald 
chi-square tests. Comparisons of specific treatments were conducted using Wald z 
tests. P values less than 0.05 were considered statistically significant. This 
analysis established the significance of any differences between the treatments 
and determined a probability of each response for each treatment (Dobson, 2002). 
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Data are presented as the probability as determined by the model that an animal 
would display an abnormal attitude (cumulative daily score > 5) or have diarrhoea 
(cumulative daily score > 5) over the course of the challenge period. 
Tissue colonisation and pre-challenge clinical assessment of the 24 h pre-
challenge vaccinates were evaluated using ANOVA; the vaccine dose and body 
weight of sheep that did and did not develop pyrexia following vaccination was 
compared using unpaired t-test; mortality results were compared using chi-square 
(Buchan I, StatsDirect statistical software http://www.statsdirect.com, 2002, 
CamCode, England). 
8.3 Results 
8.3.1. Challenge dose trial  
The virulent challenge strain, ST 06-131, is an industry relevant, multi-drug 
antimicrobial resistant strain that was isolated from an outbreak of salmonellosis 
in sheep at a commercial feedlot in Western Australia. A challenge dose trial was 
conducted in order to determine an optimum dose that would induce disease while 
minimising mortality, in order to maintain sample size and statistical power for 
measured outcomes. All of the sheep in the low (5  108 CFU) and high (5  109 
CFU) dose challenge groups developed clinical signs of salmonellosis (fever, 
diarrhoea, decreased appetite and depressed attitude) during the 13 d post-
challenge observation period. As expected, the severity of these signs was greater 
in sheep challenged at the high dose. There were significant differences in the 
severity of these outcomes (P < 0.001) when comparing low to high dose groups. 
There were four mortalities in the sheep administered the high dose on days 6, 7, 8 
and 11 post-challenge, respectively. No mortalities were observed in the low dose 
group. A challenge dose of 1  109 CFU of ST 06-131 was targeted for the 
vaccine efficacy trials to provide for predictable induction of disease with minimal 
mortality. 
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8.3.2. Effect of a S. Typhimurium dam vaccine strain when delivered in 
drinking water to adult sheep 
There was no evidence of refusal of the vaccine when delivered in-water, as 
indicated by significantly increased water consumption (P < 0.05). On 
vaccination day, water consumption was 3.5 ± 0.47 L, 3.7 ± 1.05 L and 4.0 ± 1.37 
L for the 28 d, 7 d, and 24 h pre-challenge vaccination groups respectively, which 
was 132.4, 140.3 and 151.5 percent of the mean daily water consumption during 
the 3 days preceding vaccination for each group. Sheep have been reported to 
consume between 5 and 20% of their body weight in water daily (Singh, et al., 
1976; Savage, et al., 2008). In this experiment, sheep consumed 7-12% of their 
body weight per day, which was within the normal range. The mean in-water 
vaccination dose of the vaccine consumed by the sheep was:  4.2  107 CFU 
(range 2.9 to 5.8 x 107 CFU/sheep) for the 28 d vaccinates, 6.7  107 CFU (range 
3.1 to 9.5  107 CFU/sheep) for the 7 d vaccinates and 1.9  107 CFU (range 9.7  
106 to 3.1  107 CFU/sheep) for the 24 h pre-challenge vaccinates. The sheep in 
the 24 h post-challenge vaccination group received 1  107 CFU/sheep in a 10 mL 
oral bolus. 
The vaccine strain was recovered 72 h post vaccination from the faeces of 11 of 
15 and 10 of 14 sheep from the 28 d and 7 d vaccinates, respectively. During the 
challenge phase of the experiment, the faeces of the sheep were monitored for the 
shedding of the vaccine. Low numbers of the vaccine strain were isolated on 
enrichment culture. The vaccine strain was isolated from the faeces of 5 of 14, 6 
of 13 , and 2 of 12 of the 24 h pre-challenge vaccinates and 7 of 14, 4 of 12  and 0 
of 11 sheep from the 24 h post-challenge vaccinates on days 3, 7 and 10 post-
challenge, respectively. The vaccine strain was isolated from the faeces of 4 of 14 
sheep from the 7 d vaccinates on day 3 post-challenge only. The vaccine strain 
was not isolated from the 28 d vaccinates during the 13 d challenge period. The 
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vaccine strain was not isolated from the faeces of the vaccinated sheep at necropsy 
(day 13), which was 42, 21, 15 and 12 d post vaccination in the 28 d, 7 d, 24 h 
pre-challenge and 24 h post-challenge vaccination groups, respectively. 
There were no biologically significant changes in attitude or faecal scores 
following vaccination in the 28 d and 7 d vaccinated sheep. No mortalities were 
associated with administration of the vaccine. It was not possible to assess the 
clinical response to vaccination in the 24 h pre- and post-challenge groups due to 
the association with virulent challenge. However, the rectal temperatures (P = 
0.7386), chaff appetites (P = 0.0745), pellet appetites (P = 0.7345), water 
consumption (P = 0.0907), attitude (P = 0.6501) and faecal scores (P = 0.7252) 
of the 24 h pre-challenge vaccinates were not significantly different from the 
controls during the 48 h period proceeding virulent challenge. 
Transient pyrexia (RT > 40.0°C (Radostits, et al., 2007; Terra, 2009)) was 
observed following vaccination with a significant interaction observed between 
time and vaccination  treatment (P < 0.001) (Figure 8-1). Pyrexia was observed in 
5 of the 15 sheep in the 28 d vaccinates and 4 of 14 sheep in the 7 d vaccinates 
during the seven day period following vaccination for a period of 1 to 3 days. One 
sheep in the 7 d vaccinates maintained a fever for 5 days (40.4 – 41.2°C). There 
was no significant interaction between vaccine dose consumed and pyrexia (P = 
0.97), however there was a trend for pyrexia to be associated with lower body 
weight (P = 0.09). 
A significant interaction between time and vaccination treatment was observed 
over the whole 7 d post-vaccination periods for chaff (P < 0.001) but not for 
pellets (P = 0.08). The 7 d vaccinates consumed less chaff than non-vaccinated 
controls from 24 to 96 h post vaccination (P < 0.05) (Figure 8-2) and fewer 
pellets at 48 h and 96 to 168 h post vaccination (P < 0.05) (Figure 8-3). Although 
there was a reduction in pellet and chaff consumption following vaccination 
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relative to the non-vaccinated sheep, the reduction was not considered biologically 
significant as the pellet and chaff consumption of vaccinated sheep remained 
within the normal range established during the 7 d acclimation period preceding 
vaccination. 
8.3.3. Immunisation with S. Typhimurium dam confers improved clinical 
disease outcomes against virulent Typhimurium in adult sheep when 
delivered in drinking water 
Here we questioned whether in-water vaccination of sheep with a S. Typhimurium 
dam can confer homologous protection against a virulent S. Typhimurium strain 
06-131. There was a significant interaction between time and vaccination 
treatment on RT during the 14 d study period (P < 0.001). Sheep receiving the 
vaccine had significantly lower mean RT when compared to non-vaccinated 
controls from days 2 to 13 post-challenge for the 28 and 7 d vaccinates, days 7 to 
10 post-challenge for the 24 h pre- challenge vaccinates and on day 7 for the 24 h 
post-challenge vaccinates (P < 0.05) (Figure 8-4). The temperatures of the 28 d 
and 7 d vaccinated sheep remained within the normal range throughout the 
challenge period. 
A significant time by vaccination treatment interaction on attitude scores was 
observed during the 14 d observation period (P < 0.001). The probability that 
non-vaccinated controls, 24 h pre-challenge vaccinates, and 24 h post-challenge 
vaccinates had an abnormal attitude score (daily attitude score greater than 3) was 
increased when compared to the 28 d and 7 d vaccinates (Figure 8-5). The 28 and 
7 d vaccinates had significantly lower attitude scores when compared to the non-
vaccinated sheep from day 3 to 13 post-challenge (P < 0.05). The attitude scores 
of the 24 h pre-challenge and 24 h post-challenge vaccinates were significantly 
lower than the non-vaccinated controls on day 8 post-challenge (P < 0.05).   
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There was a significant time by vaccination treatment interaction on faecal score 
during the 14 d observation period (P < 0.001). There was no significant 
difference between the non-vaccinated controls, 24 h pre-challenge and 24 h post-
challenge vaccinates, which experienced an increase in faecal scores during the 
middle phase of the experiment and then a decline (Figure 8-6). However the 
faecal scores of the 24 h post-challenge vaccinates were significantly increased 
when compared to the controls on day 4 post-challenge, and significantly lower on 
day 10 (P < 0.05). The 7 d vaccinates maintained significantly lower faecal scores 
than the non-vaccinated controls from days 5 to 12 post-challenge, while the 28 d 
vaccinates were significantly lower than the non-vaccinated controls from days 4 
to 13 post-challenge (P < 0.05). Additionally, the 28 d vaccinated group had 
significantly improved faecal scores when compared with the 7 d vaccinates from 
day 3 to 6 and day 11 to 13 post-challenge (P < 0.05). 
A significant interaction was observed between time and vaccination treatment on 
the faecal shedding of ST 06-131 (P < 0.001). Sheep receiving the vaccine at 28 d 
and 7 d pre-challenge had significantly reduced faecal shedding of ST 06-131 
when compared to non-vaccinated controls on days 3, 7, 10 and 13 post-challenge 
(P < 0.05) (Figure 8-7). The 24 h post-challenge vaccinates had significantly 
reduced faecal shedding of ST 06-131 when compared to non-vaccinated controls 
on day 10 post-challenge (P < 0.05). 
There were significant interactions between time and vaccination treatment on 
chaff and pellet appetite and water consumption during the 13 d observation 
period (P < 0.001). The 28 d and 7 d vaccinates had significantly lower chaff and 
pellet refusals when compared to the non-vaccinated controls from days 2 to 12 
post-challenge (P < 0.05) (Figure 8-8 and Figure 8-9). The 24 h pre-challenge 
vaccinates had significantly lower chaff refusal than controls on days 3, 4, and 6 
to 8 d post-challenge, as well as significantly lower pellet refusals on days 8 to 10 
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(P < 0.05). The 24 h post-challenge vaccinates had significantly increased chaff 
refusal on day 2 post-challenge and significantly lower refusal on day 9 post-
challenge (P < 0.05) (Figure 8-8). Additionally, 24 h post-challenge vaccinates 
had significantly increased pellet refusals on days 2 and 3 post-challenge and 
significantly lower refusal on day 8 post-challenge (P < 0.05) (Figure 8-9). Water 
consumption when compared to the non-vaccinated controls was significantly 
increased in the 28 d vaccinates from day 4 to 9 post-challenge (P < 0.05) (Figure 
8-10). The 7 d vaccinates had significantly increased water consumption from day 
2 to 11 post-challenge (P < 0.05). The 24 h pre-challenge vaccinates had 
significantly increased water consumption when compared to the non-vaccinated 
controls on days 3, 6 and 10 post-challenge, while the 24 h post-challenge 
vaccinates were increased on days 9 and 10 post-challenge (P < 0.05).  
There were significant interactions between time and vaccination treatment on 
body weight over the study period (P < 0.001). Weights day 13 post-challenge in 
the 28 d and 7 d vaccinate groups were significantly higher than those of the non-
vaccinated controls (P < 0.05) (Figure 8-11). There was no difference between the 
weights of the 24 h pre-challenge vaccinates and the non-vaccinated controls on 
day 13 post-challenge, however, the 24 h post-challenge vaccinate body weights 
were significantly less than the non-vaccinated controls (P < 0.05). 
8.3.4. Immunisation with S. Typhimurium dam confers protection 
against virulent S. Typhimurium colonisation of tissue in adult 
sheep 
The ability of S. Typhimurium dam to confer protection against colonisation of 
lymph nodes and visceral organs with ST 06-131 was evaluated in sheep.  
Vaccine efficacy was determined by enumeration of ST 06-131 recovered from 
mesenteric lymph nodes, lungs, spleen, liver, and ileum wall 13 d post-challenge. 
Significantly lower numbers of ST 06-131 were recovered from mesenteric lymph 
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nodes and ileum of the 28 d and 7 d vaccinates when compared to the non-
vaccinated controls (Figure 8-12; P < 0.0001). Significantly lower numbers of ST 
06-131 were recovered from the liver (P < 0.005), spleen (P < 0.05) and lungs (P 
< 0.05) of the 28 d vaccinates and from the liver (P < 0.005) and spleen (P < 
0.01) of the 7 d vaccinates when compared to non-vaccinates. There was no 
significant difference in tissue colonisation of ST 06-131 in the 24 h pre- and 
post-challenge vaccinates when compared to the controls (P > 0.5).  The vaccine 
strain was isolated from the MLN of 1 of 14 sheep from the 7 d vaccinates and 1 
of 10 sheep from 24 h pre-challenge vaccinates following necropsy using 
enrichment culture. 
These data suggest that immunisation with S. Typhimurium dam conferred 
significant protection against a virulent S. Typhimurium challenge as evidenced 
by attenuation of clinical disease, improved appetite, weight gains, reduced faecal 
shedding and reduced colonisation in tissues when administered 28 d and 7 d prior 
to virulent challenge. 
8.3.5. Immunisation with S. Typhimurium dam confers protection 
against mortality in adult sheep challenged with virulent S. 
Typhimurium 
Sixteen sheep mortalities were observed during the conduct of these trials. No 
mortalities were seen in the 28 d and 7 d vaccination groups. Eight mortalities 
were observed in the non-vaccinated sheep on days 5 (n = 1), 8 (n = 3), 11 (n = 3) 
and 12 (n = 1) post-challenge. Four mortalities were observed in the 24 h pre-
challenge vaccinates on days 6 (n = 1), 7 (n = 1), and 12 (n = 2) post-challenge, 
and four mortalities were observed in the 24 h post-challenge vaccinates on days 6 
(n = 1), 7 (n = 2), and 11 (n = 1) post-challenge. When compared to the non-
vaccinated controls, improved survival was observed in the 28 d vaccinates (P = 
0.006) and 7 d vaccinates (P = 0.007). There was no statistical difference in the 
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mortality rates of the non-vaccinates when compared to the 24 h pre- and post-
challenge vaccinates following challenge with virulent ST 06-131 (P = 0.95) 
8.4 Discussion 
The increase in the incidence of disease and contamination of livestock-derived 
food products imposes a significant risk to food safety via consumption of 
contaminated meat and milk products (CDC, 1996; Roels, et al., 1997; CDC, 
2002, 2006). Salmonella infections are estimated to be the cause of 1.4 to 1.6 
million food borne illnesses in the U.S. annually (Mead, et al., 1999; CDC, 2006, 
2009, 2010; Scharff, 2010) at an estimated economic cost of between $2.6 and 
$14.6 billion (CDC, 2010; Scharff, 2010). Epidemiological studies of salmonellae 
on dairy farms and feedlots have failed to identify effective and reliable avenues 
for salmonellae control (Norris, et al., 1989a; Higgs, et al., 1993; Fossler, et al., 
2005a; Vanselow, et al., 2007b). The development and application of an effective 
Salmonella vaccine offers a means of reducing industry Salmonella-associated 
losses and public health risks. The challenge is to develop an ideal livestock 
Salmonella vaccine that is safe, affordable, practical to administer, stimulates 
rapid and sustained immunity and provides protection against the diversity of 
salmonellae serovars that may be encountered. 
It has previously been reported that S. Typhimurium dam vaccines provide 
homologous and heterologous protection against diverse Salmonella serovars 
when administered to mice, chickens, and calves (Norris, et al., 1989a; Dueger, et 
al., 2001; Heithoff, et al., 2001; Dueger, et al., 2003a, 2003b; Mohler, et al., 
2006; Mohler, et al., 2008). Oral delivery of vaccines via drinking water to 
livestock has a number of potential advantages. Large numbers of animals can be 
immunised rapidly, no stressful handling is required for vaccination, no carcass 
damage is induced by injection site reactions and the cost of vaccination should be 
minimised due to the minimal packaging requirements. However, the volatile fatty 
187 
acids produced in the rumen have previously been demonstrated to attenuate the 
survival of Salmonella in vivo (Chambers and Lysons, 1979; Mattila, et al., 1988) 
and bile salts have been shown to reduce the ability of Salmonella to invade 
epithelial cells (Heithoff, et al., 2001; Begley, et al., 2005). Thus, either 
environmental condition could potentially limit the efficacy of oral delivery of 
live attenuated Salmonella vaccines in adult ruminants and had to be investigated.  
The S. Typhimurium dam vaccine was readily consumed by sheep when delivered 
in drinking water. Sheep consume between 5 and 20% of their body weight in 
water daily (Singh, et al., 1976; Savage, et al., 2008). In this experiment, the 
water consumption of sheep was 7-10% of their body weight per day during the 
three days prior to vaccination and 10-12% of their body weight during the 24 h 
vaccination period. The S. Typhimurium dam vaccine was recovered from the 
faeces of a high proportion of sheep 72 h following vaccination, indicating the 
organism was capable of bypassing the rumen and establishing a vaccination 
response. At post mortem, the vaccine was isolated at low concentrations using 
enrichment cultures from the lymph nodes of two sheep at 14 d and 21 d post 
vaccination.  The S. Typhimurium dam vaccine was not isolated from the lung, 
liver, spleen, ileum or faeces of any sheep at necropsy. These low concentrations 
suggest minimal carcass contamination if appropriate withholding periods are 
applied to sheep destined for slaughter. 
Pyrexia was observed in nine of the 29 vaccinated sheep following vaccination 
prior to virulent challenge. Mild pyrexia was observed over 1 to 3 days in 8 of 9 
pyretic animals and was not associated with significant changes in attitude or 
appetite. In the current experiment there was no association between pyrexia and 
the vaccine dose consumed, however, there was a trend for pyrexia to be observed 
in the lighter weight sheep. In previous studies conducted in neonatal calves, no 
fevers were observed in calves receiving an oral vaccine bolus of 107 CFU 
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(Mohler, et al., 2006; Mohler, et al., 2008). The pyrexia observed was consistent 
with responses to commercially available vaccines (Allen, et al., 1996; Villarreal-
Ramos, et al., 1998). 
This experiment was designed to reflect realistic scenarios commonly encountered 
during feedlot entry. Feedlots typically acquire livestock from multiple sources, 
often from diverse geographical locations. Such diversity of sources is an 
important variable for prior pathogen exposure. The purpose of administering a 
vaccine to livestock on entry to a feedlot is to provide protection against an 
infectious agent that is likely to be encountered in the feedlot. It is, however, 
possible that some stock may be infected prior to arrival on the feedlot. In this 
experiment, the S. Typhimurium dam vaccine was administered to sheep pre- and 
post-virulent Salmonella challenge. Experiments conducted with aro attenuated 
Salmonella vaccines have suggested the potential for vaccination to exacerbate 
virulent disease (Foster, et al., 2008). Although the sheep vaccinated with S. 
Typhimurium dam following virulent challenge had reduced appetites for 2 d 
following vaccination, the trend for the group across attitude, appetite and faecal 
score variables was for a more rapid return to clinical normality when compared 
to non-vaccinated controls. There was no evidence that administration of the S. 
Typhimurium dam vaccine as a prophylaxis or concurrent with infection 
exacerbated clinical disease or mortality in adult sheep. This may reflect the fact 
that S. Typhimurium dam infection is associated with reduced multi-tissue innate 
immune cytokine responses relative to wild type (Shtrichman, et al., 2002; Simon, 
et al., 2007), and does not induce the immune suppression associated with virulent 
challenge and aro attenuated Salmonella vaccines (Alramadi, et al., 1991; 
Heithoff, et al., 2008a). 
The time taken for the development of protective immunity following vaccination 
of livestock entering feedlots is a significant issue. The interval from arrival to 
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pathogen exposure is likely to be short and highly variable. In this study, 
administration of the S. Typhimurium dam vaccine via drinking water prevented 
clinical disease associated with virulent S. Typhimurium infection within seven 
days of vaccination. Aro attenuated Salmonella vaccines have previously been 
demonstrated to elicit early onset of protection via intra-peritoneal vaccination of 
mice and intramuscular vaccination of sheep (Mukkur and Walker, 1992; Schafer 
and Eisenstein, 1992). However, onset of protective immunity has been shown to 
be delayed (21 d) following oral vaccination (Mukkur and Walker, 1992). The 
difference in the time to onset of protective immunity between dam and aro 
attenuated Salmonella vaccines may be related to the expansion of myeloid-
derived suppressor cells and resultant immune suppression associated with aro 
Salmonella infection (Heithoff, et al., 2001; Heithoff, et al., 2008a). Vaccination 
with S. Typhimurium dam vaccine protected against mortality and permitted the 
sheep to maintain appetites and body weight in spite of virulent challenge. While 
there was some evidence of protection associated with vaccination 24 h prior to 
challenge, it was limited and insignificant compared to the robust protection 
observed within 7 d. Salmonellosis and inanition are common causes of sheep 
mortality in feedlots and during live export (Norris, et al., 1989a; Richards, et al., 
1989; Higgs, et al., 1993; Richards, et al., 1993; Vanselow, et al., 2007a). In these 
studies, administration of the S. Typhimurium dam vaccine protected sheep from 
inanition associated with virulent Salmonella challenge within seven days of 
administration. Causes of inanition in feedlot animals are multi-factorial, 
however, protection of susceptible populations of animals from salmonellosis 
could significantly reduce losses associated with inanition and feed refusal in 
addition to protecting against virulent salmonella carcass contamination. 
The study demonstrates that vaccination of adult ruminants with S. Typhimurium 
dam confers protective immunity against a homologous S. Typhimurium virulent 
challenge assessed by attenuation of clinical disease, reduced faecal shedding, 
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reduced tissue colonisation, increased appetite and weight gain, and reduced 
mortality. Additionally, the above results indicate that vaccination via in-water 
inoculation of S. Typhimurium dam is a viable alternative to parenteral 
administration. Homologous Salmonella protection supports the potential validity 
of in-water vaccination for the prevention and control of Salmonella infections in 
commercial livestock production systems. 
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Figure 8-1.  Predicted mean rectal temperatures following in-water immunisation of adult sheep with S. Typhimurium dam 
Data are presented as predicted mean RT ± SE; in the context of the normal range (dashed grey lines) and baseline (solid grey line) established pre-
vaccination; and the threshold for pyrexia (dashed black line). *RT of the 28 d vaccinates when compared to the unvaccinated sheep, 7 d and non-vaccinated 
controls, were significantly different at day -25, and day -22 pre-challenge (P < 0.05).  #RT of 7 d vaccination group exhibited significantly elevated RT when 
compared to the non-vaccinated controls days -5 to -2 pre-challenge (P < 0.05). 
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Figure 8-2.  Predicted mean chaff consumption following in-water immunisation of adult sheep with S. Typhimurium dam 
Chaff appetite is presented as the predicted mean chaff consumption ± SE. The normal range for chaff consumption for sheep used in these experiments was 
based on the pre-vaccination mean ± two standard deviations (dashed grey lines). *Chaff consumption was significantly reduced in the 7 d vaccination group 
when compared to the non-vaccinated controls from days -7 to -4 pre-challenge (P < 0.05). 
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Figure 8-3.  Predicted mean pellet consumption following in-water immunisation of adult sheep with S. Typhimurium dam. 
Pellet appetite is presented as the predicted mean pellet consumption ± SE. *Pellet consumption was significantly reduced in the 7 d vaccination group when 
compared to the non-vaccinated controls at days -6 and -4 to -1 pre-challenge (P < 0.05). 
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Figure 8-4.  Predicted mean rectal temperatures of S. Typhimurium dam immunised sheep following virulent Typhimurium challenge. 
RT were measured daily for 13 d following challenge. Data are depicted as a predicted mean RT ± SE. The data are presented in the context of the normal 
range (dashed grey lines) and baseline (solid grey line) established pre-vaccination. *RT were significantly lower in 28 d and 7 d vaccinates on days 2 to 13 
post-virulent challenge, and the 24 h pre vaccinates on days 7 to 10 post-virulent challenge and on day 7 in the post-challenge vaccinates when compared to 
the non-vaccinated controls (P < 0.05).   
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Figure 8-5.  Probability of abnormal attitude score in S. Typhimurium dam immunised sheep following virulent Typhimurium challenge 
Attitude was scored twice a day. Data are presented as the probability that at a sheep would display an abnormal attitude following virulent challenge. 
*The 28 d and 7 d vaccinates had significantly lower attitude scores when compared to the non-vaccinated sheep from day 3 to 13 post-virulent challenge 
(P < 0.05). *The attitude scores of the 24 h pre and 24 h post vaccinates were significantly lower than the non-vaccinated controls on day 8 post-virulent 
challenge (P < 0.05). 
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Figure 8-6.  Probability of diarrhoea in S. Typhimurium dam immunised sheep following virulent Typhimurium challenge 
Faecal scores were assessed twice a day. Data are presented as the probability that a sheep would have diarrhoea following virulent challenge. *The 7 d 
vaccinates maintained significantly lower faecal scores than the non-vaccinated controls from days 5 to 12 post-virulent challenge while the 28 d vaccinates 
were significantly lower than the non-vaccinated controls from days 4 to 13 post-virulent challenge (P < 0.05). 
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Figure 8-7.  Predicted mean faecal shedding of virulent Typhimurium following challenge in S. Typhimurium dam immunised sheep 
Data are depicted as a predicted mean log10 CFU of ST 06-131 per g of faeces post-challenge ± SE. *Significant differences in faecal shedding were observed 
on days 3, 7, 10 and 13 post-challenge in the 28 d and 7 d vaccinates and on day 10 post-challenge in the 24 h post vaccinates (P < 0.05). 
198 
 
Figure 8-8.  Predicted mean chaff refusal in S. Typhimurium dam immunised sheep following virulent Typhimurium challenge 
Predicted mean chaff refusal is depicted ± SE. *Chaff refusal was significantly lower in the 28 d and 7 d vaccinates when compared to the non-vaccinated 
controls from days 2 to 12 post-virulent challenge (P < 0.05). *The 24 h pre-vaccinates had significantly lower chaff refusal than controls on days 3, 4, and 6 
to 8 d post-virulent challenge, as well as significantly lower pellet refusals on days 8 to 10 (P < 0.05). *The 24 h post-vaccinates had significantly increased 
chaff refusal on day 2 post-virulent challenge and significantly lower refusal on day 9 post-virulent challenge (P < 0.05). 
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Figure 8-9.  Predicted mean pellet refusal in S. Typhimurium dam immunised sheep following virulent Typhimurium challenge. 
Predicted mean pellet refusal is depicted ± SE. *The pellet refusal of the 28 d and 7 d vaccinates was significantly lower when compared to the non-
vaccinated controls from days 2 to 12 post-virulent challenge (P < 0.05). *The 24 h pre-vaccinates pellet refusals were significantly lower on days 8 to 10 
(P < 0.05). *The 24 h post-vaccinate pellet refusals were significantly increased on days 2 and 3 post-challenge and significantly lower on day 8 post-
virulent challenge (P < 0.05). 
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Figure 8-10.  Predicted mean water consumption in S. Typhimurium dam immunised sheep following virulent Typhimurium challenge. 
Predicted mean water consumption in litres is depicted ± SE. *The water consumption of the 28 d vaccinates when compared to the non-vaccinated 
controls was significantly higher days 3 to 9 post-virulent challenge (P < 0.05). *The water consumption of the 7 d vaccinates was significantly 
increased from day 2 to 11 post-virulent challenge (P < 0.05) when compared to the control. *The 24 h pre-vaccinates were significantly increased when 
compared to the non-vaccinated controls on days 3, 6 and 10 post-virulent challenge while the 24 h post vaccinates were increased on days 9 and 10 
post-virulent challenge (P < 0.05).   
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Figure 8-11.  Predicted mean body weight of S. Typhimurium dam immunised sheep following virulent Typhimurium challenge. 
Data are depicted in predicted mean BWT in Kg ± SE at 2 days pre-challenge and day 13 post-challenge.  *BWT of the 28 d and 7 d vaccinates were 
significantly higher than the non-vaccinated controls 13 d following virulent challenge (P < 0.05) and the BWT of the 24 h post-vaccinates were significantly 
less than that of the non-vaccinated sheep (P < 0.05). 
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Figure 8-12.  Immunisation with S. Typhimurium dam confers homologous protection against virulent Typhimurium, ST 06-131, 
colonisation of tissues in sheep 
Tissue colonisation data are depicted as mean log10 CFU ± SE of ST 06-131, recovered by organ. *Significantly lower CFU were recovered from MLN (P 
< 0.0001), liver (P < 0.005), spleen (P < 0.05) and ileum (P < 0.0001) of the 28 d and 7 d vaccinates when compared to the non-vaccinated controls. 
*Significantly lower CFU were also recovered from the lungs (P < 0.05) of the 28 d vaccinates when compared to non-vaccinated controls. 
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CHAPTER 9. DISCUSSION AND CONCLUSIONS 
9.1 Discussion 
9.1.1. Cross protective efficacy of S. Typhimurium dam vaccine in 
neonate calves 
These studies were conducted as a continuation of research into the cross 
protective efficacy of the S. Typhimurium dam vaccine in neonate calves using a 
multi-drug antimicrobial resistant serovar of S. Newport. The vaccine had 
previously been shown to provide cross protective immunity to a host adapted S. 
Dublin, serotype D1 (Mohler, et al., 2006). Further assessment of the breadth of 
cross protective efficacy was required to determine if the vaccine would be likely 
to provide the broad protection required in livestock production systems where a 
diversity of Salmonella serovars are likely to be encountered.  
In Chapter 5, the S. Typhimurium dam vaccine attenuated clinical disease, 
reduced faecal shedding and tissue colonisation in neonatal calves challenged with 
a virulent multiple antimicrobial resistant S. Newport strain.  These results, along 
with those from Mohler et al. (2006) and Dueger et al. (2003b), provide 
convincing evidence that the S. Typhimurium dam vaccine provides robust 
protection against homologous and heterologous salmonella challenge in neonatal 
calves. This is encouraging as the most common isolates reported to infect cattle 
in Australia are S. Typhimurium (B), S. Dublin (D1), S. Bovismorbificans (C2-C3), 
and S. Anatum (E1) (IMVS, 2010).  Future challenge efficacy trials in the neonatal 
salmonellosis model should include S. Bovismorbificans (C2-C3), and S. Anatum 
(E1) to further demonstrate the cross protective efficacy of the  S. Typhimurium 
dam vaccine and its relevance in the Australian livestock industry. 
9.1.2. Salmonellosis in sheep 
The dose range finding studies described in Chapter 6 established comprehensive 
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models of salmonellosis in sheep.  Previously published ruminant models of 
salmonellosis utilised mortality, rectal temperature and observation of diarrhoea 
as outcome assessments. Some studies also measured cytokine and antibody 
responses, however, these did not equate with protective immunity.  Previous 
studies have not measured attitudes (mentation), appetite and water consumption, 
nor established normal baselines prior to initiation of challenge.  These dose range 
finding studies in sheep established a comprehensive model for evaluating the 
effects of salmonellosis on adult ruminants that included behaviour, feeding 
preferences, water consumption and body weight change, in addition to body 
temperature and faecal composition.  These models of ruminant salmonellosis will 
be useful in studying animal behaviour, treatment protocols and future vaccination 
trials.   
Interesting findings in the development of the salmonellosis models were the 
observations of food preference in sheep during the acclimation period along with 
inappetence and anorexia following virulent salmonellae challenge.  Prior to 
virulent challenge, several of the sheep demonstrated food preferences and 
avoidance of either pellets or chaff.  This was expected as the animals were raised 
on pastures and most had never been exposed to pellets or eating from feeders for 
that matter.  However, following entry into the housing facility, none of the sheep 
in these trials were observed with poor rumen fill.  Most of the animals readily 
adapted to the diets offered, accepting both components, however, some did 
refuse parts of the diet.   
Following virulent salmonellae challenge, inappetence and anorexia were 
observed in all sheep within 48 h of challenge.  Taken together with the 
observation that the prevalence of Salmonella excretion in sheep during the 
feedlot period rises from 0-2% to 26 - 97% following entry (Higgs, et al., 1993; 
Richards, et al., 1993; Kelly, 1995; Makin, 2011), the interval between 
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Salmonella exposure and inappetence in sheep could explain the 'neophobia' 
observed in sheep entering feedlots.  Additionally, the observation that sheep 
infected with Salmonella preferred chaff over a pelleted high energy diet during 
the post challenge period, even when animals were considered recovered, may 
also explain avoidance of pellets by feedlot sheep classified as 'neophobic' The 
significance of this finding deserves further research, as it may be useful in 
explaining the observation of 'neophobia' in feedlot sheep.  Additionally, the 
feeding preferences observed in these models of ovine salmonellosis may be 
useful in the management of convalescing sheep during, and following, a 
salmonellae outbreak.     
9.1.3. Development of novel in-water vaccination protocol for ruminants 
In Chapter 7 the feasibility of in-water vaccination with S. Typhimurium dam 
attenuated vaccine was investigated.  The S. Typhimurium dam was stable in 
drinking water with or without buffering agents for up to 24 h, remained viable 
under temperatures between 20°C and 37°C and did not proliferate in drinking 
water contaminated with animal faeces.  A potential limitation to oral vaccine 
delivery in ruminants is the capacity of volatile fatty acids produced in the rumen 
to attenuate the survival of bacteria, e.g., Salmonella. The S. Typhimurium dam 
successfully established in the MLN of adult sheep demonstrated that the vaccine 
was capable of bypassing the rumen and surviving in the gastrointestinal tract of 
adult sheep. These results indicated the in-water prophylaxis of S. Typhimurium 
dam  in adult ruminants was feasible. 
Application of an in-water vaccination protocol on-farm will provide additional 
challenges that go beyond the scope of this research.  On-farm or in feedlot 
scenarios, water is supplied to animals via communal water troughs.  This could 
introduce more variability in dose of vaccine consumed.  Ensuring that all animals 
consume an effective dose of the vaccine from trough water may be a limiting 
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factor. Environmental factors such as ultraviolet radiation, ambient temperature 
and water quality may play important roles in delivering an effective, safe dose of 
the vaccine.  Unfortunately, due to the current QC2 quarantine status of the S. 
Typhimurium dam vaccine, in-field trials could not be performed.  Future research 
with the vaccine in-water protocols should include administration of the vaccine 
from trough water to group housed sheep; vaccine-challenge efficacy trials 
following in-trough vaccination; as well as determination of the minimal dose of 
vaccine required to induce cross-protective efficacy in sheep. 
9.1.4. Homologous efficacy of the vaccine in sheep 
In Chapter 8 the safety and efficacy of a S. Typhimurium dam vaccine 
administered to sheep via oral delivery in drinking water (ad libitum) was 
assessed.  The S. Typhimurium dam vaccine significantly attenuated clinical 
disease (temperature, appetite, and attitude), reduced mortality, faecal Salmonella 
shedding and tissue colonisation following virulent S Typhimurium ST 06-131 
challenge within 7 d of vaccination.  Biologically, animals receiving the vaccine 
28 d or 7 d prior to virulent challenge with S Typhimurium ST 06-131  were 
clinically normal during the post-challenge period.  In fact, these animals did not 
display any signs of clinical disease and, more importantly, gained or maintained 
body weight over the post challenge period.  Further, vaccination with S. 
Typhimurium dam did not pose a risk to stock previously infected with virulent 
Salmonella, which makes this vaccine useful in outbreak scenarios where animals 
are already immunologically compromised.  The capacity of dam attenuated 
Salmonella vaccines delivered in drinking water to protect livestock from virulent 
Salmonella challenge offers an effective, economical, stressor free Salmonella 
prophylaxis for intensive livestock production systems. 
9.2 Future Research 
Controlled vaccine-challenge trials are critical in establishing efficacy and safety 
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of a vaccine candidate. However, field trails are essential in establishing efficacy 
of the vaccine candidate in production systems where salmonellae prevalence and 
exposure are unpredictable and host immunity may be variable.  Under field 
conditions, the vaccine would be applied to a diversity of host genetics and the  
animals in the field are exposed to varying risk factors, e.g., season, social stress, 
parturition, transport, feed changes, and concurrent infections that can increase 
risk to salmonellae infections. The research with the attenuated S. Typhimurium 
dam vaccine has been conducted in a controlled laboratory setting to prevent 
introduction of such confounders. Future research of the vaccine should include 
continued safety and efficacy testing in livestock species in larger field trials. 
Application of the vaccine to production systems where salmonellosis is endemic 
is the next logical step. 
9.2.1. Further efficacy testing of the vaccine 
Further efficacy testing of S. Typhimurium dam vaccine is warranted, however  
the current vaccine formulation is problematic for commercial application.  In the 
conduct of this research, vaccinations were carried out with S. Typhimurium dam 
vaccine strain MT2313 that contained an insertion element that allowed the 
vaccine to express resistance to chloramphenicol (Cmr).  This antibiotic resistance 
gene was inserted into the MT2313 vaccine strain in order to facilitate re-
isolation, enumeration and identification.  With growing concern regarding multi-
drug resistant strains of salmonellae, regulatory agencies such as OGTR, AQIS 
and APVMA would not favour a vaccine candidate carrying antimicrobial 
resistance.  
Therefore, commercial application of the vaccine will necessitate formulation of 
the dam attenuated S. Typhimurium vaccine without the Cmr gene. While removal 
of the Cmr gene from the dam S. Typhimurium vaccine is unlikely to have a 
significant effect on the efficacy, verification of the genetic construct and 
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additionally safety and efficacy trials that verify performance, as well as 
environmental stability and persistence, are going to be necessary prior to 
application in field trials.  
Additionally, a second attenuating deletion should also be considered to improve 
safety of the vaccine, as well as to ensure that vaccine is unable to revert to the 
level of virulence observed in the parent strain.  A second attenuating deletion is 
likely to have more of an effect on performance of the vaccine and would require 
multiple safety and efficacy trials in murine, avian, and bovine models of 
salmonellosis.    While this may seem an unnecessary duplication from an animal 
welfare perspective, it is absolutely vital to demonstrate that the new formulation 
of the dam S. Typhimurium is safe in livestock and, even more importantly, 
efficacious prior to initiating field trials.     
9.2.1. Efficacy of the S. Typhimurium dam vaccine in swine 
Salmonella is an important pathogen of pigs and is an important food safety 
consideration for pork producers.  Between 5% and 30% of all cases of foodborne 
salmonellosis list pork as the source of infection (Berends, et al., 1997).  In one 
Australian study, Salmonella spp. were isolated from the caecal contents of more 
than 20% of slaughtered pigs (Jackowiak, et al., 2006). There are no published 
efficacy trials using a S. Typhimurium dam mutant vaccine in pigs.  The 
development of models of porcine salmonellosis similar to those outlined in 
Chapters 4 and 6 and the conduct of efficacy trials in pigs would provide wider 
application of the vaccine in promoting animal health and welfare and food safety. 
9.2.2. Safety of the S. Typhimurium dam vaccine in the environment 
The S. Typhimurium dam vaccine has been safely administered to mice, chickens, 
calves and sheep and demonstrated to provide robust protection against virulent 
Salmonella challenge. Further studies are required to evaluate persistence of the S. 
Typhimurium dam vaccine in the environment.  As with all modified live 
attenuated vaccines there is a potential for reversion to virulent form (Cardenas 
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and Clements, 1993; Mastroeni, et al., 2000; Babiuk, 2002) by mechanisms of 
transformation, transduction and conjugations (Cardenas and Clements, 1993; 
Wray and Davies, 2000; Bueno, et al., 2009). Environmental passage experiments 
are indicated in order to evaluate the stability of the S. Typhimurium dam when 
exposed to the environment.  
9.2.3. Future application of the S. Typhimurium dam  
Another potential application for the S. Typhimurium dam is the use of the 
bacteria as a novel antigen delivery system in the construction of multivalent 
vaccines. Salmonella can be used as a targeted antigen delivery system capable of 
presenting antigen by way of major histocompatibility complex (MHC) classes I 
and II. Salmonella can be used to directly transfer plasmids that encode foreign 
antigens to antigen presenting cells, e.g., macrophages, dendritic cells and B-cells 
(Paglia, et al., 1998; Mastroeni, et al., 2000; Tizard, 2000), thus allowing the 
antigen to be produced within the host cells. Some of the difficulties associated 
with the use of plasmids are instability of the plasmid, toxicity of the proteins 
expressed to the host bacteria, degradation within the host bacteria, and incorrect 
expression of the antigen (Mastroeni, et al., 2000). Recombination of Salmonella 
through blending or insertion of foreign antigens into the genome has been used to 
overcome difficulties associated with the use of plasmids (Cardenas and 
Clements, 1993; Bueno, et al., 2009). Fimbrial colonisation factors of 
enterotoxigenic Escherichia coli (Morona, et al., 1994) and non-toxic fragment C 
of tetanus toxins (Villarreal-Ramos, et al., 2000b) have been successfully 
incorporated into Salmonella, where they have been expressed and elicited 
protective immune responses. Future applications of the dam attenuated vaccine to 
human, poultry and livestock medicine are promising. 
9.2.4. Development of PC2/QC2 laboratory and animal housing facilities 
at the University of Sydney 
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Vaccination-efficacy trials are labour intensive and require facilities that are 
approved for the use of infectious pathogens and can handle large numbers of 
livestock. In Australia, PC2 and QC2 compatible animal house facilities are 
limited and demand for use is high. Unfortunately, at the University of Sydney, 
there are no such facilities available and researchers are required to seek space in 
facilities which can uphold these standards at considerable cost.  As of 2011, in 
New South Wales there are no QC2 animal research facilities capable of handling 
livestock due to changes in AQIS animal facility accreditation requirements.  The 
EMAI PC2/QC2 animal house no longer meets QC2 standards and EMAI has 
elected to downgrade the facility to PC2/QC1 status. 
Emerging infectious diseases are becoming more relevant to Australian 
aquaculture, agriculture and livestock, requiring development and research into 
control strategies. The limited availability of animal research housing facilities 
capable of handling quarantine organisms and infectious agents seriously hampers 
the ability of researchers to investigate emerging disease pathogens.  The 
candidate experienced an 18 month delay due to researchers at EMAI being given 
preferential access to the animal research facilities over outsiders.   In a 
government sponsored facility such as EMAI, research into emerging diseases or 
emergency disease outbreaks will always take precedence over an outside 
researchers project. There are now no longer any facilities in the greater Sydney 
Area accredited to handle livestock infected with an AQIS QC2 biological agent.   
Therefore, it is strongly recommended that the University of Sydney establish 
livestock housing facilities suitable for the research of PC2 and QC2 class 
organisms.  
9.3 Conclusions 
The global trend toward intensive livestock production is associated with 
increased oro-faecal pathogen transmission resulting in a high prevalence of 
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Salmonella. Outbreaks of salmonellosis in livestock often reflect a series of events 
that compromise host immunity and increase pathogen exposure.  In many 
livestock industries, these events are inherent and difficult to overcome through 
husbandry and management.  The associated increase in the incidence of disease 
and contamination of livestock-derived food products imposes a significant risk to 
food safety via consumption of contaminated meat and milk products (Roels, et 
al., 1997). 
The development and application of an effective Salmonella vaccine offers a 
potential means of reducing industry associated losses and public health risks.  
The principal challenge in meeting this goal is that multiple Salmonella serovars 
are endemic to many livestock production systems and high risk groups that 
include neonates, post partum cows, and inappetent and stressed sheep. Effective 
Salmonella vaccination therefore requires induction of early onset, adaptive, cross 
protective immune mechanisms in order to provide protection against several 
Salmonella serovars in these high risk groups as well as stimulation of both innate 
and acquired immune mechanisms. 
This research demonstrates rapid induction of cross protective immunity in 
ruminants vaccinated with dam attenuated S. Typhimurium challenged with 
virulent homologous and heterologous Salmonella and establishes an affordable, 
stress-free vaccine delivery option with in-water vaccination of adult ruminants. 
These data, along with research conducted in murine and avian models, provide 
robust evidence that support application of the dam attenuated S. Typhimurium in 
the control and prevention of salmonellosis in livestock and food producing 
species. 
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Appendix II:  Individual Daily Animal Observation Record for Calves 
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Appendix III:  Individual Daily Animal Observation Record for Sheep 
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Appendix IV:  Standard Operating Procedure Animal Room Husbandry 
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Appendix IV (continued) 
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Appendix IV (continued) 
 
 
 
 
 
262 
Appendix IV (continued) 
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Appendix IV (continued) 
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Appendix IV (continued) 
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Appendix IV (continued) 
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Appendix V:  Standard Operating Procedure for Exit and Entry into Animal Rooms 
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Appendix V (continued) 
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Appendix V (continued) 
 
 
 269 
Appendix V (continued) 
 
 
 
 270 
Appendix V (continued) 
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Appendix V (continued) 
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Appendix VI:  Quantitative/Qualitative Faecal Culture Worksheet 
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Appendix VII:  Individual Animal Necropsy Quantitative Culture Worksheet 
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Appendix VIII:  Salmonella Identification Testing Results Worksheet 
 
 
